Trial Outcomes & Findings for Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults (NCT NCT03746015)
NCT ID: NCT03746015
Last Updated: 2025-09-08
Results Overview
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by microneutralization test 50% (MNT50).
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
30 participants
Primary outcome timeframe
Day 15
Results posted on
2025-09-08
Participant Flow
Participants took part in the study at 2 investigative sites in the United States from 28 December 2018 to 1 March 2021.
Healthy participants were enrolled in this study to receive Tetravalent Dengue Vaccine (TDV) on Days 1 and 90. One participant did not meet the randomization criteria and was not allocated to any of the pre-defined study groups and was excluded from all analyses except safety analysis.
Participant milestones
| Measure |
TDV: Flavivirus-naïve
Tetravalent Dengue Vaccine (TDV) 0.5 mL, subcutaneous (SC) injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by wild type dengue virus serotype-1 (DENV-1) were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
|---|---|---|---|
|
Overall Study
STARTED
|
22
|
4
|
3
|
|
Overall Study
Safety Population
|
22
|
4
|
3
|
|
Overall Study
COMPLETED
|
21
|
4
|
3
|
|
Overall Study
NOT COMPLETED
|
1
|
0
|
0
|
Reasons for withdrawal
| Measure |
TDV: Flavivirus-naïve
Tetravalent Dengue Vaccine (TDV) 0.5 mL, subcutaneous (SC) injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by wild type dengue virus serotype-1 (DENV-1) were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
|---|---|---|---|
|
Overall Study
Withdrawal of Consent
|
1
|
0
|
0
|
Baseline Characteristics
Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults
Baseline characteristics by cohort
| Measure |
TDV: Flavivirus-naïve
n=21 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=4 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Total
n=28 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
33.57 years
n=5 Participants
|
42.25 years
n=7 Participants
|
35.00 years
n=5 Participants
|
34.96 years
n=4 Participants
|
|
Sex: Female, Male
Female
|
10 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
12 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
11 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
16 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
21 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
27 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
|
Race (NIH/OMB)
White
|
17 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
21 Participants
n=4 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Region of Enrollment
United States
|
21 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
28 Participants
n=4 Participants
|
|
Height
|
169.18 centimeter (cm)
n=5 Participants
|
175.01 centimeter (cm)
n=7 Participants
|
174.33 centimeter (cm)
n=5 Participants
|
170.56 centimeter (cm)
n=4 Participants
|
|
Weight
|
71.54 kilogram (kg)
n=5 Participants
|
71.86 kilogram (kg)
n=7 Participants
|
79.15 kilogram (kg)
n=5 Participants
|
72.4 kilogram (kg)
n=4 Participants
|
|
Body Mass Index (BMI)
|
24.74 kilogram per meter square (kg/m^2)
n=5 Participants
|
23.48 kilogram per meter square (kg/m^2)
n=7 Participants
|
25.90 kilogram per meter square (kg/m^2)
n=5 Participants
|
24.68 kilogram per meter square (kg/m^2)
n=4 Participants
|
PRIMARY outcome
Timeframe: Day 15Population: Per Protocol Set (PPS) included all participants in the Full Analysis Set (FAS) who had no major protocol violations.
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by microneutralization test 50% (MNT50).
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=21 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=2 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 15
DENV-1
|
58.9 titer
Interval 28.9 to 120.0
|
15325.2 titer
Interval 32.4 to 7241076.9
|
5510.0 titer
Interval 1271.4 to 23879.4
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 15
DENV-2
|
11.2 titer
Interval 6.5 to 19.2
|
5200.2 titer
Interval 13.9 to 1947484.8
|
4142.7 titer
Interval 694.3 to 24718.0
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 15
DENV-3
|
42.1 titer
Interval 16.2 to 109.8
|
2468.7 titer
Interval 0.0 to 272077002.4
|
7244.0 titer
Interval 5083.2 to 10323.3
|
—
|
|
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 15
DENV-4
|
19.7 titer
Interval 10.6 to 36.7
|
1996.4 titer
Interval 0.5 to 8424572.5
|
4909.2 titer
Interval 2503.2 to 9628.0
|
—
|
PRIMARY outcome
Timeframe: Day 30 (Month 1)Population: PPS included all participants in the FAS who had no major protocol violations.
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=21 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=2 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 30 (Month 1)
DENV-1
|
336.1 titer
Interval 168.8 to 669.3
|
45437.3 titer
Interval 58.0 to 35607948.4
|
11091.9 titer
Interval 706.7 to 174081.3
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 30 (Month 1)
DENV-2
|
11557.1 titer
Interval 6408.8 to 20841.2
|
12317.0 titer
Interval 2677.3 to 56665.6
|
12221.9 titer
Interval 1004.9 to 148651.5
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 30 (Month 1)
DENV-3
|
344.7 titer
Interval 146.3 to 812.6
|
7273.6 titer
Interval 2983.8 to 17730.9
|
19062.2 titer
Interval 3584.4 to 101373.6
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 30 (Month 1)
DENV-4
|
141.1 titer
Interval 69.1 to 288.0
|
5094.3 titer
Interval 888.2 to 29218.2
|
5231.1 titer
Interval 2064.2 to 13256.7
|
—
|
PRIMARY outcome
Timeframe: Day 60 (Month 2)Population: PPS included all participants in the FAS who had no major protocol violations.
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=21 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=2 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 60 (Month 2)
DENV-1
|
258.5 titer
Interval 102.0 to 655.4
|
28109.0 titer
Interval 65.7 to 12030804.9
|
7827.8 titer
Interval 1701.7 to 36007.3
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 60 (Month 2)
DENV-2
|
6293.0 titer
Interval 3655.7 to 10833.1
|
9641.1 titer
Interval 4219.1 to 22030.9
|
7236.5 titer
Interval 432.9 to 120961.1
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 60 (Month 2)
DENV-3
|
174.6 titer
Interval 79.7 to 382.9
|
6174.2 titer
Interval 200.8 to 189874.6
|
15536.5 titer
Interval 3282.7 to 73532.6
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 60 (Month 2)
DENV-4
|
78.2 titer
Interval 35.0 to 174.7
|
6122.7 titer
Interval 1974.7 to 18984.1
|
4254.8 titer
Interval 720.8 to 25116.0
|
—
|
PRIMARY outcome
Timeframe: Day 90 (Month 3)Population: PPS included all participants in the FAS who had no major protocol violations.
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=21 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=2 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 90 (Month 3)
DENV-1
|
197.5 titer
Interval 82.7 to 471.7
|
24989.5 titer
Interval 244.4 to 2554755.6
|
8111.3 titer
Interval 2866.7 to 22950.5
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 90 (Month 3)
DENV-2
|
4077.0 titer
Interval 2535.6 to 6555.5
|
9167.4 titer
Interval 4646.6 to 18086.6
|
5450.5 titer
Interval 857.1 to 34661.2
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 90 (Month 3)
DENV-3
|
145.7 titer
Interval 82.0 to 258.9
|
7043.3 titer
Interval 1348.3 to 36792.6
|
10172.1 titer
Interval 3690.3 to 28038.7
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 90 (Month 3)
DENV-4
|
79.2 titer
Interval 37.3 to 168.0
|
3240.2 titer
Interval 9.6 to 1095309.8
|
4372.2 titer
Interval 857.1 to 22304.5
|
—
|
PRIMARY outcome
Timeframe: Day 105Population: PPS included all participants in the FAS who had no major protocol violations. Overall number analyzed are the number of participants with data available for analyses.
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=6 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=1 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 105
DENV-3
|
221.0 titer
Interval 55.9 to 873.8
|
2360.0 titer
The 95% CI was not estimable due to insufficient number of observations.
|
12835.4 titer
Interval 3232.2 to 50971.0
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 105
DENV-4
|
211.6 titer
Interval 73.5 to 609.2
|
2181.0 titer
The 95% CI was not estimable due to insufficient number of observations.
|
4011.8 titer
Interval 1075.2 to 14969.0
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 105
DENV-1
|
326.0 titer
Interval 117.8 to 902.2
|
13354.0 titer
The 95% confidence interval (CI) was not estimable due to insufficient number of observations.
|
6720.6 titer
Interval 3035.5 to 14879.7
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 105
DENV-2
|
3784.9 titer
Interval 1419.9 to 10088.5
|
5810.0 titer
The 95% CI was not estimable due to insufficient number of observations.
|
5635.6 titer
Interval 1094.4 to 29020.9
|
—
|
PRIMARY outcome
Timeframe: Day 120 (Month 4)Population: PPS included all participants in the FAS who had no major protocol violations. Overall number analyzed are the number of participants with data available for analyses.
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=12 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=2 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 120 (Month 4)
DENV-2
|
3636.1 titer
Interval 1912.1 to 6914.5
|
7424.1 titer
Interval 1187.8 to 46402.4
|
6187.5 titer
Interval 1220.4 to 31371.1
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 120 (Month 4)
DENV-3
|
132.1 titer
Interval 58.7 to 297.5
|
4179.0 titer
Interval 16.5 to 1060298.0
|
10402.8 titer
Interval 3725.1 to 29051.2
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 120 (Month 4)
DENV-4
|
112.3 titer
Interval 67.4 to 187.3
|
2428.6 titer
Interval 16.2 to 364777.8
|
3835.1 titer
Interval 619.1 to 23755.8
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 120 (Month 4)
DENV-1
|
433.8 titer
Interval 149.0 to 1262.8
|
27123.8 titer
Interval 5.1 to 144760235.6
|
9242.2 titer
Interval 3693.4 to 23127.1
|
—
|
PRIMARY outcome
Timeframe: Day 150 (Month 5)Population: PPS included all participants in the FAS who had no major protocol violations. Overall number analyzed are the number of participants with data available for analyses.
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=15 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=1 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 150 (Month 5)
DENV-1
|
266.7 titer
Interval 125.5 to 566.7
|
15703.0 titer
The 95% CI was not estimable due to insufficient number of observations.
|
7652.0 titer
Interval 3152.7 to 18572.6
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 150 (Month 5)
DENV-2
|
2415.2 titer
Interval 1355.6 to 4303.0
|
7081.0 titer
The 95% CI was not estimable due to insufficient number of observations.
|
4589.6 titer
Interval 586.8 to 35898.7
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 150 (Month 5)
DENV-3
|
137.0 titer
Interval 76.4 to 245.5
|
2829.0 titer
The 95% CI was not estimable due to insufficient number of observations.
|
8627.9 titer
Interval 2944.9 to 25277.7
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 150 (Month 5)
DENV-4
|
120.5 titer
Interval 64.1 to 226.8
|
1729.0 titer
The 95% CI was not estimable due to insufficient number of observations.
|
3593.4 titer
Interval 585.2 to 22065.1
|
—
|
PRIMARY outcome
Timeframe: Day 180 (Month 6)Population: PPS included all participants in the FAS who had no major protocol violations. Overall number analyzed are the number of participants with data available for analyses.
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=15 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=2 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 180 (Month 6)
DENV-1
|
194.4 titer
Interval 92.8 to 407.4
|
22880.8 titer
Interval 2540.1 to 206105.7
|
4101.6 titer
Interval 466.2 to 36082.4
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 180 (Month 6)
DENV-2
|
1920.1 titer
Interval 1070.8 to 3443.2
|
10697.4 titer
Interval 138.0 to 829066.2
|
5458.3 titer
Interval 622.8 to 47838.6
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 180 (Month 6)
DENV-3
|
98.2 titer
Interval 55.2 to 174.6
|
4198.3 titer
Interval 601.5 to 29302.7
|
7495.0 titer
Interval 3027.3 to 18556.1
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 180 (Month 6)
DENV-4
|
76.1 titer
Interval 37.9 to 152.8
|
2797.3 titer
Interval 122.6 to 63824.0
|
2742.4 titer
Interval 769.7 to 9770.8
|
—
|
PRIMARY outcome
Timeframe: Day 270 (Month 9)Population: PPS included all participants in the FAS who had no major protocol violations. Overall number analyzed are the number of participants with data available for analyses.
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=11 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=1 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 270 (Month 9)
DENV-1
|
121.7 titer
Interval 23.4 to 631.8
|
16158.0 titer
The 95% CI was not estimable due to insufficient number of observations.
|
3913.9 titer
Interval 982.7 to 15587.9
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 270 (Month 9)
DENV-2
|
1584.0 titer
Interval 1038.1 to 2417.1
|
8585.0 titer
The 95% CI was not estimable due to insufficient number of observations.
|
3925.6 titer
Interval 520.5 to 29606.8
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 270 (Month 9)
DENV-3
|
85.6 titer
Interval 44.3 to 165.2
|
3727.0 titer
The 95% CI was not estimable due to insufficient number of observations.
|
5985.8 titer
Interval 5342.8 to 6706.1
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 270 (Month 9)
DENV-4
|
39.5 titer
Interval 16.8 to 92.9
|
1684.0 titer
The 95% CI was not estimable due to insufficient number of observations.
|
2021.3 titer
Interval 400.1 to 10210.5
|
—
|
PRIMARY outcome
Timeframe: Day 360 (Month 12)Population: PPS included all participants in the FAS who had no major protocol violations. Overall number analyzed are the number of participants with data available for analyses.
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=11 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=1 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=2 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 360 (Month 12)
DENV-4
|
29.8 titer
Interval 11.7 to 75.9
|
1171.0 titer
The 95% CI was not estimable due to insufficient number of observations.
|
1695.3 titer
Interval 92.1 to 31197.8
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 360 (Month 12)
DENV-1
|
154.6 titer
Interval 36.5 to 655.2
|
17546.0 titer
The 95% CI was not estimable due to insufficient number of observations.
|
2623.5 titer
Interval 149.6 to 46022.7
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 360 (Month 12)
DENV-2
|
1287.8 titer
Interval 581.0 to 2854.6
|
9623.0 titer
The 95% CI was not estimable due to insufficient number of observations.
|
1523.7 titer
Interval 4.8 to 479413.6
|
—
|
|
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 360 (Month 12)
DENV-3
|
77.0 titer
Interval 48.2 to 122.9
|
4112.0 titer
The 95% CI was not estimable due to insufficient number of observations.
|
5287.8 titer
Interval 613.1 to 45608.8
|
—
|
SECONDARY outcome
Timeframe: Days 30 (Month 1), 90 (Month 3), 120 (Month 4), 180 (Month 6), 360 (Month 12)Population: PPS included all participants in the FAS who had no major protocol violations. Number analyzed is the number of participants with data available for analysis for the specified timepoint.
IFN-γ ELISpot response \>3 times higher compared with baseline (no peptide) and ≥5 spots per 10\^6 peripheral blood mononuclear cells (PBMCs) was defined as cellular immune response. Cellular immune response to any peptide pool was reported. The peptide pools included pre-membrane envelope (prME), capsid (C), non-structural proteins (NS): NS1, NS2, NS3, NS4 and NS5 for DENV-1, DENV-2, DENV-3 and DENV-4.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=21 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=2 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-1 Day 90 (Month 3)
|
95.2 percentage of participants
Interval 83.2 to 100.0
|
100 percentage of participants
Interval 15.8 to 100.0
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-1 Day 360 (Month 12)
|
90.9 percentage of participants
Interval 69.2 to 100.0
|
100 percentage of participants
Interval 2.5 to 100.0
|
100 percentage of participants
Interval 15.8 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-2 Day 90 (Month 3)
|
100 percentage of participants
Interval 83.9 to 100.0
|
100 percentage of participants
Interval 15.8 to 100.0
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-2 Day 180 (Month 6)
|
100 percentage of participants
Interval 78.2 to 100.0
|
100 percentage of participants
Interval 15.8 to 100.0
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-3 Day 120 (Month 4)
|
100 percentage of participants
Interval 73.5 to 100.0
|
100 percentage of participants
Interval 15.8 to 100.0
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-4 Day 30 (Month 1)
|
76.2 percentage of participants
Interval 52.8 to 91.8
|
100 percentage of participants
Interval 15.8 to 100.0
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-4 Day 90 (Month 3)
|
81.0 percentage of participants
Interval 62.1 to 96.8
|
100 percentage of participants
Interval 15.8 to 100.0
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-3 Day 30 (Month 1)
|
90.5 percentage of participants
Interval 69.6 to 98.8
|
100 percentage of participants
Interval 15.8 to 100.0
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-3 Day 90 (Month 3)
|
85.7 percentage of participants
Interval 63.7 to 97.0
|
100 percentage of participants
Interval 15.8 to 100.0
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-3 Day 180 (Month 6)
|
73.3 percentage of participants
Interval 44.9 to 92.2
|
100 percentage of participants
Interval 15.8 to 100.0
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-3 Day 360 (Month 12)
|
90.9 percentage of participants
Interval 58.7 to 99.8
|
100 percentage of participants
Interval 2.5 to 100.0
|
100 percentage of participants
Interval 15.8 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-4 Day 120 (Month 4)
|
100 percentage of participants
Interval 73.5 to 100.0
|
100 percentage of participants
Interval 15.8 to 100.0
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-4 Day 180 (Month 6)
|
93.3 percentage of participants
Interval 68.1 to 99.8
|
50.0 percentage of participants
Interval 1.3 to 98.7
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-4 Day 360 (Month 12)
|
54.5 percentage of participants
Interval 42.1 to 99.6
|
100 percentage of participants
Interval 2.5 to 100.0
|
100 percentage of participants
Interval 15.8 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-1 Day 30 (Month 1)
|
100 percentage of participants
Interval 83.9 to 100.0
|
100 percentage of participants
Interval 15.8 to 100.0
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-1 Day 120 (Month 4)
|
100 percentage of participants
Interval 73.5 to 100.0
|
100 percentage of participants
Interval 15.8 to 100.0
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-1 Day 180 (Month 6)
|
93.3 percentage of participants
Interval 68.1 to 99.8
|
100 percentage of participants
Interval 15.8 to 100.0
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-2 Day 30 (Month 1)
|
100 percentage of participants
Interval 83.9 to 100.0
|
100 percentage of participants
Interval 15.8 to 100.0
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-2 Day 120 (Month 4)
|
100 percentage of participants
Interval 73.5 to 100.0
|
100 percentage of participants
Interval 15.8 to 100.0
|
100 percentage of participants
Interval 29.2 to 100.0
|
—
|
|
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
DENV-2 Day 360 (Month 12)
|
100 percentage of participants
Interval 71.5 to 100.0
|
100 percentage of participants
Interval 2.5 to 100.0
|
100 percentage of participants
Interval 15.8 to 100.0
|
—
|
SECONDARY outcome
Timeframe: Days 30 (Month 1), 90 (Month 3), 120 (Month 4), 180 (Month 6), 360 (Month 12)Population: PPS included all participants in the FAS who had no major protocol violations. Number analyzed is the number of participants with data available for analysis for the specified timepoint.
The magnitude of cellular immune response was assessed by the number of SFC/10\^6 PBMCs. IFN-γ ELISpot response \>3 times higher compared with baseline (no peptide) and ≥5 spots per 10\^6 PBMCs was defined as cellular immune response. Cellular immune response to any peptide pool was reported. The peptide pools included prME, C, NS1, NS2, NS3, NS4 and NS5 for DENV-1, DENV-2, DENV-3 and DENV-4.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=21 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=2 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-1 Day 90 (Month 3)
|
189.5834 SFC/10^6 PBMCs
Standard Deviation 350.89563
|
1772.5000 SFC/10^6 PBMCs
Standard Deviation 2485.48034
|
235.0000 SFC/10^6 PBMCs
Standard Deviation 109.65856
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-2 Day 30 (Month 1)
|
1156.9048 SFC/10^6 PBMCs
Standard Deviation 1676.59869
|
1847.5000 SFC/10^6 PBMCs
Standard Deviation 2365.27218
|
551.6667 SFC/10^6 PBMCs
Standard Deviation 309.89245
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-2 Day 90 (Month 3)
|
912.4603 SFC/10^6 PBMCs
Standard Deviation 979.81060
|
1462.5000 SFC/10^6 PBMCs
Standard Deviation 1750.08928
|
352.2223 SFC/10^6 PBMCs
Standard Deviation 267.42243
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-2 Day 120 (Month 4)
|
999.3056 SFC/10^6 PBMCs
Standard Deviation 1416.74554
|
1237.5000 SFC/10^6 PBMCs
Standard Deviation 1566.24152
|
161.6667 SFC/10^6 PBMCs
Standard Deviation 150.52685
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-1 Day 30 (Month 1)
|
232.3016 SFC/10^6 PBMCs
Standard Deviation 407.55450
|
2480.0000 SFC/10^6 PBMCs
Standard Deviation 3486.03643
|
301.6667 SFC/10^6 PBMCs
Standard Deviation 159.39992
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-1 Day 120 (Month 4)
|
209.8611 SFC/10^6 PBMCs
Standard Deviation 329.52941
|
1517.5000 SFC/10^6 PBMCs
Standard Deviation 2138.99801
|
116.6667 SFC/10^6 PBMCs
Standard Deviation 76.53975
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-1 Day 180 (Month 6)
|
162.5000 SFC/10^6 PBMCs
Standard Deviation 237.01829
|
1994.1665 SFC/10^6 PBMCs
Standard Deviation 2806.03517
|
242.7777 SFC/10^6 PBMCs
Standard Deviation 166.35251
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-1 Day 360 (Month 12)
|
235.1667 SFC/10^6 PBMCs
Standard Deviation 340.48572
|
5.0000 SFC/10^6 PBMCs
Standard Deviation NA
Standard deviation (SD) was not estimable for a single participant.
|
104.1665 SFC/10^6 PBMCs
Standard Deviation 69.53193
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-2 Day 180 (Month 6)
|
965.1111 SFC/10^6 PBMCs
Standard Deviation 1154.31464
|
2070.0000 SFC/10^6 PBMCs
Standard Deviation 2807.21392
|
375.5557 SFC/10^6 PBMCs
Standard Deviation 70.56015
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-2 Day 360 (Month 12)
|
974.0909 SFC/10^6 PBMCs
Standard Deviation 1266.49305
|
180.0000 SFC/10^6 PBMCs
Standard Deviation NA
Standard deviation (SD) was not estimable for a single participant.
|
149.1665 SFC/10^6 PBMCs
Standard Deviation 93.10263
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-3 Day 30 (Month 1)
|
246.5789 SFC/10^6 PBMCs
Standard Deviation 331.14209
|
2035.0000 SFC/10^6 PBMCs
Standard Deviation 2807.21392
|
295.0000 SFC/10^6 PBMCs
Standard Deviation 115.32563
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-3 Day 90 (Month 3)
|
184.8148 SFC/10^6 PBMCs
Standard Deviation 273.48687
|
215.0000 SFC/10^6 PBMCs
Standard Deviation 282.84271
|
226.1113 SFC/10^6 PBMCs
Standard Deviation 212.99673
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-3 Day 120 (Month 4)
|
156.1112 SFC/10^6 PBMCs
Standard Deviation 280.56878
|
1565.0000 SFC/10^6 PBMCs
Standard Deviation 2192.03102
|
353.3333 SFC/10^6 PBMCs
Standard Deviation 158.61379
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-3 Day 180 (Month 6)
|
164.0909 SFC/10^6 PBMCs
Standard Deviation 233.54441
|
1726.6665 SFC/10^6 PBMCs
Standard Deviation 2413.59091
|
120.5553 SFC/10^6 PBMCs
Standard Deviation 132.31197
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-3 Day 360 (Month 12)
|
137.6666 SFC/10^6 PBMCs
Standard Deviation 194.74138
|
5.0000 SFC/10^6 PBMCs
Standard Deviation NA
Standard deviation (SD) was not estimable for a single participant.
|
123.3335 SFC/10^6 PBMCs
Standard Deviation 16.49892
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-4 Day 30 (Month 1)
|
224.0625 SFC/10^6 PBMCs
Standard Deviation 420.90109
|
395.0000 SFC/10^6 PBMCs
Standard Deviation 473.76154
|
153.3333 SFC/10^6 PBMCs
Standard Deviation 219.10804
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-4 Day 90 (Month 3)
|
153.0392 SFC/10^6 PBMCs
Standard Deviation 290.81317
|
362.5000 SFC/10^6 PBMCs
Standard Deviation 477.29708
|
71.6667 SFC/10^6 PBMCs
Standard Deviation 38.11558
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-4 Day 120 (Month 4)
|
172.6388 SFC/10^6 PBMCs
Standard Deviation 373.16791
|
57.5000 SFC/10^6 PBMCs
Standard Deviation 74.24621
|
160.0000 SFC/10^6 PBMCs
Standard Deviation 205.36553
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-4 Day 180 (Month 6)
|
162.2619 SFC/10^6 PBMCs
Standard Deviation 378.98856
|
573.3330 SFC/10^6 PBMCs
Standard Deviation NA
Standard deviation (SD) was not estimable for a single participant.
|
155.0000 SFC/10^6 PBMCs
Standard Deviation 165.86485
|
—
|
|
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
DENV-4 Day 360 (Month 12)
|
215.0000 SFC/10^6 PBMCs
Standard Deviation 325.02308
|
40.0000 SFC/10^6 PBMCs
Standard Deviation NA
Standard deviation (SD) was not estimable for a single participant.
|
75.8335 SFC/10^6 PBMCs
Standard Deviation 62.46086
|
—
|
SECONDARY outcome
Timeframe: Days 15, 30 (Month 1), 90 (Month 3), 105, 120 (Month 4), and 360 (Month 12)Population: Intracellular Cytokine Staining (ICS) Subset included participants from PPS (all participants in the FAS who had no major protocol violations) who had IFN-γ ELISPOT responses \> 50 SFC/10\^6 PBMCs and availability of sufficient cells for analysis. Number analyzed is the number of participants with data available for analysis for the specified timepoint.
Phenotype characterization of cellular immune response was performed in a subset of participants with IFN- γ ELISPOT responses \>50 SFC/10\^6 cells and availability of sufficient cells. Markers included cluster of differentiation (CD) 4, CD8, IFN-γ, tumor necrosis factor-alpha (TNF-α) and interleukin-2 (IL-2). The peptide pools included C, NS1, NS2/4, NS3, NS5 for DENV-2 and prME for DENV-1, DENV-2, DENV-3 and DENV-4.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=21 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=2 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 120 (Month 4)
|
0.0092000 percentage of CD4+ T cells
Standard Deviation 0.01536808
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0080000 percentage of CD4+ T cells
Standard Deviation 0.00608276
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 360 (Month 12)
|
0.0023000 percentage of CD4+ T cells
Standard Deviation 0.00188396
|
0.0025300 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0019185 percentage of CD4+ T cells
Standard Deviation 0.00261842
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 90 (Month 3)
|
0.0006646 percentage of CD4+ T cells
Standard Deviation 0.00100992
|
0.0077600 percentage of CD4+ T cells
Standard Deviation 0.01097430
|
0.0049000 percentage of CD4+ T cells
Standard Deviation 0.00652393
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 120 (Month 4)
|
0.0015773 percentage of CD4+ T cells
Standard Deviation 0.00239811
|
0.0087700 percentage of CD4+ T cells
Standard Deviation 0.01240265
|
0.0031500 percentage of CD4+ T cells
Standard Deviation 0.00279426
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 90 (Month 3)
|
0.0012968 percentage of CD4+ T cells
Standard Deviation 0.00161555
|
0.0055000 percentage of CD4+ T cells
Standard Deviation 0.00777817
|
0.0011827 percentage of CD4+ T cells
Standard Deviation 0.00198127
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 30 (Month 1)
|
0.0035320 percentage of CD4+ T cells
Standard Deviation 0.00412765
|
0.0050000 percentage of CD4+ T cells
Standard Deviation 0.00707107
|
0.0050000 percentage of CD4+ T cells
Standard Deviation 0.00866025
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 360 (Month 12)
|
0.0025411 percentage of CD4+ T cells
Standard Deviation 0.00555028
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0480000 percentage of CD4+ T cells
Standard Deviation 0.02828427
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 15
|
0.0007143 percentage of CD4+ T cells
Standard Deviation 0.00197846
|
0.0010000 percentage of CD4+ T cells
Standard Deviation 0.00141421
|
0.0009033 percentage of CD4+ T cells
Standard Deviation 0.00156462
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 15
|
0.0156338 percentage of CD4+ T cells
Standard Deviation 0.01341318
|
0.0345000 percentage of CD4+ T cells
Standard Deviation 0.00070711
|
0.0156567 percentage of CD4+ T cells
Standard Deviation 0.01987399
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
|
0.0024256 percentage of CD4+ T cells
Standard Deviation 0.00231885
|
0.0024550 percentage of CD4+ T cells
Standard Deviation 0.00338704
|
0.0020033 percentage of CD4+ T cells
Standard Deviation 0.00186162
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 15
|
0.0195281 percentage of CD4+ T cells
Standard Deviation 0.01605864
|
0.0345000 percentage of CD4+ T cells
Standard Deviation 0.02757716
|
0.0396233 percentage of CD4+ T cells
Standard Deviation 0.02896264
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 90 (Month 3)
|
0.0010054 percentage of CD4+ T cells
Standard Deviation 0.00138756
|
0.0000650 percentage of CD4+ T cells
Standard Deviation 0.00009192
|
0.0005967 percentage of CD4+ T cells
Standard Deviation 0.00103346
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
|
0.0009544 percentage of CD4+ T cells
Standard Deviation 0.00127228
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0010335 percentage of CD4+ T cells
Standard Deviation 0.00146159
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, C, Day 90 (Month 3)
|
0.0054914 percentage of CD4+ T cells
Standard Deviation 0.00581130
|
0.0224000 percentage of CD4+ T cells
Standard Deviation 0.00582656
|
0.0014500 percentage of CD4+ T cells
Standard Deviation 0.00146010
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 120 (Month 4)
|
0.0013082 percentage of CD4+ T cells
Standard Deviation 0.00189986
|
0.0134350 percentage of CD4+ T cells
Standard Deviation 0.01711906
|
0.0126110 percentage of CD4+ T cells
Standard Deviation 0.01695829
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 360 (Month 12)
|
0.0036009 percentage of CD4+ T cells
Standard Deviation 0.00879474
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0004275 percentage of CD4+ T cells
Standard Deviation 0.00058336
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, C, Day 360 (Month 12)
|
0.0032638 percentage of CD4+ T cells
Standard Deviation 0.00481301
|
0.0138000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0005985 percentage of CD4+ T cells
Standard Deviation 0.00084641
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 90 (Month 3)
|
0.0022710 percentage of CD4+ T cells
Standard Deviation 0.00378206
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0303333 percentage of CD4+ T cells
Standard Deviation 0.05253887
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 105
|
0.0032733 percentage of CD4+ T cells
Standard Deviation 0.00561714
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0096600 percentage of CD4+ T cells
Standard Deviation 0.01002032
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 360 (Month 12)
|
0.0057482 percentage of CD4+ T cells
Standard Deviation 0.01145463
|
0.0010000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 15
|
0.0023484 percentage of CD4+ T cells
Standard Deviation 0.00373999
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0019433 percentage of CD4+ T cells
Standard Deviation 0.00336595
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
|
0.0027084 percentage of CD4+ T cells
Standard Deviation 0.00347026
|
0.0115000 percentage of CD4+ T cells
Standard Deviation 0.00636396
|
0.0010000 percentage of CD4+ T cells
Standard Deviation 0.00173205
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
|
0.0004250 percentage of CD4+ T cells
Standard Deviation 0.00128026
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0060000 percentage of CD4+ T cells
Standard Deviation 0.01039230
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 105
|
0.0034460 percentage of CD4+ T cells
Standard Deviation 0.00473493
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0003333 percentage of CD4+ T cells
Standard Deviation 0.00057735
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
|
0.0040230 percentage of CD4+ T cells
Standard Deviation 0.00533216
|
0.0051500 percentage of CD4+ T cells
Standard Deviation 0.00728320
|
0.0026467 percentage of CD4+ T cells
Standard Deviation 0.00458416
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
|
0.0028144 percentage of CD4+ T cells
Standard Deviation 0.00395317
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0175000 percentage of CD4+ T cells
Standard Deviation 0.00070711
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 15
|
0.0020638 percentage of CD4+ T cells
Standard Deviation 0.00335443
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0045367 percentage of CD4+ T cells
Standard Deviation 0.00785774
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 30 (Month 1)
|
0.0061967 percentage of CD4+ T cells
Standard Deviation 0.01073863
|
0.0030000 percentage of CD4+ T cells
Standard Deviation 0.00424264
|
0.0050000 percentage of CD4+ T cells
Standard Deviation 0.00866025
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 90 (Month 3)
|
0.0028243 percentage of CD4+ T cells
Standard Deviation 0.00657932
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 105
|
0.0043583 percentage of CD4+ T cells
Standard Deviation 0.00586855
|
0.0010000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0016667 percentage of CD4+ T cells
Standard Deviation 0.00152753
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 120 (Month 4)
|
0.0041158 percentage of CD4+ T cells
Standard Deviation 0.00481914
|
0.0056500 percentage of CD4+ T cells
Standard Deviation 0.00799031
|
0.0109800 percentage of CD4+ T cells
Standard Deviation 0.00962191
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 360 (Month 12)
|
0.0043409 percentage of CD4+ T cells
Standard Deviation 0.00775431
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 15
|
0.0029114 percentage of CD4+ T cells
Standard Deviation 0.00457042
|
0.0040100 percentage of CD4+ T cells
Standard Deviation 0.00567100
|
0.0095367 percentage of CD4+ T cells
Standard Deviation 0.01244163
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 30 (Month 1)
|
0.0060424 percentage of CD4+ T cells
Standard Deviation 0.00716413
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0081633 percentage of CD4+ T cells
Standard Deviation 0.00851998
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 90 (Month 3)
|
0.0029867 percentage of CD4+ T cells
Standard Deviation 0.00872447
|
0.0025000 percentage of CD4+ T cells
Standard Deviation 0.00353553
|
0.0134067 percentage of CD4+ T cells
Standard Deviation 0.02049576
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 105
|
0.0023333 percentage of CD4+ T cells
Standard Deviation 0.00297921
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 120 (Month 4)
|
0.0031367 percentage of CD4+ T cells
Standard Deviation 0.00432011
|
0.0015750 percentage of CD4+ T cells
Standard Deviation 0.00222739
|
0.0053133 percentage of CD4+ T cells
Standard Deviation 0.00920296
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 30 (Month 1)
|
0.0110019 percentage of CD4+ T cells
Standard Deviation 0.01406371
|
0.0010000 percentage of CD4+ T cells
Standard Deviation 0.00141421
|
0.0033333 percentage of CD4+ T cells
Standard Deviation 0.00577350
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 105
|
0.0066667 percentage of CD4+ T cells
Standard Deviation 0.01114750
|
0.0090000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0086667 percentage of CD4+ T cells
Standard Deviation 0.01078579
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 90 (Month 3)
|
0.0041111 percentage of CD4+ T cells
Standard Deviation 0.00669406
|
0.0050000 percentage of CD4+ T cells
Standard Deviation 0.00707107
|
0.0173333 percentage of CD4+ T cells
Standard Deviation 0.02746513
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 105
|
0.0008000 percentage of CD4+ T cells
Standard Deviation 0.00130384
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0010000 percentage of CD4+ T cells
Standard Deviation 0.00173205
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, C, Day 360 (Month 12)
|
0.0786250 percentage of CD4+ T cells
Standard Deviation 0.07674250
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0350000 percentage of CD4+ T cells
Standard Deviation 0.02121320
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 15
|
0.0007143 percentage of CD4+ T cells
Standard Deviation 0.00327327
|
0.0200000 percentage of CD4+ T cells
Standard Deviation 0.02828427
|
0.0500000 percentage of CD4+ T cells
Standard Deviation 0.07810250
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 90 (Month 3)
|
0.0009887 percentage of CD4+ T cells
Standard Deviation 0.00117522
|
0.0008700 percentage of CD4+ T cells
Standard Deviation 0.00123037
|
0.0009033 percentage of CD4+ T cells
Standard Deviation 0.00078932
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 105
|
0.0011940 percentage of CD4+ T cells
Standard Deviation 0.00117362
|
0.0000290 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0009600 percentage of CD4+ T cells
Standard Deviation 0.00088386
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 120 (Month 4)
|
0.0020154 percentage of CD4+ T cells
Standard Deviation 0.00212428
|
0.0013950 percentage of CD4+ T cells
Standard Deviation 0.00007778
|
0.0016910 percentage of CD4+ T cells
Standard Deviation 0.00108924
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 15
|
0.0029003 percentage of CD4+ T cells
Standard Deviation 0.00272483
|
0.0194500 percentage of CD4+ T cells
Standard Deviation 0.02521543
|
0.0487733 percentage of CD4+ T cells
Standard Deviation 0.04944810
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 360 (Month 12)
|
0.0014281 percentage of CD4+ T cells
Standard Deviation 0.00135883
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0019985 percentage of CD4+ T cells
Standard Deviation 0.00102036
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 30 (Month 1)
|
0.0019231 percentage of CD4+ T cells
Standard Deviation 0.00285971
|
0.0025200 percentage of CD4+ T cells
Standard Deviation 0.00213546
|
0.0119560 percentage of CD4+ T cells
Standard Deviation 0.00976035
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 90 (Month 3)
|
0.0012856 percentage of CD4+ T cells
Standard Deviation 0.00145620
|
0.0023950 percentage of CD4+ T cells
Standard Deviation 0.00338704
|
0.0028307 percentage of CD4+ T cells
Standard Deviation 0.00290989
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 105
|
0.0004400 percentage of CD4+ T cells
Standard Deviation 0.00061192
|
0.0005900 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0047467 percentage of CD4+ T cells
Standard Deviation 0.00638064
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 120 (Month 4)
|
0.0020605 percentage of CD4+ T cells
Standard Deviation 0.00152830
|
0.0021700 percentage of CD4+ T cells
Standard Deviation 0.00306884
|
0.0043733 percentage of CD4+ T cells
Standard Deviation 0.00330736
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 360 (Month 12)
|
0.0007457 percentage of CD4+ T cells
Standard Deviation 0.00106006
|
0.0000300 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0009135 percentage of CD4+ T cells
Standard Deviation 0.00126784
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 30 (Month 1)
|
0.0037725 percentage of CD4+ T cells
Standard Deviation 0.00540746
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0034967 percentage of CD4+ T cells
Standard Deviation 0.00303810
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 90 (Month 3)
|
0.0016332 percentage of CD4+ T cells
Standard Deviation 0.00284966
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0176733 percentage of CD4+ T cells
Standard Deviation 0.02887941
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 105
|
0.0024340 percentage of CD4+ T cells
Standard Deviation 0.00417459
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0038967 percentage of CD4+ T cells
Standard Deviation 0.00400400
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 120 (Month 4)
|
0.0026618 percentage of CD4+ T cells
Standard Deviation 0.00395446
|
0.0006850 percentage of CD4+ T cells
Standard Deviation 0.00096874
|
0.0020133 percentage of CD4+ T cells
Standard Deviation 0.00348720
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 360 (Month 12)
|
0.0042078 percentage of CD4+ T cells
Standard Deviation 0.00647931
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0170000 percentage of CD4+ T cells
Standard Deviation 0.02404163
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 15
|
0.0026390 percentage of CD4+ T cells
Standard Deviation 0.00478957
|
0.0030000 percentage of CD4+ T cells
Standard Deviation 0.00424264
|
0.0126667 percentage of CD4+ T cells
Standard Deviation 0.02193931
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 30 (Month 1)
|
0.0052020 percentage of CD4+ T cells
Standard Deviation 0.00685207
|
0.0085000 percentage of CD4+ T cells
Standard Deviation 0.01202082
|
0.0060000 percentage of CD4+ T cells
Standard Deviation 0.00871780
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 90 (Month 3)
|
0.0022105 percentage of CD4+ T cells
Standard Deviation 0.00432793
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0173333 percentage of CD4+ T cells
Standard Deviation 0.03002221
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 105
|
0.0040000 percentage of CD4+ T cells
Standard Deviation 0.00616441
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0013333 percentage of CD4+ T cells
Standard Deviation 0.00230940
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 120 (Month 4)
|
0.0047273 percentage of CD4+ T cells
Standard Deviation 0.00864975
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0113333 percentage of CD4+ T cells
Standard Deviation 0.01001665
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 360 (Month 12)
|
0.0103333 percentage of CD4+ T cells
Standard Deviation 0.01298075
|
0.0020000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0200000 percentage of CD4+ T cells
Standard Deviation 0.01272792
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 30 (Month 1)
|
0.0037000 percentage of CD4+ T cells
Standard Deviation 0.00877856
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0700000 percentage of CD4+ T cells
Standard Deviation 0.10440307
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 360 (Month 12)
|
0.0488889 percentage of CD4+ T cells
Standard Deviation 0.08153595
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0250000 percentage of CD4+ T cells
Standard Deviation 0.03535534
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 105
|
0.0007540 percentage of CD4+ T cells
Standard Deviation 0.00168600
|
0.0064500 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0004667 percentage of CD4+ T cells
Standard Deviation 0.00080829
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 30 (Month 1)
|
0.0014351 percentage of CD4+ T cells
Standard Deviation 0.00201558
|
0.0349770 percentage of CD4+ T cells
Standard Deviation 0.04811579
|
0.0028800 percentage of CD4+ T cells
Standard Deviation 0.00258519
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 105
|
0.0021520 percentage of CD4+ T cells
Standard Deviation 0.00374127
|
0.0012200 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0014633 percentage of CD4+ T cells
Standard Deviation 0.00168138
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 30 (Month 1)
|
0.0019537 percentage of CD4+ T cells
Standard Deviation 0.00217059
|
0.0150950 percentage of CD4+ T cells
Standard Deviation 0.02123442
|
0.0018260 percentage of CD4+ T cells
Standard Deviation 0.00126872
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 90 (Month 3)
|
0.0011930 percentage of CD4+ T cells
Standard Deviation 0.00181994
|
0.0050000 percentage of CD4+ T cells
Standard Deviation 0.00707107
|
0.0021353 percentage of CD4+ T cells
Standard Deviation 0.00311525
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 105
|
0.0013140 percentage of CD4+ T cells
Standard Deviation 0.00138036
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0015733 percentage of CD4+ T cells
Standard Deviation 0.00166677
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 120 (Month 4)
|
0.0009293 percentage of CD4+ T cells
Standard Deviation 0.00129407
|
0.0019950 percentage of CD4+ T cells
Standard Deviation 0.00094045
|
0.0006533 percentage of CD4+ T cells
Standard Deviation 0.00106308
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 30 (Month 1)
|
0.0137000 percentage of CD4+ T cells
Standard Deviation 0.02625202
|
0.0250000 percentage of CD4+ T cells
Standard Deviation 0.03535534
|
0.1056667 percentage of CD4+ T cells
Standard Deviation 0.10390541
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 15
|
0.0063455 percentage of CD4+ T cells
Standard Deviation 0.00700260
|
0.0061800 percentage of CD4+ T cells
Standard Deviation 0.00004243
|
0.0146700 percentage of CD4+ T cells
Standard Deviation 0.01675231
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 15
|
0.0098571 percentage of CD4+ T cells
Standard Deviation 0.02431930
|
0.0250000 percentage of CD4+ T cells
Standard Deviation 0.03535534
|
0.0376667 percentage of CD4+ T cells
Standard Deviation 0.01569501
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, C, Day 15
|
0.0184117 percentage of CD4+ T cells
Standard Deviation 0.02426237
|
0.0855000 percentage of CD4+ T cells
Standard Deviation 0.01202082
|
0.0023033 percentage of CD4+ T cells
Standard Deviation 0.00268712
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 30 (Month 1)
|
0.0063500 percentage of CD4+ T cells
Standard Deviation 0.01307177
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0466667 percentage of CD4+ T cells
Standard Deviation 0.08082904
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 90 (Month 3)
|
0.0040542 percentage of CD4+ T cells
Standard Deviation 0.01131730
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0310000 percentage of CD4+ T cells
Standard Deviation 0.04293018
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 15
|
0.0039595 percentage of CD4+ T cells
Standard Deviation 0.00434343
|
0.0190000 percentage of CD4+ T cells
Standard Deviation 0.01272792
|
0.0010800 percentage of CD4+ T cells
Standard Deviation 0.00175923
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 30 (Month 1)
|
0.0040266 percentage of CD4+ T cells
Standard Deviation 0.00433388
|
0.0235670 percentage of CD4+ T cells
Standard Deviation 0.03188062
|
0.0042860 percentage of CD4+ T cells
Standard Deviation 0.00392989
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 90 (Month 3)
|
0.0022368 percentage of CD4+ T cells
Standard Deviation 0.00317381
|
0.0023500 percentage of CD4+ T cells
Standard Deviation 0.00332340
|
0.0013000 percentage of CD4+ T cells
Standard Deviation 0.00162631
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 105
|
0.0013760 percentage of CD4+ T cells
Standard Deviation 0.00241658
|
0.0024200 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0005800 percentage of CD4+ T cells
Standard Deviation 0.00100459
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 120 (Month 4)
|
0.0027200 percentage of CD4+ T cells
Standard Deviation 0.00460175
|
0.0108200 percentage of CD4+ T cells
Standard Deviation 0.00950352
|
0.0039300 percentage of CD4+ T cells
Standard Deviation 0.00413312
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 15
|
0.0015836 percentage of CD4+ T cells
Standard Deviation 0.00205944
|
0.0017250 percentage of CD4+ T cells
Standard Deviation 0.00023335
|
0.0010800 percentage of CD4+ T cells
Standard Deviation 0.00175923
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 30 (Month 1)
|
0.0028357 percentage of CD4+ T cells
Standard Deviation 0.00490865
|
0.0029000 percentage of CD4+ T cells
Standard Deviation 0.00410122
|
0.0008220 percentage of CD4+ T cells
Standard Deviation 0.00084058
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 90 (Month 3)
|
0.0010256 percentage of CD4+ T cells
Standard Deviation 0.00147028
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0005700 percentage of CD4+ T cells
Standard Deviation 0.00098727
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 360 (Month 12)
|
0.0006709 percentage of CD4+ T cells
Standard Deviation 0.00088977
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0010335 percentage of CD4+ T cells
Standard Deviation 0.00146159
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 105
|
0.0010760 percentage of CD4+ T cells
Standard Deviation 0.00089456
|
0.0000600 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 120 (Month 4)
|
0.0018854 percentage of CD4+ T cells
Standard Deviation 0.00346501
|
0.0006950 percentage of CD4+ T cells
Standard Deviation 0.00098288
|
0.0009263 percentage of CD4+ T cells
Standard Deviation 0.00157941
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 360 (Month 12)
|
0.0005916 percentage of CD4+ T cells
Standard Deviation 0.00126206
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 15
|
0.0024555 percentage of CD4+ T cells
Standard Deviation 0.00404542
|
0.0196200 percentage of CD4+ T cells
Standard Deviation 0.02214658
|
0.0061433 percentage of CD4+ T cells
Standard Deviation 0.00488514
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 30 (Month 1)
|
0.0023374 percentage of CD4+ T cells
Standard Deviation 0.00257822
|
0.0230380 percentage of CD4+ T cells
Standard Deviation 0.03247317
|
0.0075220 percentage of CD4+ T cells
Standard Deviation 0.00887617
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 105
|
0.0036640 percentage of CD4+ T cells
Standard Deviation 0.00370999
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0069667 percentage of CD4+ T cells
Standard Deviation 0.01073570
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 360 (Month 12)
|
0.0004526 percentage of CD4+ T cells
Standard Deviation 0.00059075
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0024485 percentage of CD4+ T cells
Standard Deviation 0.00167089
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 15
|
0.0027775 percentage of CD4+ T cells
Standard Deviation 0.00490646
|
0.0013760 percentage of CD4+ T cells
Standard Deviation 0.00084004
|
0.0132000 percentage of CD4+ T cells
Standard Deviation 0.00930161
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 30 (Month 1)
|
0.0034686 percentage of CD4+ T cells
Standard Deviation 0.00432300
|
0.0065550 percentage of CD4+ T cells
Standard Deviation 0.00927017
|
0.0021460 percentage of CD4+ T cells
Standard Deviation 0.00082412
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 105
|
0.0015260 percentage of CD4+ T cells
Standard Deviation 0.00124341
|
0.0018300 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0022467 percentage of CD4+ T cells
Standard Deviation 0.00267792
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 120 (Month 4)
|
0.0015054 percentage of CD4+ T cells
Standard Deviation 0.00148462
|
0.0013500 percentage of CD4+ T cells
Standard Deviation 0.00002828
|
0.0000833 percentage of CD4+ T cells
Standard Deviation 0.00014434
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 360 (Month 12)
|
0.0009971 percentage of CD4+ T cells
Standard Deviation 0.00173995
|
0.0000400 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0003185 percentage of CD4+ T cells
Standard Deviation 0.00045043
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 15
|
0.0007662 percentage of CD4+ T cells
Standard Deviation 0.00172488
|
0.0030100 percentage of CD4+ T cells
Standard Deviation 0.00425678
|
0.0029133 percentage of CD4+ T cells
Standard Deviation 0.00493389
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 90 (Month 3)
|
0.0057832 percentage of CD4+ T cells
Standard Deviation 0.02013270
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 105
|
0.0037280 percentage of CD4+ T cells
Standard Deviation 0.00833606
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0063267 percentage of CD4+ T cells
Standard Deviation 0.01095811
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 120 (Month 4)
|
0.0017955 percentage of CD4+ T cells
Standard Deviation 0.00255443
|
0.0041500 percentage of CD4+ T cells
Standard Deviation 0.00586899
|
0.0049800 percentage of CD4+ T cells
Standard Deviation 0.00862561
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 30 (Month 1)
|
0.0059520 percentage of CD4+ T cells
Standard Deviation 0.00996730
|
0.0145000 percentage of CD4+ T cells
Standard Deviation 0.02050610
|
0.0050000 percentage of CD4+ T cells
Standard Deviation 0.00500000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 90 (Month 3)
|
0.0070000 percentage of CD4+ T cells
Standard Deviation 0.01086278
|
0.0060000 percentage of CD4+ T cells
Standard Deviation 0.00848528
|
0.0043333 percentage of CD4+ T cells
Standard Deviation 0.00585947
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
FNg-, IL2+, TNFa-, DENV-1, prME, Day 105
|
0.0046000 percentage of CD4+ T cells
Standard Deviation 0.00638749
|
0.0100000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0040000 percentage of CD4+ T cells
Standard Deviation 0.00608276
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
FNg-, IL2+, TNFa-, DENV-1, prME, Day 120 (Month 4)
|
0.0057273 percentage of CD4+ T cells
Standard Deviation 0.00553337
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0030000 percentage of CD4+ T cells
Standard Deviation 0.00519615
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
FNg-, IL2+, TNFa-, DENV-1, prME, Day 360 (Month 12)
|
0.0095556 percentage of CD4+ T cells
Standard Deviation 0.01255101
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0205000 percentage of CD4+ T cells
Standard Deviation 0.01060660
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 105
|
0.0147960 percentage of CD4+ T cells
Standard Deviation 0.02254635
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0733333 percentage of CD4+ T cells
Standard Deviation 0.11846237
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 120 (Month 4)
|
0.0192727 percentage of CD4+ T cells
Standard Deviation 0.03854372
|
0.0400000 percentage of CD4+ T cells
Standard Deviation 0.05656854
|
0.0580000 percentage of CD4+ T cells
Standard Deviation 0.06009992
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 360 (Month 12)
|
0.0537778 percentage of CD4+ T cells
Standard Deviation 0.07350813
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 30 (Month 1)
|
0.0122825 percentage of CD4+ T cells
Standard Deviation 0.01207005
|
0.0126170 percentage of CD4+ T cells
Standard Deviation 0.00213122
|
0.0140527 percentage of CD4+ T cells
Standard Deviation 0.01124558
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 90 (Month 3)
|
0.0069514 percentage of CD4+ T cells
Standard Deviation 0.00806641
|
0.0024950 percentage of CD4+ T cells
Standard Deviation 0.00133643
|
0.0038167 percentage of CD4+ T cells
Standard Deviation 0.00109573
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 105
|
0.0085950 percentage of CD4+ T cells
Standard Deviation 0.00881973
|
0.0080000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0026967 percentage of CD4+ T cells
Standard Deviation 0.00223813
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 120 (Month 4)
|
0.0114250 percentage of CD4+ T cells
Standard Deviation 0.00754569
|
0.0070200 percentage of CD4+ T cells
Standard Deviation 0.00021213
|
0.0055467 percentage of CD4+ T cells
Standard Deviation 0.00026764
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 360 (Month 12)
|
0.0113109 percentage of CD4+ T cells
Standard Deviation 0.00863169
|
0.0013000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0020875 percentage of CD4+ T cells
Standard Deviation 0.00290267
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 15
|
0.0055626 percentage of CD4+ T cells
Standard Deviation 0.00618103
|
0.0069450 percentage of CD4+ T cells
Standard Deviation 0.00426385
|
0.0016633 percentage of CD4+ T cells
Standard Deviation 0.00144057
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
|
0.0037906 percentage of CD4+ T cells
Standard Deviation 0.00471970
|
0.0058220 percentage of CD4+ T cells
Standard Deviation 0.00022910
|
0.0065793 percentage of CD4+ T cells
Standard Deviation 0.00473908
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 105
|
0.0011180 percentage of CD4+ T cells
Standard Deviation 0.00155249
|
0.0029100 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0021767 percentage of CD4+ T cells
Standard Deviation 0.00293742
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
|
0.0018340 percentage of CD4+ T cells
Standard Deviation 0.00213001
|
0.0006150 percentage of CD4+ T cells
Standard Deviation 0.00086974
|
0.0039667 percentage of CD4+ T cells
Standard Deviation 0.00308171
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
|
0.0016511 percentage of CD4+ T cells
Standard Deviation 0.00156732
|
0.0012900 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0032340 percentage of CD4+ T cells
Standard Deviation 0.00314804
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 30 (Month 1)
|
0.0129087 percentage of CD4+ T cells
Standard Deviation 0.01001686
|
0.0339320 percentage of CD4+ T cells
Standard Deviation 0.03984971
|
0.0194627 percentage of CD4+ T cells
Standard Deviation 0.01535958
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 90 (Month 3)
|
0.0074276 percentage of CD4+ T cells
Standard Deviation 0.00487590
|
0.0110000 percentage of CD4+ T cells
Standard Deviation 0.01555635
|
0.0150933 percentage of CD4+ T cells
Standard Deviation 0.00694661
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 105
|
0.0066833 percentage of CD4+ T cells
Standard Deviation 0.00676771
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0109133 percentage of CD4+ T cells
Standard Deviation 0.00335871
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 120 (Month 4)
|
0.0061417 percentage of CD4+ T cells
Standard Deviation 0.00294097
|
0.0113650 percentage of CD4+ T cells
Standard Deviation 0.01014698
|
0.0142633 percentage of CD4+ T cells
Standard Deviation 0.00845533
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 360 (Month 12)
|
0.0051673 percentage of CD4+ T cells
Standard Deviation 0.00437134
|
0.0000200 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0063440 percentage of CD4+ T cells
Standard Deviation 0.00014991
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 15
|
0.0122905 percentage of CD4+ T cells
Standard Deviation 0.01136975
|
0.0166300 percentage of CD4+ T cells
Standard Deviation 0.01466539
|
0.0158833 percentage of CD4+ T cells
Standard Deviation 0.01526418
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 30 (Month 1)
|
0.0086183 percentage of CD4+ T cells
Standard Deviation 0.00744631
|
0.0184670 percentage of CD4+ T cells
Standard Deviation 0.02212254
|
0.0049393 percentage of CD4+ T cells
Standard Deviation 0.00441403
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 90 (Month 3)
|
0.0049071 percentage of CD4+ T cells
Standard Deviation 0.00312169
|
0.0030300 percentage of CD4+ T cells
Standard Deviation 0.00428507
|
0.0027600 percentage of CD4+ T cells
Standard Deviation 0.00079265
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 105
|
0.0013000 percentage of CD4+ T cells
Standard Deviation 0.00209346
|
0.0028600 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0003333 percentage of CD4+ T cells
Standard Deviation 0.00057735
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 120 (Month 4)
|
0.0017842 percentage of CD4+ T cells
Standard Deviation 0.00228371
|
0.0049750 percentage of CD4+ T cells
Standard Deviation 0.00504167
|
0.0037833 percentage of CD4+ T cells
Standard Deviation 0.00366041
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 360 (Month 12)
|
0.0029951 percentage of CD4+ T cells
Standard Deviation 0.00407349
|
0.0000500 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0012250 percentage of CD4+ T cells
Standard Deviation 0.00173241
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, C, Day 30 (Month 1)
|
0.0253419 percentage of CD4+ T cells
Standard Deviation 0.03739564
|
0.0681170 percentage of CD4+ T cells
Standard Deviation 0.01978909
|
0.0055893 percentage of CD4+ T cells
Standard Deviation 0.00486565
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, C, Day 90 (Month 3)
|
0.0180388 percentage of CD4+ T cells
Standard Deviation 0.01628354
|
0.0261400 percentage of CD4+ T cells
Standard Deviation 0.01677257
|
0.0015433 percentage of CD4+ T cells
Standard Deviation 0.00167828
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, C, Day 105
|
0.0155460 percentage of CD4+ T cells
Standard Deviation 0.00736598
|
0.0304700 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0010267 percentage of CD4+ T cells
Standard Deviation 0.00177824
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, C, Day 120 (Month 4)
|
0.0255438 percentage of CD4+ T cells
Standard Deviation 0.02222056
|
0.0345400 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0046400 percentage of CD4+ T cells
Standard Deviation 0.00643170
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, C, Day 360 (Month 12)
|
0.0188425 percentage of CD4+ T cells
Standard Deviation 0.01749239
|
0.0208000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0046440 percentage of CD4+ T cells
Standard Deviation 0.00532593
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 15
|
0.0022795 percentage of CD4+ T cells
Standard Deviation 0.00242556
|
0.0097000 percentage of CD4+ T cells
Standard Deviation 0.00608112
|
0.0175233 percentage of CD4+ T cells
Standard Deviation 0.01552713
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 30 (Month 1)
|
0.0077111 percentage of CD4+ T cells
Standard Deviation 0.00670335
|
0.0215985 percentage of CD4+ T cells
Standard Deviation 0.03042186
|
0.0106660 percentage of CD4+ T cells
Standard Deviation 0.00795335
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 90 (Month 3)
|
0.0043389 percentage of CD4+ T cells
Standard Deviation 0.00329533
|
0.0075000 percentage of CD4+ T cells
Standard Deviation 0.01060660
|
0.0064033 percentage of CD4+ T cells
Standard Deviation 0.00380907
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 105
|
0.0026940 percentage of CD4+ T cells
Standard Deviation 0.00293657
|
0.0036000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0074700 percentage of CD4+ T cells
Standard Deviation 0.00868520
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 120 (Month 4)
|
0.0034200 percentage of CD4+ T cells
Standard Deviation 0.00296355
|
0.0049350 percentage of CD4+ T cells
Standard Deviation 0.00509824
|
0.0060967 percentage of CD4+ T cells
Standard Deviation 0.00653743
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 360 (Month 12)
|
0.0043200 percentage of CD4+ T cells
Standard Deviation 0.00603465
|
0.0000300 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0012700 percentage of CD4+ T cells
Standard Deviation 0.00179605
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 15
|
0.0066462 percentage of CD4+ T cells
Standard Deviation 0.00792826
|
0.0084785 percentage of CD4+ T cells
Standard Deviation 0.01063701
|
0.0032200 percentage of CD4+ T cells
Standard Deviation 0.00404490
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 30 (Month 1)
|
0.0088740 percentage of CD4+ T cells
Standard Deviation 0.01159933
|
0.0041720 percentage of CD4+ T cells
Standard Deviation 0.00065337
|
0.0030600 percentage of CD4+ T cells
Standard Deviation 0.00204404
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 90 (Month 3)
|
0.0033060 percentage of CD4+ T cells
Standard Deviation 0.00441884
|
0.0017200 percentage of CD4+ T cells
Standard Deviation 0.00243245
|
0.0007633 percentage of CD4+ T cells
Standard Deviation 0.00085043
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 105
|
0.0079900 percentage of CD4+ T cells
Standard Deviation 0.01211394
|
0.0000390 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0043500 percentage of CD4+ T cells
Standard Deviation 0.00284628
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 120 (Month 4)
|
0.0053583 percentage of CD4+ T cells
Standard Deviation 0.00565641
|
0.0013750 percentage of CD4+ T cells
Standard Deviation 0.00194454
|
0.0026010 percentage of CD4+ T cells
Standard Deviation 0.00178568
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 360 (Month 12)
|
0.0030009 percentage of CD4+ T cells
Standard Deviation 0.00444490
|
0.0025000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0008885 percentage of CD4+ T cells
Standard Deviation 0.00125653
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 15
|
0.0015118 percentage of CD4+ T cells
Standard Deviation 0.00191718
|
0.0015700 percentage of CD4+ T cells
Standard Deviation 0.00222032
|
0.0004667 percentage of CD4+ T cells
Standard Deviation 0.00080829
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 30 (Month 1)
|
0.0021769 percentage of CD4+ T cells
Standard Deviation 0.00268205
|
0.0047200 percentage of CD4+ T cells
Standard Deviation 0.00667509
|
0.0005833 percentage of CD4+ T cells
Standard Deviation 0.00101036
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 105
|
0.0016500 percentage of CD4+ T cells
Standard Deviation 0.00232157
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0005400 percentage of CD4+ T cells
Standard Deviation 0.00093531
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 120 (Month 4)
|
0.0006177 percentage of CD4+ T cells
Standard Deviation 0.00102890
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0008543 percentage of CD4+ T cells
Standard Deviation 0.00093306
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 30 (Month 1)
|
0.0099232 percentage of CD4+ T cells
Standard Deviation 0.01006738
|
0.0043520 percentage of CD4+ T cells
Standard Deviation 0.00203364
|
0.0085767 percentage of CD4+ T cells
Standard Deviation 0.00753694
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 90 (Month 3)
|
0.0041648 percentage of CD4+ T cells
Standard Deviation 0.00370931
|
0.0016750 percentage of CD4+ T cells
Standard Deviation 0.00013435
|
0.0016000 percentage of CD4+ T cells
Standard Deviation 0.00277128
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 105
|
0.0062433 percentage of CD4+ T cells
Standard Deviation 0.00940730
|
0.0005200 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0040567 percentage of CD4+ T cells
Standard Deviation 0.00418584
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 120 (Month 4)
|
0.0036216 percentage of CD4+ T cells
Standard Deviation 0.00439516
|
0.0012550 percentage of CD4+ T cells
Standard Deviation 0.00177484
|
0.0052677 percentage of CD4+ T cells
Standard Deviation 0.00341188
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 360 (Month 12)
|
0.0016830 percentage of CD4+ T cells
Standard Deviation 0.00264616
|
0.0012200 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0016115 percentage of CD4+ T cells
Standard Deviation 0.00102601
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, C, Day 30 (Month 1)
|
0.0136346 percentage of CD4+ T cells
Standard Deviation 0.01827227
|
0.0124520 percentage of CD4+ T cells
Standard Deviation 0.00519299
|
0.0025633 percentage of CD4+ T cells
Standard Deviation 0.00102627
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 15
|
0.0039528 percentage of CD4+ T cells
Standard Deviation 0.00428498
|
0.0011750 percentage of CD4+ T cells
Standard Deviation 0.00166170
|
0.0062000 percentage of CD4+ T cells
Standard Deviation 0.00507572
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 30 (Month 1)
|
0.0043484 percentage of CD4+ T cells
Standard Deviation 0.00418555
|
0.0027520 percentage of CD4+ T cells
Standard Deviation 0.00121340
|
0.0020900 percentage of CD4+ T cells
Standard Deviation 0.00092677
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 90 (Month 3)
|
0.0019436 percentage of CD4+ T cells
Standard Deviation 0.00233770
|
0.0007700 percentage of CD4+ T cells
Standard Deviation 0.00108894
|
0.0001920 percentage of CD4+ T cells
Standard Deviation 0.00033255
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 105
|
0.0012450 percentage of CD4+ T cells
Standard Deviation 0.00195501
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 120 (Month 4)
|
0.0014041 percentage of CD4+ T cells
Standard Deviation 0.00169202
|
0.0014300 percentage of CD4+ T cells
Standard Deviation 0.00202233
|
0.0001777 percentage of CD4+ T cells
Standard Deviation 0.00030773
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 360 (Month 12)
|
0.0009221 percentage of CD4+ T cells
Standard Deviation 0.00118263
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0003085 percentage of CD4+ T cells
Standard Deviation 0.00043628
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, C, Day 15
|
0.0063457 percentage of CD4+ T cells
Standard Deviation 0.00739280
|
0.0276900 percentage of CD4+ T cells
Standard Deviation 0.03013689
|
0.0023867 percentage of CD4+ T cells
Standard Deviation 0.00266356
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, C, Day 90 (Month 3)
|
0.0102555 percentage of CD4+ T cells
Standard Deviation 0.00890732
|
0.0107550 percentage of CD4+ T cells
Standard Deviation 0.00034648
|
0.0009733 percentage of CD4+ T cells
Standard Deviation 0.00168586
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, C, Day 105
|
0.0086980 percentage of CD4+ T cells
Standard Deviation 0.00422567
|
0.0081900 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0015767 percentage of CD4+ T cells
Standard Deviation 0.00273087
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, C, Day 120 (Month 4)
|
0.0096186 percentage of CD4+ T cells
Standard Deviation 0.00919641
|
0.0014200 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0006143 percentage of CD4+ T cells
Standard Deviation 0.00065878
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, C, Day 360 (Month 12)
|
0.0051619 percentage of CD4+ T cells
Standard Deviation 0.00721208
|
0.0130000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0013275 percentage of CD4+ T cells
Standard Deviation 0.00066397
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 15
|
0.0012506 percentage of CD4+ T cells
Standard Deviation 0.00145149
|
0.0034600 percentage of CD4+ T cells
Standard Deviation 0.00052326
|
0.0049867 percentage of CD4+ T cells
Standard Deviation 0.00557140
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 30 (Month 1)
|
0.0041405 percentage of CD4+ T cells
Standard Deviation 0.00370046
|
0.0030320 percentage of CD4+ T cells
Standard Deviation 0.00143967
|
0.0044700 percentage of CD4+ T cells
Standard Deviation 0.00201167
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 90 (Month 3)
|
0.0023277 percentage of CD4+ T cells
Standard Deviation 0.00290426
|
0.0029050 percentage of CD4+ T cells
Standard Deviation 0.00410829
|
0.0034137 percentage of CD4+ T cells
Standard Deviation 0.00278951
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 105
|
0.0025060 percentage of CD4+ T cells
Standard Deviation 0.00269757
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0020167 percentage of CD4+ T cells
Standard Deviation 0.00116453
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 120 (Month 4)
|
0.0019454 percentage of CD4+ T cells
Standard Deviation 0.00182333
|
0.0014450 percentage of CD4+ T cells
Standard Deviation 0.00204354
|
0.0012343 percentage of CD4+ T cells
Standard Deviation 0.00133427
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 360 (Month 12)
|
0.0007733 percentage of CD4+ T cells
Standard Deviation 0.00127164
|
0.0012300 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0004275 percentage of CD4+ T cells
Standard Deviation 0.00058336
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 15
|
0.0060766 percentage of CD4+ T cells
Standard Deviation 0.00449815
|
0.0428850 percentage of CD4+ T cells
Standard Deviation 0.01611496
|
0.0240633 percentage of CD4+ T cells
Standard Deviation 0.03025849
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 30 (Month 1)
|
0.0037728 percentage of CD4+ T cells
Standard Deviation 0.00410557
|
0.0185620 percentage of CD4+ T cells
Standard Deviation 0.01051892
|
0.0079800 percentage of CD4+ T cells
Standard Deviation 0.00575490
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 90 (Month 3)
|
0.0015660 percentage of CD4+ T cells
Standard Deviation 0.00222761
|
0.0032600 percentage of CD4+ T cells
Standard Deviation 0.00217789
|
0.0057033 percentage of CD4+ T cells
Standard Deviation 0.00286514
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 105
|
0.0043250 percentage of CD4+ T cells
Standard Deviation 0.00738836
|
0.0045900 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0056000 percentage of CD4+ T cells
Standard Deviation 0.00592666
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 120 (Month 4)
|
0.0046358 percentage of CD4+ T cells
Standard Deviation 0.00481391
|
0.0035500 percentage of CD4+ T cells
Standard Deviation 0.00308299
|
0.0027843 percentage of CD4+ T cells
Standard Deviation 0.00263947
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 360 (Month 12)
|
0.0039912 percentage of CD4+ T cells
Standard Deviation 0.00426930
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0016035 percentage of CD4+ T cells
Standard Deviation 0.00145169
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 15
|
0.0020367 percentage of CD4+ T cells
Standard Deviation 0.00200211
|
0.0119550 percentage of CD4+ T cells
Standard Deviation 0.01460176
|
0.0034600 percentage of CD4+ T cells
Standard Deviation 0.00072547
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
|
0.0009933 percentage of CD4+ T cells
Standard Deviation 0.00141721
|
0.0047720 percentage of CD4+ T cells
Standard Deviation 0.00660155
|
0.0009560 percentage of CD4+ T cells
Standard Deviation 0.00076228
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
|
0.0005400 percentage of CD4+ T cells
Standard Deviation 0.00102516
|
0.0018050 percentage of CD4+ T cells
Standard Deviation 0.00255266
|
0.0002240 percentage of CD4+ T cells
Standard Deviation 0.00038798
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 105
|
0.0026620 percentage of CD4+ T cells
Standard Deviation 0.00525083
|
0.0000430 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0018267 percentage of CD4+ T cells
Standard Deviation 0.00165908
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
|
0.0005960 percentage of CD4+ T cells
Standard Deviation 0.00082714
|
0.0006150 percentage of CD4+ T cells
Standard Deviation 0.00086974
|
0.0015343 percentage of CD4+ T cells
Standard Deviation 0.00028065
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 15
|
0.0090109 percentage of CD4+ T cells
Standard Deviation 0.00856650
|
0.0543850 percentage of CD4+ T cells
Standard Deviation 0.05359162
|
0.0473333 percentage of CD4+ T cells
Standard Deviation 0.03165965
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 30 (Month 1)
|
0.0064879 percentage of CD4+ T cells
Standard Deviation 0.00601416
|
0.0269820 percentage of CD4+ T cells
Standard Deviation 0.03538079
|
0.0190567 percentage of CD4+ T cells
Standard Deviation 0.01080034
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 90 (Month 3)
|
0.0026280 percentage of CD4+ T cells
Standard Deviation 0.00337824
|
0.0067600 percentage of CD4+ T cells
Standard Deviation 0.00956008
|
0.0078667 percentage of CD4+ T cells
Standard Deviation 0.00525903
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 105
|
0.0031033 percentage of CD4+ T cells
Standard Deviation 0.00107483
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0076500 percentage of CD4+ T cells
Standard Deviation 0.00526430
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 120 (Month 4)
|
0.0028733 percentage of CD4+ T cells
Standard Deviation 0.00244337
|
0.0062700 percentage of CD4+ T cells
Standard Deviation 0.00886712
|
0.0048743 percentage of CD4+ T cells
Standard Deviation 0.00332532
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 360 (Month 12)
|
0.0019966 percentage of CD4+ T cells
Standard Deviation 0.00189583
|
0.0000200 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0022035 percentage of CD4+ T cells
Standard Deviation 0.00064559
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 15
|
0.0063809 percentage of CD4+ T cells
Standard Deviation 0.00759632
|
0.0236700 percentage of CD4+ T cells
Standard Deviation 0.03338958
|
0.0097900 percentage of CD4+ T cells
Standard Deviation 0.01084422
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 30 (Month 1)
|
0.0031547 percentage of CD4+ T cells
Standard Deviation 0.00278886
|
0.0170245 percentage of CD4+ T cells
Standard Deviation 0.02400698
|
0.0018733 percentage of CD4+ T cells
Standard Deviation 0.00038760
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 90 (Month 3)
|
0.0013470 percentage of CD4+ T cells
Standard Deviation 0.00190419
|
0.0007900 percentage of CD4+ T cells
Standard Deviation 0.00111723
|
0.0001920 percentage of CD4+ T cells
Standard Deviation 0.00033255
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 105
|
0.0014450 percentage of CD4+ T cells
Standard Deviation 0.00172311
|
0.0017300 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0013200 percentage of CD4+ T cells
Standard Deviation 0.00117235
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 120 (Month 4)
|
0.0009200 percentage of CD4+ T cells
Standard Deviation 0.00124907
|
0.0062700 percentage of CD4+ T cells
Standard Deviation 0.00886712
|
0.0031343 percentage of CD4+ T cells
Standard Deviation 0.00307798
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 360 (Month 12)
|
0.0032012 percentage of CD4+ T cells
Standard Deviation 0.00384132
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0003085 percentage of CD4+ T cells
Standard Deviation 0.00043628
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, C, Day 15
|
0.0043954 percentage of CD4+ T cells
Standard Deviation 0.00510405
|
0.0878850 percentage of CD4+ T cells
Standard Deviation 0.01328654
|
0.0024367 percentage of CD4+ T cells
Standard Deviation 0.00211519
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, C, Day 30 (Month 1)
|
0.0079454 percentage of CD4+ T cells
Standard Deviation 0.00902785
|
0.0505620 percentage of CD4+ T cells
Standard Deviation 0.00486207
|
0.0035200 percentage of CD4+ T cells
Standard Deviation 0.00305210
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, C, Day 105
|
0.0114020 percentage of CD4+ T cells
Standard Deviation 0.01790945
|
0.0284700 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0016133 percentage of CD4+ T cells
Standard Deviation 0.00163026
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, C, Day 120 (Month 4)
|
0.0070050 percentage of CD4+ T cells
Standard Deviation 0.00365273
|
0.0165400 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0032910 percentage of CD4+ T cells
Standard Deviation 0.00127837
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, C, Day 360 (Month 12)
|
0.0065866 percentage of CD4+ T cells
Standard Deviation 0.00631099
|
0.0188000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0022325 percentage of CD4+ T cells
Standard Deviation 0.00194384
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 15
|
0.0024265 percentage of CD4+ T cells
Standard Deviation 0.00372846
|
0.0270400 percentage of CD4+ T cells
Standard Deviation 0.03710896
|
0.0520867 percentage of CD4+ T cells
Standard Deviation 0.05471529
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 30 (Month 1)
|
0.0045850 percentage of CD4+ T cells
Standard Deviation 0.00682112
|
0.0245000 percentage of CD4+ T cells
Standard Deviation 0.03464823
|
0.0250400 percentage of CD4+ T cells
Standard Deviation 0.03055440
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 90 (Month 3)
|
0.0015112 percentage of CD4+ T cells
Standard Deviation 0.00306508
|
0.0077600 percentage of CD4+ T cells
Standard Deviation 0.01097430
|
0.0107867 percentage of CD4+ T cells
Standard Deviation 0.01190998
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 105
|
0.0011860 percentage of CD4+ T cells
Standard Deviation 0.00163110
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0098533 percentage of CD4+ T cells
Standard Deviation 0.00613096
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 15
|
0.0075520 percentage of CD4+ T cells
Standard Deviation 0.00844484
|
0.0330950 percentage of CD4+ T cells
Standard Deviation 0.02107885
|
0.0096033 percentage of CD4+ T cells
Standard Deviation 0.00523661
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 30 (Month 1)
|
0.0080525 percentage of CD4+ T cells
Standard Deviation 0.01055229
|
0.0055700 percentage of CD4+ T cells
Standard Deviation 0.00255973
|
0.0057660 percentage of CD4+ T cells
Standard Deviation 0.00370940
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 90 (Month 3)
|
0.0034662 percentage of CD4+ T cells
Standard Deviation 0.00388476
|
0.0030950 percentage of CD4+ T cells
Standard Deviation 0.00437699
|
0.0020620 percentage of CD4+ T cells
Standard Deviation 0.00178653
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, C, Day 105
|
0.0086560 percentage of CD4+ T cells
Standard Deviation 0.01075630
|
0.0087000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0010400 percentage of CD4+ T cells
Standard Deviation 0.00180133
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 105
|
0.0063400 percentage of CD4+ T cells
Standard Deviation 0.00932154
|
0.0017500 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0036733 percentage of CD4+ T cells
Standard Deviation 0.00290569
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 120 (Month 4)
|
0.0051208 percentage of CD4+ T cells
Standard Deviation 0.00397179
|
0.0021100 percentage of CD4+ T cells
Standard Deviation 0.00104652
|
0.0010100 percentage of CD4+ T cells
Standard Deviation 0.00156272
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 360 (Month 12)
|
0.0024600 percentage of CD4+ T cells
Standard Deviation 0.00277472
|
0.0013000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0029585 percentage of CD4+ T cells
Standard Deviation 0.00170908
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 15
|
0.0020206 percentage of CD4+ T cells
Standard Deviation 0.00260390
|
0.0042250 percentage of CD4+ T cells
Standard Deviation 0.00290621
|
0.0026533 percentage of CD4+ T cells
Standard Deviation 0.00089891
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 30 (Month 1)
|
0.0020286 percentage of CD4+ T cells
Standard Deviation 0.00206735
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0014793 percentage of CD4+ T cells
Standard Deviation 0.00041333
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 90 (Month 3)
|
0.0009626 percentage of CD4+ T cells
Standard Deviation 0.00123421
|
0.0016200 percentage of CD4+ T cells
Standard Deviation 0.00229103
|
0.0013687 percentage of CD4+ T cells
Standard Deviation 0.00170601
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 120 (Month 4)
|
0.0131667 percentage of CD4+ T cells
Standard Deviation 0.01259750
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0056667 percentage of CD4+ T cells
Standard Deviation 0.00550757
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 360 (Month 12)
|
0.0045455 percentage of CD4+ T cells
Standard Deviation 0.00706206
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0025000 percentage of CD4+ T cells
Standard Deviation 0.00353553
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 15
|
0.0027368 percentage of CD4+ T cells
Standard Deviation 0.00646222
|
0.0005000 percentage of CD4+ T cells
Standard Deviation 0.00070711
|
0.0032367 percentage of CD4+ T cells
Standard Deviation 0.00302788
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 30 (Month 1)
|
0.0042653 percentage of CD4+ T cells
Standard Deviation 0.00817199
|
0.0190000 percentage of CD4+ T cells
Standard Deviation 0.02687006
|
0.0066667 percentage of CD4+ T cells
Standard Deviation 0.01154701
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 90 (Month 3)
|
0.0054286 percentage of CD4+ T cells
Standard Deviation 0.00796600
|
0.0035000 percentage of CD4+ T cells
Standard Deviation 0.00494975
|
0.0043333 percentage of CD4+ T cells
Standard Deviation 0.00585947
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 360 (Month 12)
|
0.0115556 percentage of CD4+ T cells
Standard Deviation 0.01326755
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0340000 percentage of CD4+ T cells
Standard Deviation 0.02404163
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 15
|
0.0019248 percentage of CD4+ T cells
Standard Deviation 0.00358174
|
0.0030000 percentage of CD4+ T cells
Standard Deviation 0.00424264
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 30 (Month 1)
|
0.0051448 percentage of CD4+ T cells
Standard Deviation 0.00695615
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0130000 percentage of CD4+ T cells
Standard Deviation 0.00556776
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 105
|
0.0021667 percentage of CD4+ T cells
Standard Deviation 0.00325064
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0016667 percentage of CD4+ T cells
Standard Deviation 0.00288675
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 120 (Month 4)
|
0.0079167 percentage of CD4+ T cells
Standard Deviation 0.00674818
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0116667 percentage of CD4+ T cells
Standard Deviation 0.01386843
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 360 (Month 12)
|
0.0058182 percentage of CD4+ T cells
Standard Deviation 0.00726386
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0040000 percentage of CD4+ T cells
Standard Deviation 0.00565685
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 15
|
0.0029248 percentage of CD4+ T cells
Standard Deviation 0.00608645
|
0.0030000 percentage of CD4+ T cells
Standard Deviation 0.00424264
|
0.0082367 percentage of CD4+ T cells
Standard Deviation 0.01120795
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 30 (Month 1)
|
0.0050019 percentage of CD4+ T cells
Standard Deviation 0.00532053
|
0.0015000 percentage of CD4+ T cells
Standard Deviation 0.00212132
|
0.0030000 percentage of CD4+ T cells
Standard Deviation 0.00300000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 90 (Month 3)
|
0.0040476 percentage of CD4+ T cells
Standard Deviation 0.00569628
|
0.0080000 percentage of CD4+ T cells
Standard Deviation 0.01131371
|
0.0063333 percentage of CD4+ T cells
Standard Deviation 0.00709460
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 105
|
0.0020000 percentage of CD4+ T cells
Standard Deviation 0.00400000
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0010000 percentage of CD4+ T cells
Standard Deviation 0.00173205
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 120 (Month 4)
|
0.0040000 percentage of CD4+ T cells
Standard Deviation 0.00645262
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0003333 percentage of CD4+ T cells
Standard Deviation 0.00057735
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 15
|
0.0064286 percentage of CD4+ T cells
Standard Deviation 0.01567345
|
0.0300000 percentage of CD4+ T cells
Standard Deviation 0.04242641
|
0.0476667 percentage of CD4+ T cells
Standard Deviation 0.06368935
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 360 (Month 12)
|
0.0063636 percentage of CD4+ T cells
Standard Deviation 0.00868646
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0155000 percentage of CD4+ T cells
Standard Deviation 0.02192031
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 90 (Month 3)
|
0.0009037 percentage of CD4+ T cells
Standard Deviation 0.00153323
|
0.0057600 percentage of CD4+ T cells
Standard Deviation 0.00814587
|
0.0140600 percentage of CD4+ T cells
Standard Deviation 0.01672199
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, C, Day 15
|
0.0033889 percentage of CD4+ T cells
Standard Deviation 0.00726101
|
0.0010000 percentage of CD4+ T cells
Standard Deviation 0.00141421
|
0.0140067 percentage of CD4+ T cells
Standard Deviation 0.02424294
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, C, Day 30 (Month 1)
|
0.0105906 percentage of CD4+ T cells
Standard Deviation 0.01290502
|
0.0075000 percentage of CD4+ T cells
Standard Deviation 0.01060660
|
0.0056667 percentage of CD4+ T cells
Standard Deviation 0.00513160
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, C, Day 90 (Month 3)
|
0.0081765 percentage of CD4+ T cells
Standard Deviation 0.01052518
|
0.0225000 percentage of CD4+ T cells
Standard Deviation 0.00494975
|
0.0100000 percentage of CD4+ T cells
Standard Deviation 0.00916515
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 105
|
0.0024900 percentage of CD4+ T cells
Standard Deviation 0.00217522
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0164733 percentage of CD4+ T cells
Standard Deviation 0.01680245
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, C, Day 105
|
0.0106000 percentage of CD4+ T cells
Standard Deviation 0.01436315
|
0.0270000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0026667 percentage of CD4+ T cells
Standard Deviation 0.00461880
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, C, Day 120 (Month 4)
|
0.0138750 percentage of CD4+ T cells
Standard Deviation 0.01167950
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0116667 percentage of CD4+ T cells
Standard Deviation 0.00776745
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 120 (Month 4)
|
0.0007918 percentage of CD4+ T cells
Standard Deviation 0.00151918
|
0.0057700 percentage of CD4+ T cells
Standard Deviation 0.00816001
|
0.0145877 percentage of CD4+ T cells
Standard Deviation 0.01618069
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, C, Day 360 (Month 12)
|
0.0388750 percentage of CD4+ T cells
Standard Deviation 0.04258584
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0360000 percentage of CD4+ T cells
Standard Deviation 0.01272792
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 15
|
0.0018571 percentage of CD4+ T cells
Standard Deviation 0.00381164
|
0.0005000 percentage of CD4+ T cells
Standard Deviation 0.00070711
|
0.0094100 percentage of CD4+ T cells
Standard Deviation 0.01524580
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 90 (Month 3)
|
0.0032105 percentage of CD4+ T cells
Standard Deviation 0.00491685
|
0.0060000 percentage of CD4+ T cells
Standard Deviation 0.00141421
|
0.0070000 percentage of CD4+ T cells
Standard Deviation 0.01212436
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 30 (Month 1)
|
0.0100520 percentage of CD4+ T cells
Standard Deviation 0.00984572
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0060000 percentage of CD4+ T cells
Standard Deviation 0.00519615
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 90 (Month 3)
|
0.0052105 percentage of CD4+ T cells
Standard Deviation 0.00611536
|
0.0050000 percentage of CD4+ T cells
Standard Deviation 0.00707107
|
0.0113333 percentage of CD4+ T cells
Standard Deviation 0.01962991
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 105
|
0.0048000 percentage of CD4+ T cells
Standard Deviation 0.00672309
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0010000 percentage of CD4+ T cells
Standard Deviation 0.00173205
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 120 (Month 4)
|
0.0063636 percentage of CD4+ T cells
Standard Deviation 0.00569689
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0026667 percentage of CD4+ T cells
Standard Deviation 0.00461880
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 360 (Month 12)
|
0.0035556 percentage of CD4+ T cells
Standard Deviation 0.00538774
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0595000 percentage of CD4+ T cells
Standard Deviation 0.01343503
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 15
|
0.0007143 percentage of CD4+ T cells
Standard Deviation 0.00327327
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0210000 percentage of CD4+ T cells
Standard Deviation 0.03637307
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 30 (Month 1)
|
0.0033810 percentage of CD4+ T cells
Standard Deviation 0.00696043
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0233333 percentage of CD4+ T cells
Standard Deviation 0.04041452
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 90 (Month 3)
|
0.0038586 percentage of CD4+ T cells
Standard Deviation 0.01248055
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0100000 percentage of CD4+ T cells
Standard Deviation 0.01732051
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 105
|
0.0009967 percentage of CD4+ T cells
Standard Deviation 0.00199200
|
0.0200000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0133333 percentage of CD4+ T cells
Standard Deviation 0.02309401
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 120 (Month 4)
|
0.0070000 percentage of CD4+ T cells
Standard Deviation 0.01205291
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0053333 percentage of CD4+ T cells
Standard Deviation 0.00923760
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 360 (Month 12)
|
0.0233636 percentage of CD4+ T cells
Standard Deviation 0.04872838
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0050000 percentage of CD4+ T cells
Standard Deviation 0.00707107
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 15
|
0.0330526 percentage of CD4+ T cells
Standard Deviation 0.05651693
|
0.0450000 percentage of CD4+ T cells
Standard Deviation 0.06363961
|
0.0976667 percentage of CD4+ T cells
Standard Deviation 0.05173329
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
|
0.0089474 percentage of CD4+ T cells
Standard Deviation 0.01355021
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.1373333 percentage of CD4+ T cells
Standard Deviation 0.08247020
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, C, Day 90 (Month 3)
|
0.0074104 percentage of CD4+ T cells
Standard Deviation 0.00838499
|
0.0197800 percentage of CD4+ T cells
Standard Deviation 0.01241680
|
0.0011100 percentage of CD4+ T cells
Standard Deviation 0.00192258
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
|
0.0102239 percentage of CD4+ T cells
Standard Deviation 0.02008526
|
0.0600000 percentage of CD4+ T cells
Standard Deviation 0.08485281
|
0.0596667 percentage of CD4+ T cells
Standard Deviation 0.06961561
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 105
|
0.0501960 percentage of CD4+ T cells
Standard Deviation 0.10057640
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.1293333 percentage of CD4+ T cells
Standard Deviation 0.19110556
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
|
0.0088000 percentage of CD4+ T cells
Standard Deviation 0.01360392
|
0.0050000 percentage of CD4+ T cells
Standard Deviation 0.00707107
|
0.0413333 percentage of CD4+ T cells
Standard Deviation 0.04006661
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
|
0.0466667 percentage of CD4+ T cells
Standard Deviation 0.05889822
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0050000 percentage of CD4+ T cells
Standard Deviation 0.00707107
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 15
|
0.0020952 percentage of CD4+ T cells
Standard Deviation 0.00545807
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0176667 percentage of CD4+ T cells
Standard Deviation 0.01078579
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 30 (Month 1)
|
0.0015714 percentage of CD4+ T cells
Standard Deviation 0.00413003
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0500000 percentage of CD4+ T cells
Standard Deviation 0.07000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 90 (Month 3)
|
0.0060967 percentage of CD4+ T cells
Standard Deviation 0.01538351
|
0.0050000 percentage of CD4+ T cells
Standard Deviation 0.00707107
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 105
|
0.0031633 percentage of CD4+ T cells
Standard Deviation 0.00681587
|
0.0400000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0466667 percentage of CD4+ T cells
Standard Deviation 0.07234178
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 120 (Month 4)
|
0.0064167 percentage of CD4+ T cells
Standard Deviation 0.01195034
|
0.0200000 percentage of CD4+ T cells
Standard Deviation 0.02828427
|
0.0020000 percentage of CD4+ T cells
Standard Deviation 0.00346410
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 105
|
0.0003300 percentage of CD4+ T cells
Standard Deviation 0.00056303
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0005433 percentage of CD4+ T cells
Standard Deviation 0.00094108
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 120 (Month 4)
|
0.0004290 percentage of CD4+ T cells
Standard Deviation 0.00077370
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0004800 percentage of CD4+ T cells
Standard Deviation 0.00083138
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 360 (Month 12)
|
0.0009997 percentage of CD4+ T cells
Standard Deviation 0.00125950
|
0.0000400 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0003635 percentage of CD4+ T cells
Standard Deviation 0.00051407
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 15
|
0.0101574 percentage of CD4+ T cells
Standard Deviation 0.01135027
|
0.0455950 percentage of CD4+ T cells
Standard Deviation 0.00084146
|
0.0346667 percentage of CD4+ T cells
Standard Deviation 0.01833939
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 30 (Month 1)
|
0.0079673 percentage of CD4+ T cells
Standard Deviation 0.00830325
|
0.0056000 percentage of CD4+ T cells
Standard Deviation 0.00637810
|
0.0117927 percentage of CD4+ T cells
Standard Deviation 0.00809815
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 90 (Month 3)
|
0.0039573 percentage of CD4+ T cells
Standard Deviation 0.00329832
|
0.0031250 percentage of CD4+ T cells
Standard Deviation 0.00427800
|
0.0057620 percentage of CD4+ T cells
Standard Deviation 0.00888965
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 105
|
0.0045767 percentage of CD4+ T cells
Standard Deviation 0.00294576
|
0.0005200 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0025567 percentage of CD4+ T cells
Standard Deviation 0.00157912
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 120 (Month 4)
|
0.0035933 percentage of CD4+ T cells
Standard Deviation 0.00301672
|
0.0031800 percentage of CD4+ T cells
Standard Deviation 0.00055154
|
0.0034733 percentage of CD4+ T cells
Standard Deviation 0.00388177
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 360 (Month 12)
|
0.0016788 percentage of CD4+ T cells
Standard Deviation 0.00208657
|
0.0012300 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0029385 percentage of CD4+ T cells
Standard Deviation 0.00085065
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 15
|
0.0044780 percentage of CD4+ T cells
Standard Deviation 0.00694930
|
0.0130950 percentage of CD4+ T cells
Standard Deviation 0.00154856
|
0.0065773 percentage of CD4+ T cells
Standard Deviation 0.00619340
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 30 (Month 1)
|
0.0044494 percentage of CD4+ T cells
Standard Deviation 0.00362591
|
0.0060550 percentage of CD4+ T cells
Standard Deviation 0.00856306
|
0.0013160 percentage of CD4+ T cells
Standard Deviation 0.00044863
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 90 (Month 3)
|
0.0022088 percentage of CD4+ T cells
Standard Deviation 0.00270445
|
0.0037850 percentage of CD4+ T cells
Standard Deviation 0.00535280
|
0.0002120 percentage of CD4+ T cells
Standard Deviation 0.00036719
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 105
|
0.0006333 percentage of CD4+ T cells
Standard Deviation 0.00098508
|
0.0011700 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0005267 percentage of CD4+ T cells
Standard Deviation 0.00091221
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 120 (Month 4)
|
0.0015674 percentage of CD4+ T cells
Standard Deviation 0.00117213
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0011733 percentage of CD4+ T cells
Standard Deviation 0.00203227
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 360 (Month 12)
|
0.0006924 percentage of CD4+ T cells
Standard Deviation 0.00099937
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0004310 percentage of CD4+ T cells
Standard Deviation 0.00060953
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, C, Day 15
|
0.0066937 percentage of CD4+ T cells
Standard Deviation 0.00722100
|
0.0915950 percentage of CD4+ T cells
Standard Deviation 0.08259714
|
0.0062000 percentage of CD4+ T cells
Standard Deviation 0.00563205
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, C, Day 30 (Month 1)
|
0.0079714 percentage of CD4+ T cells
Standard Deviation 0.00798185
|
0.0441800 percentage of CD4+ T cells
Standard Deviation 0.02979748
|
0.0015410 percentage of CD4+ T cells
Standard Deviation 0.00085791
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, C, Day 120 (Month 4)
|
0.0060286 percentage of CD4+ T cells
Standard Deviation 0.00431794
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0003600 percentage of CD4+ T cells
Standard Deviation 0.00062354
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 15
|
0.0019264 percentage of CD4+ T cells
Standard Deviation 0.00178363
|
0.0039900 percentage of CD4+ T cells
Standard Deviation 0.00127279
|
0.0442107 percentage of CD4+ T cells
Standard Deviation 0.04821126
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 30 (Month 1)
|
0.0044725 percentage of CD4+ T cells
Standard Deviation 0.00358891
|
0.0075900 percentage of CD4+ T cells
Standard Deviation 0.00639225
|
0.0092893 percentage of CD4+ T cells
Standard Deviation 0.00950700
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 90 (Month 3)
|
0.0014555 percentage of CD4+ T cells
Standard Deviation 0.00277488
|
0.0029200 percentage of CD4+ T cells
Standard Deviation 0.00412950
|
0.0020720 percentage of CD4+ T cells
Standard Deviation 0.00091517
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 360 (Month 12)
|
0.0322727 percentage of CD4+ T cells
Standard Deviation 0.05355388
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 15
|
0.0030952 percentage of CD4+ T cells
Standard Deviation 0.00770652
|
0.0850000 percentage of CD4+ T cells
Standard Deviation 0.12020815
|
0.0710000 percentage of CD4+ T cells
Standard Deviation 0.05179768
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 30 (Month 1)
|
0.0025714 percentage of CD4+ T cells
Standard Deviation 0.00517273
|
0.0100000 percentage of CD4+ T cells
Standard Deviation 0.01414214
|
0.0996667 percentage of CD4+ T cells
Standard Deviation 0.11571661
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 90 (Month 3)
|
0.0025252 percentage of CD4+ T cells
Standard Deviation 0.00822553
|
0.0300000 percentage of CD4+ T cells
Standard Deviation 0.04242641
|
0.0336667 percentage of CD4+ T cells
Standard Deviation 0.04147690
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 105
|
0.0031633 percentage of CD4+ T cells
Standard Deviation 0.00567028
|
0.0100000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0700000 percentage of CD4+ T cells
Standard Deviation 0.12124356
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 120 (Month 4)
|
0.0063333 percentage of CD4+ T cells
Standard Deviation 0.00867948
|
0.0250000 percentage of CD4+ T cells
Standard Deviation 0.03535534
|
0.0846667 percentage of CD4+ T cells
Standard Deviation 0.10346658
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 360 (Month 12)
|
0.0237273 percentage of CD4+ T cells
Standard Deviation 0.04557212
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, C, Day 15
|
0.0109444 percentage of CD4+ T cells
Standard Deviation 0.02263644
|
0.0450000 percentage of CD4+ T cells
Standard Deviation 0.06363961
|
0.1443333 percentage of CD4+ T cells
Standard Deviation 0.09152231
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, C, Day 30 (Month 1)
|
0.0254118 percentage of CD4+ T cells
Standard Deviation 0.05545388
|
0.0850000 percentage of CD4+ T cells
Standard Deviation 0.12020815
|
0.1506667 percentage of CD4+ T cells
Standard Deviation 0.07759725
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, C, Day 90 (Month 3)
|
0.0341782 percentage of CD4+ T cells
Standard Deviation 0.05499065
|
0.0500000 percentage of CD4+ T cells
Standard Deviation 0.07071068
|
0.0906667 percentage of CD4+ T cells
Standard Deviation 0.05138417
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, C, Day 105
|
0.1933960 percentage of CD4+ T cells
Standard Deviation 0.34758253
|
0.0200000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.1556667 percentage of CD4+ T cells
Standard Deviation 0.14424401
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 105
|
0.0123960 percentage of CD4+ T cells
Standard Deviation 0.01897351
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0433333 percentage of CD4+ T cells
Standard Deviation 0.07505553
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, C, Day 120 (Month 4)
|
0.0088750 percentage of CD4+ T cells
Standard Deviation 0.01786807
|
0.0200000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.1313333 percentage of CD4+ T cells
Standard Deviation 0.16341767
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 30 (Month 1)
|
0.0050500 percentage of CD4+ T cells
Standard Deviation 0.01240745
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0570000 percentage of CD4+ T cells
Standard Deviation 0.06408588
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 90 (Month 3)
|
0.0116332 percentage of CD4+ T cells
Standard Deviation 0.02395900
|
0.0450000 percentage of CD4+ T cells
Standard Deviation 0.06363961
|
0.0133333 percentage of CD4+ T cells
Standard Deviation 0.02309401
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 105
|
0.0049960 percentage of CD4+ T cells
Standard Deviation 0.01117140
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0500000 percentage of CD4+ T cells
Standard Deviation 0.07000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 120 (Month 4)
|
0.0040909 percentage of CD4+ T cells
Standard Deviation 0.00870005
|
0.0200000 percentage of CD4+ T cells
Standard Deviation 0.02828427
|
0.0346667 percentage of CD4+ T cells
Standard Deviation 0.03500476
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 360 (Month 12)
|
0.0546667 percentage of CD4+ T cells
Standard Deviation 0.07867655
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 15
|
0.0045624 percentage of CD4+ T cells
Standard Deviation 0.00373863
|
0.0132800 percentage of CD4+ T cells
Standard Deviation 0.01657458
|
0.0156033 percentage of CD4+ T cells
Standard Deviation 0.01522844
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 30 (Month 1)
|
0.0037701 percentage of CD4+ T cells
Standard Deviation 0.00361243
|
0.0224970 percentage of CD4+ T cells
Standard Deviation 0.02915118
|
0.0166927 percentage of CD4+ T cells
Standard Deviation 0.02121306
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 90 (Month 3)
|
0.0019732 percentage of CD4+ T cells
Standard Deviation 0.00203413
|
0.0073800 percentage of CD4+ T cells
Standard Deviation 0.00794788
|
0.0066433 percentage of CD4+ T cells
Standard Deviation 0.00434298
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 105
|
0.0010780 percentage of CD4+ T cells
Standard Deviation 0.00144028
|
0.0005900 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0065467 percentage of CD4+ T cells
Standard Deviation 0.00607425
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 120 (Month 4)
|
0.0029255 percentage of CD4+ T cells
Standard Deviation 0.00304491
|
0.0072700 percentage of CD4+ T cells
Standard Deviation 0.01028133
|
0.0087367 percentage of CD4+ T cells
Standard Deviation 0.01165157
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 360 (Month 12)
|
0.0024944 percentage of CD4+ T cells
Standard Deviation 0.00265027
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0065440 percentage of CD4+ T cells
Standard Deviation 0.00147927
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 15
|
0.0020067 percentage of CD4+ T cells
Standard Deviation 0.00349245
|
0.0017650 percentage of CD4+ T cells
Standard Deviation 0.00249609
|
0.0027067 percentage of CD4+ T cells
Standard Deviation 0.00204500
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 30 (Month 1)
|
0.0027715 percentage of CD4+ T cells
Standard Deviation 0.00491943
|
0.0084820 percentage of CD4+ T cells
Standard Deviation 0.01063206
|
0.0062267 percentage of CD4+ T cells
Standard Deviation 0.00469696
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 360 (Month 12)
|
0.0004596 percentage of CD4+ T cells
Standard Deviation 0.00090723
|
0.0012300 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0009050 percentage of CD4+ T cells
Standard Deviation 0.00127986
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 30 (Month 1)
|
0.0013431 percentage of CD4+ T cells
Standard Deviation 0.00157750
|
0.0154820 percentage of CD4+ T cells
Standard Deviation 0.02053155
|
0.0255367 percentage of CD4+ T cells
Standard Deviation 0.02610415
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 15
|
0.0023851 percentage of CD4+ T cells
Standard Deviation 0.00349970
|
0.0054855 percentage of CD4+ T cells
Standard Deviation 0.00665317
|
0.0347667 percentage of CD4+ T cells
Standard Deviation 0.03185692
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 15
|
0.0006690 percentage of CD4+ T cells
Standard Deviation 0.00177413
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0182233 percentage of CD4+ T cells
Standard Deviation 0.01991388
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 105
|
0.0006000 percentage of CD4+ T cells
Standard Deviation 0.00134164
|
0.0100000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 120 (Month 4)
|
0.0055455 percentage of CD4+ T cells
Standard Deviation 0.00831100
|
0.0200000 percentage of CD4+ T cells
Standard Deviation 0.02828427
|
0.0580000 percentage of CD4+ T cells
Standard Deviation 0.05031898
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 105
|
0.0019320 percentage of CD4+ T cells
Standard Deviation 0.00391432
|
0.0006500 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0022200 percentage of CD4+ T cells
Standard Deviation 0.00384515
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 120 (Month 4)
|
0.0018336 percentage of CD4+ T cells
Standard Deviation 0.00149423
|
0.0006650 percentage of CD4+ T cells
Standard Deviation 0.00094045
|
0.0021167 percentage of CD4+ T cells
Standard Deviation 0.00171704
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 360 (Month 12)
|
0.0007334 percentage of CD4+ T cells
Standard Deviation 0.00095378
|
0.0000300 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0004200 percentage of CD4+ T cells
Standard Deviation 0.00059397
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 15
|
0.0024433 percentage of CD4+ T cells
Standard Deviation 0.00478745
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0064967 percentage of CD4+ T cells
Standard Deviation 0.00809850
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 30 (Month 1)
|
0.0087252 percentage of CD4+ T cells
Standard Deviation 0.01274292
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0004767 percentage of CD4+ T cells
Standard Deviation 0.00082561
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 120 (Month 4)
|
0.0054000 percentage of CD4+ T cells
Standard Deviation 0.00546757
|
0.0014550 percentage of CD4+ T cells
Standard Deviation 0.00205768
|
0.0101467 percentage of CD4+ T cells
Standard Deviation 0.01719490
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 105
|
0.0014640 percentage of CD4+ T cells
Standard Deviation 0.00259932
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0043267 percentage of CD4+ T cells
Standard Deviation 0.00749401
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 120 (Month 4)
|
0.0057182 percentage of CD4+ T cells
Standard Deviation 0.00781389
|
0.0013200 percentage of CD4+ T cells
Standard Deviation 0.00186676
|
0.0043133 percentage of CD4+ T cells
Standard Deviation 0.00447823
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 360 (Month 12)
|
0.0034000 percentage of CD4+ T cells
Standard Deviation 0.00501189
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0120000 percentage of CD4+ T cells
Standard Deviation 0.01697056
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 15
|
0.0048771 percentage of CD4+ T cells
Standard Deviation 0.00855424
|
0.0030000 percentage of CD4+ T cells
Standard Deviation 0.00282843
|
0.0032367 percentage of CD4+ T cells
Standard Deviation 0.00336125
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 30 (Month 1)
|
0.0055520 percentage of CD4+ T cells
Standard Deviation 0.00738344
|
0.0030000 percentage of CD4+ T cells
Standard Deviation 0.00424264
|
0.0073333 percentage of CD4+ T cells
Standard Deviation 0.01021437
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 120 (Month 4)
|
0.0093636 percentage of CD4+ T cells
Standard Deviation 0.01344078
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0040000 percentage of CD4+ T cells
Standard Deviation 0.00692820
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 360 (Month 12)
|
0.0072222 percentage of CD4+ T cells
Standard Deviation 0.01328324
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0145000 percentage of CD4+ T cells
Standard Deviation 0.02050610
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 15
|
0.0128095 percentage of CD4+ T cells
Standard Deviation 0.02841939
|
0.1150000 percentage of CD4+ T cells
Standard Deviation 0.16263456
|
0.1576667 percentage of CD4+ T cells
Standard Deviation 0.05173329
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 90 (Month 3)
|
0.0117384 percentage of CD4+ T cells
Standard Deviation 0.01908793
|
0.0750000 percentage of CD4+ T cells
Standard Deviation 0.10606602
|
0.0540000 percentage of CD4+ T cells
Standard Deviation 0.03751000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 105
|
0.0123960 percentage of CD4+ T cells
Standard Deviation 0.01978191
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0733333 percentage of CD4+ T cells
Standard Deviation 0.08736895
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 120 (Month 4)
|
0.0190000 percentage of CD4+ T cells
Standard Deviation 0.02560078
|
0.0400000 percentage of CD4+ T cells
Standard Deviation 0.05656854
|
0.0880000 percentage of CD4+ T cells
Standard Deviation 0.07830709
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 360 (Month 12)
|
0.0607778 percentage of CD4+ T cells
Standard Deviation 0.06849777
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0600000 percentage of CD4+ T cells
Standard Deviation 0.08485281
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 90 (Month 3)
|
0.0040016 percentage of CD4+ T cells
Standard Deviation 0.01133985
|
0.0150000 percentage of CD4+ T cells
Standard Deviation 0.02121320
|
0.0370000 percentage of CD4+ T cells
Standard Deviation 0.03517101
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 15
|
0.0042128 percentage of CD4+ T cells
Standard Deviation 0.00495148
|
0.0280000 percentage of CD4+ T cells
Standard Deviation 0.01272792
|
0.0013133 percentage of CD4+ T cells
Standard Deviation 0.00119605
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 30 (Month 1)
|
0.0041551 percentage of CD4+ T cells
Standard Deviation 0.00511084
|
0.0273970 percentage of CD4+ T cells
Standard Deviation 0.03353525
|
0.0045693 percentage of CD4+ T cells
Standard Deviation 0.00367278
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 90 (Month 3)
|
0.0018916 percentage of CD4+ T cells
Standard Deviation 0.00291470
|
0.0120550 percentage of CD4+ T cells
Standard Deviation 0.01689278
|
0.0010800 percentage of CD4+ T cells
Standard Deviation 0.00183608
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 120 (Month 4)
|
0.0028073 percentage of CD4+ T cells
Standard Deviation 0.00241349
|
0.0101050 percentage of CD4+ T cells
Standard Deviation 0.01051468
|
0.0018300 percentage of CD4+ T cells
Standard Deviation 0.00189834
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 360 (Month 12)
|
0.0034077 percentage of CD4+ T cells
Standard Deviation 0.00388535
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0009250 percentage of CD4+ T cells
Standard Deviation 0.00130815
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 15
|
0.0010586 percentage of CD4+ T cells
Standard Deviation 0.00123430
|
0.0072000 percentage of CD4+ T cells
Standard Deviation 0.00026870
|
0.0002150 percentage of CD4+ T cells
Standard Deviation 0.00037239
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 30 (Month 1)
|
0.0015226 percentage of CD4+ T cells
Standard Deviation 0.00145884
|
0.0106670 percentage of CD4+ T cells
Standard Deviation 0.00471357
|
0.0004867 percentage of CD4+ T cells
Standard Deviation 0.00084293
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 90 (Month 3)
|
0.0013921 percentage of CD4+ T cells
Standard Deviation 0.00146570
|
0.0009150 percentage of CD4+ T cells
Standard Deviation 0.00129401
|
0.0002013 percentage of CD4+ T cells
Standard Deviation 0.00034872
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 105
|
0.0020120 percentage of CD4+ T cells
Standard Deviation 0.00343865
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0012300 percentage of CD4+ T cells
Standard Deviation 0.00111665
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 120 (Month 4)
|
0.0016538 percentage of CD4+ T cells
Standard Deviation 0.00147798
|
0.0013500 percentage of CD4+ T cells
Standard Deviation 0.00002828
|
0.0010277 percentage of CD4+ T cells
Standard Deviation 0.00133012
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 360 (Month 12)
|
0.0005131 percentage of CD4+ T cells
Standard Deviation 0.00105742
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000010 percentage of CD4+ T cells
Standard Deviation 0.00000141
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 15
|
0.0019679 percentage of CD4+ T cells
Standard Deviation 0.00226430
|
0.0298850 percentage of CD4+ T cells
Standard Deviation 0.02884289
|
0.0026567 percentage of CD4+ T cells
Standard Deviation 0.00243097
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 90 (Month 3)
|
0.0005243 percentage of CD4+ T cells
Standard Deviation 0.00078972
|
0.0102600 percentage of CD4+ T cells
Standard Deviation 0.01450983
|
0.0006033 percentage of CD4+ T cells
Standard Deviation 0.00104500
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 120 (Month 4)
|
0.0010900 percentage of CD4+ T cells
Standard Deviation 0.00094653
|
0.0082700 percentage of CD4+ T cells
Standard Deviation 0.01169555
|
0.0021233 percentage of CD4+ T cells
Standard Deviation 0.00266215
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 360 (Month 12)
|
0.0009091 percentage of CD4+ T cells
Standard Deviation 0.00135131
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0003085 percentage of CD4+ T cells
Standard Deviation 0.00043628
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 15
|
0.0021766 percentage of CD4+ T cells
Standard Deviation 0.00325195
|
0.0180950 percentage of CD4+ T cells
Standard Deviation 0.00296278
|
0.0010083 percentage of CD4+ T cells
Standard Deviation 0.00123090
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 360 (Month 12)
|
0.0006534 percentage of CD4+ T cells
Standard Deviation 0.00095082
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000010 percentage of CD4+ T cells
Standard Deviation 0.00000141
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 15
|
0.0010538 percentage of CD4+ T cells
Standard Deviation 0.00210085
|
0.0035100 percentage of CD4+ T cells
Standard Deviation 0.00352139
|
0.0018700 percentage of CD4+ T cells
Standard Deviation 0.00323894
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 30 (Month 1)
|
0.0053990 percentage of CD4+ T cells
Standard Deviation 0.00689308
|
0.0010000 percentage of CD4+ T cells
Standard Deviation 0.00141421
|
0.0051633 percentage of CD4+ T cells
Standard Deviation 0.00690000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 90 (Month 3)
|
0.0027358 percentage of CD4+ T cells
Standard Deviation 0.00322179
|
0.0010000 percentage of CD4+ T cells
Standard Deviation 0.00141421
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 360 (Month 12)
|
0.0074518 percentage of CD4+ T cells
Standard Deviation 0.01318948
|
0.0010000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, C, Day 15
|
0.0077311 percentage of CD4+ T cells
Standard Deviation 0.01847127
|
0.0080100 percentage of CD4+ T cells
Standard Deviation 0.00425678
|
0.0044800 percentage of CD4+ T cells
Standard Deviation 0.00577678
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, C, Day 30 (Month 1)
|
0.0105571 percentage of CD4+ T cells
Standard Deviation 0.00966628
|
0.0120000 percentage of CD4+ T cells
Standard Deviation 0.00989949
|
0.0074967 percentage of CD4+ T cells
Standard Deviation 0.00705266
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, C, Day 90 (Month 3)
|
0.0085371 percentage of CD4+ T cells
Standard Deviation 0.01020675
|
0.0090000 percentage of CD4+ T cells
Standard Deviation 0.00282843
|
0.0017500 percentage of CD4+ T cells
Standard Deviation 0.00303109
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, C, Day 105
|
0.0227280 percentage of CD4+ T cells
Standard Deviation 0.03716463
|
0.0050000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0069933 percentage of CD4+ T cells
Standard Deviation 0.00607619
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, C, Day 120 (Month 4)
|
0.0100288 percentage of CD4+ T cells
Standard Deviation 0.01429998
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0099800 percentage of CD4+ T cells
Standard Deviation 0.01728587
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, C, Day 360 (Month 12)
|
0.0138388 percentage of CD4+ T cells
Standard Deviation 0.01736932
|
0.0020000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0485000 percentage of CD4+ T cells
Standard Deviation 0.03181981
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 15
|
0.0006881 percentage of CD4+ T cells
Standard Deviation 0.00163780
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0222033 percentage of CD4+ T cells
Standard Deviation 0.03371578
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 30 (Month 1)
|
0.0083430 percentage of CD4+ T cells
Standard Deviation 0.01049993
|
0.0000000 percentage of CD4+ T cells
Standard Deviation 0.00000000
|
0.0081633 percentage of CD4+ T cells
Standard Deviation 0.00851998
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 90 (Month 3)
|
0.0039411 percentage of CD4+ T cells
Standard Deviation 0.00506722
|
0.0075000 percentage of CD4+ T cells
Standard Deviation 0.01060660
|
0.0193333 percentage of CD4+ T cells
Standard Deviation 0.03348632
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 105
|
0.0057280 percentage of CD4+ T cells
Standard Deviation 0.00796431
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0019900 percentage of CD4+ T cells
Standard Deviation 0.00262874
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 120 (Month 4)
|
0.0058000 percentage of CD4+ T cells
Standard Deviation 0.00727803
|
0.0031500 percentage of CD4+ T cells
Standard Deviation 0.00445477
|
0.0023100 percentage of CD4+ T cells
Standard Deviation 0.00400104
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 360 (Month 12)
|
0.0055411 percentage of CD4+ T cells
Standard Deviation 0.00703655
|
0.0000000 percentage of CD4+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0770000 percentage of CD4+ T cells
Standard Deviation 0.00989949
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 15
|
0.0048771 percentage of CD4+ T cells
Standard Deviation 0.00581334
|
0.0010000 percentage of CD4+ T cells
Standard Deviation 0.00141421
|
0.0055700 percentage of CD4+ T cells
Standard Deviation 0.00649882
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 90 (Month 3)
|
0.0048095 percentage of CD4+ T cells
Standard Deviation 0.00757376
|
0.0055000 percentage of CD4+ T cells
Standard Deviation 0.00212132
|
0.0146667 percentage of CD4+ T cells
Standard Deviation 0.01616581
|
—
|
SECONDARY outcome
Timeframe: Days 15, 30 (Month 1), 90 (Month 3), 105, 120 (Month 4), and 360 (Month 12)Population: ICS Subset included participants from PPS (all participants in the FAS who had no major protocol violations) who had IFN-γ ELISPOT responses \>50 SFC/10\^6 PBMCs and availability of sufficient cells for analysis. Number analyzed is the number of participants with data available for analysis for the specified timepoint.
Phenotype characterization of cellular immune response was performed in a subset of participants with IFN- γ ELISPOT responses \>50 SFC/10\^6 cells and availability of sufficient cells. Markers included CD4, CD8, IFN-γ, tumor necrosis factor-alpha (TNF-α) and interleukin-2 (IL-2). The peptide pools included C, NS1, NS2/4, NS3, NS5 for DENV-2 and prME for DENV-1, DENV-2, DENV-3 and DENV-4.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=21 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=2 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 105
|
0.0174000 percentage of CD8+ T cells
Standard Deviation 0.01399286
|
0.0080000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0080000 percentage of CD8+ T cells
Standard Deviation 0.01216553
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 30 (Month 1)
|
0.0047007 percentage of CD8+ T cells
Standard Deviation 0.01502896
|
0.0000750 percentage of CD8+ T cells
Standard Deviation 0.00010607
|
0.0008833 percentage of CD8+ T cells
Standard Deviation 0.00152998
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 15
|
0.0024200 percentage of CD8+ T cells
Standard Deviation 0.00800006
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0025900 percentage of CD8+ T cells
Standard Deviation 0.00448601
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 360 (Month 12)
|
0.0019478 percentage of CD8+ T cells
Standard Deviation 0.00186916
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 360 (Month 12)
|
0.0386067 percentage of CD8+ T cells
Standard Deviation 0.03656897
|
0.0030000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 120 (Month 4)
|
0.0090928 percentage of CD8+ T cells
Standard Deviation 0.01602139
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0134433 percentage of CD8+ T cells
Standard Deviation 0.02214271
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 360 (Month 12)
|
0.0115891 percentage of CD8+ T cells
Standard Deviation 0.01525538
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0003415 percentage of CD8+ T cells
Standard Deviation 0.00048295
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 15
|
0.0115911 percentage of CD8+ T cells
Standard Deviation 0.02556364
|
0.0034050 percentage of CD8+ T cells
Standard Deviation 0.00481540
|
0.0230000 percentage of CD8+ T cells
Standard Deviation 0.02523886
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
|
0.0235620 percentage of CD8+ T cells
Standard Deviation 0.03383365
|
0.0034850 percentage of CD8+ T cells
Standard Deviation 0.00492853
|
0.0246667 percentage of CD8+ T cells
Standard Deviation 0.02247962
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
|
0.0097230 percentage of CD8+ T cells
Standard Deviation 0.01765134
|
0.0025150 percentage of CD8+ T cells
Standard Deviation 0.00355675
|
0.0270000 percentage of CD8+ T cells
Standard Deviation 0.03044667
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 15
|
0.0173215 percentage of CD8+ T cells
Standard Deviation 0.02522769
|
0.0258900 percentage of CD8+ T cells
Standard Deviation 0.03126826
|
0.0195800 percentage of CD8+ T cells
Standard Deviation 0.02908452
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 105
|
0.0066317 percentage of CD8+ T cells
Standard Deviation 0.00614863
|
0.0026400 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0005333 percentage of CD8+ T cells
Standard Deviation 0.00092376
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 15
|
0.0577929 percentage of CD8+ T cells
Standard Deviation 0.07400744
|
0.1345000 percentage of CD8+ T cells
Standard Deviation 0.16334167
|
0.0337727 percentage of CD8+ T cells
Standard Deviation 0.01914939
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 90 (Month 3)
|
0.1645845 percentage of CD8+ T cells
Standard Deviation 0.33473334
|
0.0448850 percentage of CD8+ T cells
Standard Deviation 0.05715544
|
0.0257167 percentage of CD8+ T cells
Standard Deviation 0.01956887
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 15
|
0.0506306 percentage of CD8+ T cells
Standard Deviation 0.07605994
|
0.0575000 percentage of CD8+ T cells
Standard Deviation 0.05727565
|
0.0524000 percentage of CD8+ T cells
Standard Deviation 0.01247678
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, C, Day 120 (Month 4)
|
0.0031775 percentage of CD8+ T cells
Standard Deviation 0.00663800
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0003180 percentage of CD8+ T cells
Standard Deviation 0.00033860
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, C, Day 360 (Month 12)
|
0.0023488 percentage of CD8+ T cells
Standard Deviation 0.00154967
|
0.0062500 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0005100 percentage of CD8+ T cells
Standard Deviation 0.00072125
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 105
|
0.0072940 percentage of CD8+ T cells
Standard Deviation 0.00965853
|
0.0055000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0006200 percentage of CD8+ T cells
Standard Deviation 0.00107387
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 30 (Month 1)
|
0.0012376 percentage of CD8+ T cells
Standard Deviation 0.00387489
|
0.0000400 percentage of CD8+ T cells
Standard Deviation 0.00005657
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
|
0.0005805 percentage of CD8+ T cells
Standard Deviation 0.00114013
|
0.0023600 percentage of CD8+ T cells
Standard Deviation 0.00333754
|
0.0004017 percentage of CD8+ T cells
Standard Deviation 0.00055503
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
|
0.0004906 percentage of CD8+ T cells
Standard Deviation 0.00099670
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0073200 percentage of CD8+ T cells
Standard Deviation 0.01007451
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
|
0.0023900 percentage of CD8+ T cells
Standard Deviation 0.00325169
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0102150 percentage of CD8+ T cells
Standard Deviation 0.00596091
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 30 (Month 1)
|
0.0012721 percentage of CD8+ T cells
Standard Deviation 0.00302348
|
0.0000450 percentage of CD8+ T cells
Standard Deviation 0.00006364
|
0.0000467 percentage of CD8+ T cells
Standard Deviation 0.00008083
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 90 (Month 3)
|
0.0018919 percentage of CD8+ T cells
Standard Deviation 0.00612723
|
0.0016550 percentage of CD8+ T cells
Standard Deviation 0.00234052
|
0.0059367 percentage of CD8+ T cells
Standard Deviation 0.01028261
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 105
|
0.0000050 percentage of CD8+ T cells
Standard Deviation 0.00001225
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 120 (Month 4)
|
0.0005142 percentage of CD8+ T cells
Standard Deviation 0.00121641
|
0.0015450 percentage of CD8+ T cells
Standard Deviation 0.00218496
|
0.0070000 percentage of CD8+ T cells
Standard Deviation 0.01212436
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, C, Day 30 (Month 1)
|
0.0008947 percentage of CD8+ T cells
Standard Deviation 0.00141229
|
0.0065000 percentage of CD8+ T cells
Standard Deviation 0.00919239
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 120 (Month 4)
|
0.0004136 percentage of CD8+ T cells
Standard Deviation 0.00137188
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0053333 percentage of CD8+ T cells
Standard Deviation 0.00923760
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 105
|
0.0010000 percentage of CD8+ T cells
Standard Deviation 0.00200000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0070000 percentage of CD8+ T cells
Standard Deviation 0.00888819
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 90 (Month 3)
|
0.0030861 percentage of CD8+ T cells
Standard Deviation 0.00437015
|
0.0010000 percentage of CD8+ T cells
Standard Deviation 0.00141421
|
0.0046667 percentage of CD8+ T cells
Standard Deviation 0.00808290
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 105
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0053333 percentage of CD8+ T cells
Standard Deviation 0.00757188
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 90 (Month 3)
|
0.0029057 percentage of CD8+ T cells
Standard Deviation 0.00488854
|
0.0075000 percentage of CD8+ T cells
Standard Deviation 0.01060660
|
0.0013333 percentage of CD8+ T cells
Standard Deviation 0.00230940
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 15
|
0.0101905 percentage of CD8+ T cells
Standard Deviation 0.01632825
|
0.0415000 percentage of CD8+ T cells
Standard Deviation 0.02616295
|
0.0160000 percentage of CD8+ T cells
Standard Deviation 0.01969772
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 360 (Month 12)
|
0.0526782 percentage of CD8+ T cells
Standard Deviation 0.05324075
|
0.0530000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 15
|
0.0088638 percentage of CD8+ T cells
Standard Deviation 0.01482118
|
0.0350000 percentage of CD8+ T cells
Standard Deviation 0.02262742
|
0.0426667 percentage of CD8+ T cells
Standard Deviation 0.05021288
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 30 (Month 1)
|
0.0344576 percentage of CD8+ T cells
Standard Deviation 0.03851547
|
0.0780000 percentage of CD8+ T cells
Standard Deviation 0.05656854
|
0.0683333 percentage of CD8+ T cells
Standard Deviation 0.08251263
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 90 (Month 3)
|
0.0603471 percentage of CD8+ T cells
Standard Deviation 0.11313845
|
0.0870000 percentage of CD8+ T cells
Standard Deviation 0.12303658
|
0.0323333 percentage of CD8+ T cells
Standard Deviation 0.01778576
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 105
|
0.0643333 percentage of CD8+ T cells
Standard Deviation 0.09686004
|
0.0410000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0390000 percentage of CD8+ T cells
Standard Deviation 0.00871780
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 120 (Month 4)
|
0.0471067 percentage of CD8+ T cells
Standard Deviation 0.06000386
|
0.0940000 percentage of CD8+ T cells
Standard Deviation 0.11879394
|
0.0090000 percentage of CD8+ T cells
Standard Deviation 0.01558846
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 360 (Month 12)
|
0.0758600 percentage of CD8+ T cells
Standard Deviation 0.11250364
|
0.0090000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, C, Day 30 (Month 1)
|
0.0085812 percentage of CD8+ T cells
Standard Deviation 0.01180887
|
0.0285000 percentage of CD8+ T cells
Standard Deviation 0.00777817
|
0.0773333 percentage of CD8+ T cells
Standard Deviation 0.06971609
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, C, Day 90 (Month 3)
|
0.0198388 percentage of CD8+ T cells
Standard Deviation 0.04371084
|
0.0065000 percentage of CD8+ T cells
Standard Deviation 0.00919239
|
0.0423333 percentage of CD8+ T cells
Standard Deviation 0.03516153
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, C, Day 105
|
0.0380000 percentage of CD8+ T cells
Standard Deviation 0.05251190
|
0.0100000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0653333 percentage of CD8+ T cells
Standard Deviation 0.06033517
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, C, Day 120 (Month 4)
|
0.0123363 percentage of CD8+ T cells
Standard Deviation 0.01514560
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0233333 percentage of CD8+ T cells
Standard Deviation 0.01527525
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, C, Day 360 (Month 12)
|
0.0363138 percentage of CD8+ T cells
Standard Deviation 0.05384733
|
0.0440000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0050000 percentage of CD8+ T cells
Standard Deviation 0.00707107
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 15
|
0.0054286 percentage of CD8+ T cells
Standard Deviation 0.00981311
|
0.0110000 percentage of CD8+ T cells
Standard Deviation 0.00141421
|
0.0326667 percentage of CD8+ T cells
Standard Deviation 0.04051337
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 30 (Month 1)
|
0.0054275 percentage of CD8+ T cells
Standard Deviation 0.00814845
|
0.0130000 percentage of CD8+ T cells
Standard Deviation 0.00141421
|
0.0266667 percentage of CD8+ T cells
Standard Deviation 0.04618802
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 90 (Month 3)
|
0.0091942 percentage of CD8+ T cells
Standard Deviation 0.01593313
|
0.0165000 percentage of CD8+ T cells
Standard Deviation 0.02333452
|
0.0060000 percentage of CD8+ T cells
Standard Deviation 0.01039230
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 120 (Month 4)
|
0.0141164 percentage of CD8+ T cells
Standard Deviation 0.02282460
|
0.0350000 percentage of CD8+ T cells
Standard Deviation 0.03818377
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 30 (Month 1)
|
0.0120563 percentage of CD8+ T cells
Standard Deviation 0.02306468
|
0.0000650 percentage of CD8+ T cells
Standard Deviation 0.00009192
|
0.0008400 percentage of CD8+ T cells
Standard Deviation 0.00145492
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 90 (Month 3)
|
0.0025821 percentage of CD8+ T cells
Standard Deviation 0.00448167
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 105
|
0.0009780 percentage of CD8+ T cells
Standard Deviation 0.00177382
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0007567 percentage of CD8+ T cells
Standard Deviation 0.00131059
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 120 (Month 4)
|
0.0114040 percentage of CD8+ T cells
Standard Deviation 0.01887834
|
0.0008900 percentage of CD8+ T cells
Standard Deviation 0.00125865
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 360 (Month 12)
|
0.0016822 percentage of CD8+ T cells
Standard Deviation 0.00344548
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 15
|
0.0030476 percentage of CD8+ T cells
Standard Deviation 0.01094264
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0011667 percentage of CD8+ T cells
Standard Deviation 0.00202073
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 90 (Month 3)
|
0.0023789 percentage of CD8+ T cells
Standard Deviation 0.00539609
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 105
|
0.0012082 percentage of CD8+ T cells
Standard Deviation 0.00231967
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 120 (Month 4)
|
0.0042031 percentage of CD8+ T cells
Standard Deviation 0.01075305
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 360 (Month 12)
|
0.0001489 percentage of CD8+ T cells
Standard Deviation 0.00044667
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 15
|
0.0184242 percentage of CD8+ T cells
Standard Deviation 0.02939174
|
0.0089250 percentage of CD8+ T cells
Standard Deviation 0.00717713
|
0.0051230 percentage of CD8+ T cells
Standard Deviation 0.00771231
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 30 (Month 1)
|
0.0591005 percentage of CD8+ T cells
Standard Deviation 0.11403676
|
0.0210900 percentage of CD8+ T cells
Standard Deviation 0.02391435
|
0.0164220 percentage of CD8+ T cells
Standard Deviation 0.01587121
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 90 (Month 3)
|
0.0313922 percentage of CD8+ T cells
Standard Deviation 0.04328981
|
0.0190000 percentage of CD8+ T cells
Standard Deviation 0.02687006
|
0.0114300 percentage of CD8+ T cells
Standard Deviation 0.01150064
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 105
|
0.0078900 percentage of CD8+ T cells
Standard Deviation 0.00938985
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0081933 percentage of CD8+ T cells
Standard Deviation 0.00716934
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 120 (Month 4)
|
0.0976318 percentage of CD8+ T cells
Standard Deviation 0.16524353
|
0.0153650 percentage of CD8+ T cells
Standard Deviation 0.02172939
|
0.0053067 percentage of CD8+ T cells
Standard Deviation 0.00378127
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 360 (Month 12)
|
0.0295267 percentage of CD8+ T cells
Standard Deviation 0.04211372
|
0.0029900 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0051685 percentage of CD8+ T cells
Standard Deviation 0.00321239
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 30 (Month 1)
|
0.0130950 percentage of CD8+ T cells
Standard Deviation 0.01958094
|
0.0180000 percentage of CD8+ T cells
Standard Deviation 0.02545584
|
0.0733333 percentage of CD8+ T cells
Standard Deviation 0.09451631
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 30 (Month 1)
|
0.3096533 percentage of CD8+ T cells
Standard Deviation 0.30258266
|
1.7050000 percentage of CD8+ T cells
Standard Deviation 2.10010714
|
0.4185000 percentage of CD8+ T cells
Standard Deviation 0.53648089
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 120 (Month 4)
|
0.0327508 percentage of CD8+ T cells
Standard Deviation 0.05413463
|
0.0385000 percentage of CD8+ T cells
Standard Deviation 0.01484924
|
0.0526667 percentage of CD8+ T cells
Standard Deviation 0.09122134
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 30 (Month 1)
|
0.0043576 percentage of CD8+ T cells
Standard Deviation 0.00713583
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0060000 percentage of CD8+ T cells
Standard Deviation 0.00600000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 30 (Month 1)
|
0.0233062 percentage of CD8+ T cells
Standard Deviation 0.04002720
|
0.0185000 percentage of CD8+ T cells
Standard Deviation 0.00777817
|
0.0058683 percentage of CD8+ T cells
Standard Deviation 0.00636956
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 90 (Month 3)
|
0.0169390 percentage of CD8+ T cells
Standard Deviation 0.03074260
|
0.0085000 percentage of CD8+ T cells
Standard Deviation 0.01202082
|
0.0062367 percentage of CD8+ T cells
Standard Deviation 0.00856318
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 105
|
0.0045183 percentage of CD8+ T cells
Standard Deviation 0.00427166
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0046667 percentage of CD8+ T cells
Standard Deviation 0.00808290
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 120 (Month 4)
|
0.0146317 percentage of CD8+ T cells
Standard Deviation 0.02786861
|
0.0055000 percentage of CD8+ T cells
Standard Deviation 0.00777817
|
0.0018967 percentage of CD8+ T cells
Standard Deviation 0.00184717
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 360 (Month 12)
|
0.0047727 percentage of CD8+ T cells
Standard Deviation 0.00882216
|
0.0089800 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0006650 percentage of CD8+ T cells
Standard Deviation 0.00094045
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 15
|
0.0046910 percentage of CD8+ T cells
Standard Deviation 0.00688923
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0007403 percentage of CD8+ T cells
Standard Deviation 0.00074504
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 30 (Month 1)
|
0.0375398 percentage of CD8+ T cells
Standard Deviation 0.08260377
|
0.0105000 percentage of CD8+ T cells
Standard Deviation 0.01484924
|
0.0037760 percentage of CD8+ T cells
Standard Deviation 0.00368127
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 90 (Month 3)
|
0.0233700 percentage of CD8+ T cells
Standard Deviation 0.04004137
|
0.0054650 percentage of CD8+ T cells
Standard Deviation 0.00176070
|
0.0013300 percentage of CD8+ T cells
Standard Deviation 0.00135044
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 120 (Month 4)
|
0.0185150 percentage of CD8+ T cells
Standard Deviation 0.03662069
|
0.0045000 percentage of CD8+ T cells
Standard Deviation 0.00636396
|
0.0015990 percentage of CD8+ T cells
Standard Deviation 0.00101474
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 360 (Month 12)
|
0.0123264 percentage of CD8+ T cells
Standard Deviation 0.02486600
|
0.0031200 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, C, Day 15
|
0.0004213 percentage of CD8+ T cells
Standard Deviation 0.00110644
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, C, Day 30 (Month 1)
|
0.0004506 percentage of CD8+ T cells
Standard Deviation 0.00101312
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, C, Day 90 (Month 3)
|
0.0009306 percentage of CD8+ T cells
Standard Deviation 0.00314498
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, C, Day 105
|
0.0032000 percentage of CD8+ T cells
Standard Deviation 0.00715542
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, C, Day 120 (Month 4)
|
0.0010313 percentage of CD8+ T cells
Standard Deviation 0.00198803
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, C, Day 360 (Month 12)
|
0.0003888 percentage of CD8+ T cells
Standard Deviation 0.00109955
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 15
|
0.0033314 percentage of CD8+ T cells
Standard Deviation 0.01348231
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 30 (Month 1)
|
0.0037375 percentage of CD8+ T cells
Standard Deviation 0.01220309
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 90 (Month 3)
|
0.0020895 percentage of CD8+ T cells
Standard Deviation 0.00598185
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 105
|
0.0001374 percentage of CD8+ T cells
Standard Deviation 0.00030724
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 120 (Month 4)
|
0.0027273 percentage of CD8+ T cells
Standard Deviation 0.00904534
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 360 (Month 12)
|
0.0007944 percentage of CD8+ T cells
Standard Deviation 0.00238333
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 15
|
0.0127219 percentage of CD8+ T cells
Standard Deviation 0.01763276
|
0.0130000 percentage of CD8+ T cells
Standard Deviation 0.01838478
|
0.0251227 percentage of CD8+ T cells
Standard Deviation 0.03459943
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 30 (Month 1)
|
0.1050295 percentage of CD8+ T cells
Standard Deviation 0.20473645
|
0.0500000 percentage of CD8+ T cells
Standard Deviation 0.07071068
|
0.0724367 percentage of CD8+ T cells
Standard Deviation 0.10037912
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 90 (Month 3)
|
0.0778682 percentage of CD8+ T cells
Standard Deviation 0.14369053
|
0.0325000 percentage of CD8+ T cells
Standard Deviation 0.04596194
|
0.0842333 percentage of CD8+ T cells
Standard Deviation 0.14123712
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 105
|
0.0423867 percentage of CD8+ T cells
Standard Deviation 0.04081753
|
0.0013300 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0353100 percentage of CD8+ T cells
Standard Deviation 0.05329149
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 120 (Month 4)
|
0.0899900 percentage of CD8+ T cells
Standard Deviation 0.12840170
|
0.0433650 percentage of CD8+ T cells
Standard Deviation 0.06132737
|
0.1106733 percentage of CD8+ T cells
Standard Deviation 0.17709757
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 360 (Month 12)
|
0.1513091 percentage of CD8+ T cells
Standard Deviation 0.21942879
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0108285 percentage of CD8+ T cells
Standard Deviation 0.01438467
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 15
|
0.0509037 percentage of CD8+ T cells
Standard Deviation 0.10340779
|
0.0475000 percentage of CD8+ T cells
Standard Deviation 0.06717514
|
0.2024327 percentage of CD8+ T cells
Standard Deviation 0.30965583
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
|
0.1922011 percentage of CD8+ T cells
Standard Deviation 0.32578940
|
0.0861200 percentage of CD8+ T cells
Standard Deviation 0.11862423
|
0.2125000 percentage of CD8+ T cells
Standard Deviation 0.20614012
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
|
0.1737812 percentage of CD8+ T cells
Standard Deviation 0.29061637
|
0.1272350 percentage of CD8+ T cells
Standard Deviation 0.17361593
|
0.2045333 percentage of CD8+ T cells
Standard Deviation 0.26081536
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 105
|
0.1034720 percentage of CD8+ T cells
Standard Deviation 0.10489211
|
0.0026600 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.1804967 percentage of CD8+ T cells
Standard Deviation 0.22221367
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
|
0.1805500 percentage of CD8+ T cells
Standard Deviation 0.26929623
|
0.1188100 percentage of CD8+ T cells
Standard Deviation 0.16393564
|
0.2122567 percentage of CD8+ T cells
Standard Deviation 0.28717008
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
|
0.1934944 percentage of CD8+ T cells
Standard Deviation 0.22273972
|
0.0030800 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.2921435 percentage of CD8+ T cells
Standard Deviation 0.39194010
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 15
|
0.0559643 percentage of CD8+ T cells
Standard Deviation 0.06460712
|
0.3345000 percentage of CD8+ T cells
Standard Deviation 0.38961584
|
0.1204393 percentage of CD8+ T cells
Standard Deviation 0.09431396
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 90 (Month 3)
|
0.3367906 percentage of CD8+ T cells
Standard Deviation 0.39199700
|
1.3950000 percentage of CD8+ T cells
Standard Deviation 1.81726443
|
0.4077633 percentage of CD8+ T cells
Standard Deviation 0.53498698
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 105
|
0.1848933 percentage of CD8+ T cells
Standard Deviation 0.10624645
|
0.1200000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.2482033 percentage of CD8+ T cells
Standard Deviation 0.29841232
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 120 (Month 4)
|
0.4698942 percentage of CD8+ T cells
Standard Deviation 0.59554812
|
1.4208650 percentage of CD8+ T cells
Standard Deviation 1.91465424
|
0.2656767 percentage of CD8+ T cells
Standard Deviation 0.28387658
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 360 (Month 12)
|
0.3919327 percentage of CD8+ T cells
Standard Deviation 0.07020651
|
0.0840000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0696435 percentage of CD8+ T cells
Standard Deviation 0.07020651
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 30 (Month 1)
|
0.4733376 percentage of CD8+ T cells
Standard Deviation 0.74274218
|
0.8520000 percentage of CD8+ T cells
Standard Deviation 1.15682669
|
0.1478333 percentage of CD8+ T cells
Standard Deviation 0.11273901
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 90 (Month 3)
|
0.4983025 percentage of CD8+ T cells
Standard Deviation 0.59609158
|
0.8565000 percentage of CD8+ T cells
Standard Deviation 1.19288914
|
0.1278067 percentage of CD8+ T cells
Standard Deviation 0.11606138
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 105
|
0.3420600 percentage of CD8+ T cells
Standard Deviation 0.35216040
|
0.0250000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0825367 percentage of CD8+ T cells
Standard Deviation 0.07078845
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 120 (Month 4)
|
0.6520608 percentage of CD8+ T cells
Standard Deviation 1.02666427
|
0.9169950 percentage of CD8+ T cells
Standard Deviation 1.28373115
|
0.1260100 percentage of CD8+ T cells
Standard Deviation 0.08686409
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 360 (Month 12)
|
0.5487509 percentage of CD8+ T cells
Standard Deviation 0.61534681
|
0.0370000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0216435 percentage of CD8+ T cells
Standard Deviation 0.00898945
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, C, Day 15
|
0.0018039 percentage of CD8+ T cells
Standard Deviation 0.00272657
|
0.0009250 percentage of CD8+ T cells
Standard Deviation 0.00130815
|
0.0011667 percentage of CD8+ T cells
Standard Deviation 0.00202073
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, C, Day 30 (Month 1)
|
0.0043176 percentage of CD8+ T cells
Standard Deviation 0.00745474
|
0.0086150 percentage of CD8+ T cells
Standard Deviation 0.00337290
|
0.0041833 percentage of CD8+ T cells
Standard Deviation 0.00218836
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, C, Day 90 (Month 3)
|
0.0365866 percentage of CD8+ T cells
Standard Deviation 0.13503691
|
0.0105000 percentage of CD8+ T cells
Standard Deviation 0.01484924
|
0.0013533 percentage of CD8+ T cells
Standard Deviation 0.00117309
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, C, Day 105
|
0.0321340 percentage of CD8+ T cells
Standard Deviation 0.06596445
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0021467 percentage of CD8+ T cells
Standard Deviation 0.00199362
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, C, Day 120 (Month 4)
|
0.0212825 percentage of CD8+ T cells
Standard Deviation 0.04543103
|
0.0087300 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0020933 percentage of CD8+ T cells
Standard Deviation 0.00313690
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, C, Day 360 (Month 12)
|
0.0078913 percentage of CD8+ T cells
Standard Deviation 0.01390167
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0025400 percentage of CD8+ T cells
Standard Deviation 0.00359210
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 15
|
0.0084024 percentage of CD8+ T cells
Standard Deviation 0.02103704
|
0.0042950 percentage of CD8+ T cells
Standard Deviation 0.00607405
|
0.0026897 percentage of CD8+ T cells
Standard Deviation 0.00335374
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 30 (Month 1)
|
0.0400210 percentage of CD8+ T cells
Standard Deviation 0.12804631
|
0.0171950 percentage of CD8+ T cells
Standard Deviation 0.01810900
|
0.0093150 percentage of CD8+ T cells
Standard Deviation 0.01317661
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 90 (Month 3)
|
0.0304975 percentage of CD8+ T cells
Standard Deviation 0.07184977
|
0.0080000 percentage of CD8+ T cells
Standard Deviation 0.01131371
|
0.0027633 percentage of CD8+ T cells
Standard Deviation 0.00478623
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 105
|
0.0108580 percentage of CD8+ T cells
Standard Deviation 0.01167522
|
0.0027500 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0049600 percentage of CD8+ T cells
Standard Deviation 0.00751799
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 120 (Month 4)
|
0.0512582 percentage of CD8+ T cells
Standard Deviation 0.13375503
|
0.0078650 percentage of CD8+ T cells
Standard Deviation 0.01112279
|
0.0045967 percentage of CD8+ T cells
Standard Deviation 0.00557157
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 360 (Month 12)
|
0.0308133 percentage of CD8+ T cells
Standard Deviation 0.07834697
|
0.0030300 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0026885 percentage of CD8+ T cells
Standard Deviation 0.00176989
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 15
|
0.0122389 percentage of CD8+ T cells
Standard Deviation 0.01635494
|
0.0070000 percentage of CD8+ T cells
Standard Deviation 0.00989949
|
0.0557333 percentage of CD8+ T cells
Standard Deviation 0.06982874
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 30 (Month 1)
|
0.1276062 percentage of CD8+ T cells
Standard Deviation 0.23983604
|
0.0304150 percentage of CD8+ T cells
Standard Deviation 0.04005760
|
0.0969917 percentage of CD8+ T cells
Standard Deviation 0.10487019
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 90 (Month 3)
|
0.0542124 percentage of CD8+ T cells
Standard Deviation 0.11503390
|
0.0071500 percentage of CD8+ T cells
Standard Deviation 0.01011163
|
0.0521167 percentage of CD8+ T cells
Standard Deviation 0.07641460
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 105
|
0.0434533 percentage of CD8+ T cells
Standard Deviation 0.06315100
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0259533 percentage of CD8+ T cells
Standard Deviation 0.03276050
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 120 (Month 4)
|
0.0605858 percentage of CD8+ T cells
Standard Deviation 0.09889217
|
0.0070000 percentage of CD8+ T cells
Standard Deviation 0.00989949
|
0.0488133 percentage of CD8+ T cells
Standard Deviation 0.05397085
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 360 (Month 12)
|
0.0296555 percentage of CD8+ T cells
Standard Deviation 0.03699595
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0032750 percentage of CD8+ T cells
Standard Deviation 0.00269408
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 15
|
0.0444316 percentage of CD8+ T cells
Standard Deviation 0.07748289
|
0.0130000 percentage of CD8+ T cells
Standard Deviation 0.01838478
|
0.0280367 percentage of CD8+ T cells
Standard Deviation 0.03627084
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 30 (Month 1)
|
0.3801521 percentage of CD8+ T cells
Standard Deviation 0.67068473
|
0.0512350 percentage of CD8+ T cells
Standard Deviation 0.06293957
|
0.0415883 percentage of CD8+ T cells
Standard Deviation 0.03264917
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 105
|
0.1067160 percentage of CD8+ T cells
Standard Deviation 0.18769742
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0320700 percentage of CD8+ T cells
Standard Deviation 0.03599368
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 120 (Month 4)
|
0.1580330 percentage of CD8+ T cells
Standard Deviation 0.28256426
|
0.0249450 percentage of CD8+ T cells
Standard Deviation 0.03119048
|
0.0141700 percentage of CD8+ T cells
Standard Deviation 0.01698637
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 360 (Month 12)
|
0.0614767 percentage of CD8+ T cells
Standard Deviation 0.11059188
|
0.0030800 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0240000 percentage of CD8+ T cells
Standard Deviation 0.03394113
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 15
|
0.0470239 percentage of CD8+ T cells
Standard Deviation 0.06626524
|
0.1770000 percentage of CD8+ T cells
Standard Deviation 0.11737973
|
0.1204000 percentage of CD8+ T cells
Standard Deviation 0.08449249
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 30 (Month 1)
|
0.3655695 percentage of CD8+ T cells
Standard Deviation 0.32065242
|
0.7938700 percentage of CD8+ T cells
Standard Deviation 0.68429552
|
0.1697217 percentage of CD8+ T cells
Standard Deviation 0.15709417
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 90 (Month 3)
|
0.1878077 percentage of CD8+ T cells
Standard Deviation 0.16247089
|
0.3366500 percentage of CD8+ T cells
Standard Deviation 0.37002898
|
0.0923333 percentage of CD8+ T cells
Standard Deviation 0.09666609
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 105
|
0.2131617 percentage of CD8+ T cells
Standard Deviation 0.26290060
|
0.0650000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0487367 percentage of CD8+ T cells
Standard Deviation 0.03451214
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 120 (Month 4)
|
0.2064808 percentage of CD8+ T cells
Standard Deviation 0.20421574
|
0.2475000 percentage of CD8+ T cells
Standard Deviation 0.27223611
|
0.0493700 percentage of CD8+ T cells
Standard Deviation 0.03374277
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 360 (Month 12)
|
0.0857582 percentage of CD8+ T cells
Standard Deviation 0.08578152
|
0.0630000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0191600 percentage of CD8+ T cells
Standard Deviation 0.01674429
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 30 (Month 1)
|
0.4990933 percentage of CD8+ T cells
Standard Deviation 0.64014167
|
0.3928700 percentage of CD8+ T cells
Standard Deviation 0.50186197
|
0.1050550 percentage of CD8+ T cells
Standard Deviation 0.03026614
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 90 (Month 3)
|
0.2820981 percentage of CD8+ T cells
Standard Deviation 0.37844969
|
0.1433750 percentage of CD8+ T cells
Standard Deviation 0.19081276
|
0.0326667 percentage of CD8+ T cells
Standard Deviation 0.01106044
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 105
|
0.1576200 percentage of CD8+ T cells
Standard Deviation 0.17541417
|
0.0092500 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0218933 percentage of CD8+ T cells
Standard Deviation 0.02273292
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 120 (Month 4)
|
0.2221475 percentage of CD8+ T cells
Standard Deviation 0.32806338
|
0.1045000 percentage of CD8+ T cells
Standard Deviation 0.12091526
|
0.0220367 percentage of CD8+ T cells
Standard Deviation 0.00571385
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 360 (Month 12)
|
0.1124982 percentage of CD8+ T cells
Standard Deviation 0.16603829
|
0.0062300 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0027100 percentage of CD8+ T cells
Standard Deviation 0.00186676
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, C, Day 15
|
0.0020544 percentage of CD8+ T cells
Standard Deviation 0.00530875
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0033700 percentage of CD8+ T cells
Standard Deviation 0.00583701
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, C, Day 30 (Month 1)
|
0.0057029 percentage of CD8+ T cells
Standard Deviation 0.01291375
|
0.0010400 percentage of CD8+ T cells
Standard Deviation 0.00147078
|
0.0006167 percentage of CD8+ T cells
Standard Deviation 0.00106810
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, C, Day 90 (Month 3)
|
0.0476683 percentage of CD8+ T cells
Standard Deviation 0.19290073
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0002203 percentage of CD8+ T cells
Standard Deviation 0.00038163
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, C, Day 105
|
0.0042000 percentage of CD8+ T cells
Standard Deviation 0.00939149
|
0.0011900 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0004167 percentage of CD8+ T cells
Standard Deviation 0.00072169
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 15
|
0.0178773 percentage of CD8+ T cells
Standard Deviation 0.06036485
|
0.0035250 percentage of CD8+ T cells
Standard Deviation 0.00229810
|
0.0024100 percentage of CD8+ T cells
Standard Deviation 0.00301442
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 30 (Month 1)
|
0.0834539 percentage of CD8+ T cells
Standard Deviation 0.27160793
|
0.0172600 percentage of CD8+ T cells
Standard Deviation 0.01199253
|
0.0023883 percentage of CD8+ T cells
Standard Deviation 0.00272227
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 90 (Month 3)
|
0.0340990 percentage of CD8+ T cells
Standard Deviation 0.08904184
|
0.0061500 percentage of CD8+ T cells
Standard Deviation 0.00281428
|
0.0009000 percentage of CD8+ T cells
Standard Deviation 0.00155885
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 15
|
0.0056604 percentage of CD8+ T cells
Standard Deviation 0.01627332
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 90 (Month 3)
|
0.0014703 percentage of CD8+ T cells
Standard Deviation 0.00267161
|
0.0026650 percentage of CD8+ T cells
Standard Deviation 0.00376888
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 105
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0013600 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 120 (Month 4)
|
0.0082836 percentage of CD8+ T cells
Standard Deviation 0.01892632
|
0.0008700 percentage of CD8+ T cells
Standard Deviation 0.00123037
|
0.0009333 percentage of CD8+ T cells
Standard Deviation 0.00161658
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 360 (Month 12)
|
0.0016900 percentage of CD8+ T cells
Standard Deviation 0.00330848
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 30 (Month 1)
|
0.0055525 percentage of CD8+ T cells
Standard Deviation 0.02087829
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0003040 percentage of CD8+ T cells
Standard Deviation 0.00052654
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 90 (Month 3)
|
0.0011563 percentage of CD8+ T cells
Standard Deviation 0.00285872
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0009200 percentage of CD8+ T cells
Standard Deviation 0.00159349
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 105
|
0.0014160 percentage of CD8+ T cells
Standard Deviation 0.00316627
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0004400 percentage of CD8+ T cells
Standard Deviation 0.00076210
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 120 (Month 4)
|
0.0039800 percentage of CD8+ T cells
Standard Deviation 0.01170301
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 360 (Month 12)
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 15
|
0.0144803 percentage of CD8+ T cells
Standard Deviation 0.02730440
|
0.0025450 percentage of CD8+ T cells
Standard Deviation 0.00359917
|
0.0023033 percentage of CD8+ T cells
Standard Deviation 0.00203952
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 30 (Month 1)
|
0.0370610 percentage of CD8+ T cells
Standard Deviation 0.11025384
|
0.0332550 percentage of CD8+ T cells
Standard Deviation 0.03782314
|
0.0102833 percentage of CD8+ T cells
Standard Deviation 0.01232115
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 90 (Month 3)
|
0.0241643 percentage of CD8+ T cells
Standard Deviation 0.03587491
|
0.0205000 percentage of CD8+ T cells
Standard Deviation 0.02899138
|
0.0075367 percentage of CD8+ T cells
Standard Deviation 0.01031316
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 105
|
0.0077060 percentage of CD8+ T cells
Standard Deviation 0.00514342
|
0.0013600 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0043933 percentage of CD8+ T cells
Standard Deviation 0.00382467
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 120 (Month 4)
|
0.0602155 percentage of CD8+ T cells
Standard Deviation 0.15407711
|
0.0198650 percentage of CD8+ T cells
Standard Deviation 0.02809335
|
0.0059600 percentage of CD8+ T cells
Standard Deviation 0.00785521
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 360 (Month 12)
|
0.0112811 percentage of CD8+ T cells
Standard Deviation 0.01654078
|
0.0031000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0021250 percentage of CD8+ T cells
Standard Deviation 0.00300520
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 15
|
0.0159699 percentage of CD8+ T cells
Standard Deviation 0.04359877
|
0.0017000 percentage of CD8+ T cells
Standard Deviation 0.00240416
|
0.0004900 percentage of CD8+ T cells
Standard Deviation 0.00084870
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 30 (Month 1)
|
0.0707734 percentage of CD8+ T cells
Standard Deviation 0.25211961
|
0.0278700 percentage of CD8+ T cells
Standard Deviation 0.01820093
|
0.0029790 percentage of CD8+ T cells
Standard Deviation 0.00433441
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 90 (Month 3)
|
0.0288527 percentage of CD8+ T cells
Standard Deviation 0.08127031
|
0.0117600 percentage of CD8+ T cells
Standard Deviation 0.01066317
|
0.0032033 percentage of CD8+ T cells
Standard Deviation 0.00444653
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 105
|
0.0070820 percentage of CD8+ T cells
Standard Deviation 0.01452614
|
0.0040800 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0012633 percentage of CD8+ T cells
Standard Deviation 0.00114718
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 120 (Month 4)
|
0.0560967 percentage of CD8+ T cells
Standard Deviation 0.15418829
|
0.0060000 percentage of CD8+ T cells
Standard Deviation 0.00848528
|
0.0022283 percentage of CD8+ T cells
Standard Deviation 0.00320135
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 15
|
0.0003281 percentage of CD8+ T cells
Standard Deviation 0.00087119
|
0.0008500 percentage of CD8+ T cells
Standard Deviation 0.00120208
|
0.0016667 percentage of CD8+ T cells
Standard Deviation 0.00288675
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 30 (Month 1)
|
0.0014660 percentage of CD8+ T cells
Standard Deviation 0.00368403
|
0.0070000 percentage of CD8+ T cells
Standard Deviation 0.00989949
|
0.0015217 percentage of CD8+ T cells
Standard Deviation 0.00263560
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 90 (Month 3)
|
0.0018853 percentage of CD8+ T cells
Standard Deviation 0.00779198
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 105
|
0.0008120 percentage of CD8+ T cells
Standard Deviation 0.00181569
|
0.0018800 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0038700 percentage of CD8+ T cells
Standard Deviation 0.00670304
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 120 (Month 4)
|
0.0004069 percentage of CD8+ T cells
Standard Deviation 0.00077459
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0120000 percentage of CD8+ T cells
Standard Deviation 0.02078461
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 360 (Month 12)
|
0.0017656 percentage of CD8+ T cells
Standard Deviation 0.00266025
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0312150 percentage of CD8+ T cells
Standard Deviation 0.02010305
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 15
|
0.0030481 percentage of CD8+ T cells
Standard Deviation 0.00520443
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0043333 percentage of CD8+ T cells
Standard Deviation 0.00378594
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 30 (Month 1)
|
0.0029060 percentage of CD8+ T cells
Standard Deviation 0.00436453
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0023333 percentage of CD8+ T cells
Standard Deviation 0.00404145
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 90 (Month 3)
|
0.0040816 percentage of CD8+ T cells
Standard Deviation 0.00613449
|
0.0085000 percentage of CD8+ T cells
Standard Deviation 0.01202082
|
0.0023333 percentage of CD8+ T cells
Standard Deviation 0.00404145
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 105
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0110000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0033333 percentage of CD8+ T cells
Standard Deviation 0.00305505
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 120 (Month 4)
|
0.0020000 percentage of CD8+ T cells
Standard Deviation 0.00300000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0010000 percentage of CD8+ T cells
Standard Deviation 0.00173205
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 360 (Month 12)
|
0.0062678 percentage of CD8+ T cells
Standard Deviation 0.01052641
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0070000 percentage of CD8+ T cells
Standard Deviation 0.00848528
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 15
|
0.0148095 percentage of CD8+ T cells
Standard Deviation 0.02511227
|
0.0195000 percentage of CD8+ T cells
Standard Deviation 0.01767767
|
0.0060000 percentage of CD8+ T cells
Standard Deviation 0.01039230
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 30 (Month 1)
|
0.0115435 percentage of CD8+ T cells
Standard Deviation 0.01646364
|
0.0235000 percentage of CD8+ T cells
Standard Deviation 0.01343503
|
0.0253333 percentage of CD8+ T cells
Standard Deviation 0.03106981
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 90 (Month 3)
|
0.0093311 percentage of CD8+ T cells
Standard Deviation 0.01492871
|
0.0250000 percentage of CD8+ T cells
Standard Deviation 0.03535534
|
0.0316667 percentage of CD8+ T cells
Standard Deviation 0.03102150
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 105
|
0.0246000 percentage of CD8+ T cells
Standard Deviation 0.02815670
|
0.0110000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0266667 percentage of CD8+ T cells
Standard Deviation 0.04532475
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 120 (Month 4)
|
0.0250255 percentage of CD8+ T cells
Standard Deviation 0.03675944
|
0.0295000 percentage of CD8+ T cells
Standard Deviation 0.03323402
|
0.0080000 percentage of CD8+ T cells
Standard Deviation 0.01385641
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 15
|
0.0042606 percentage of CD8+ T cells
Standard Deviation 0.00562943
|
0.0025550 percentage of CD8+ T cells
Standard Deviation 0.00361332
|
0.0019520 percentage of CD8+ T cells
Standard Deviation 0.00148274
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 30 (Month 1)
|
0.0194350 percentage of CD8+ T cells
Standard Deviation 0.06157246
|
0.0088700 percentage of CD8+ T cells
Standard Deviation 0.01254407
|
0.0116087 percentage of CD8+ T cells
Standard Deviation 0.01939586
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 90 (Month 3)
|
0.0105474 percentage of CD8+ T cells
Standard Deviation 0.02561865
|
0.0055000 percentage of CD8+ T cells
Standard Deviation 0.00777817
|
0.0080000 percentage of CD8+ T cells
Standard Deviation 0.01385641
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 105
|
0.0006717 percentage of CD8+ T cells
Standard Deviation 0.00164524
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0016067 percentage of CD8+ T cells
Standard Deviation 0.00278283
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
|
0.0331987 percentage of CD8+ T cells
Standard Deviation 0.06119374
|
0.0022800 percentage of CD8+ T cells
Standard Deviation 0.00322441
|
0.0284400 percentage of CD8+ T cells
Standard Deviation 0.02579343
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 105
|
0.0246240 percentage of CD8+ T cells
Standard Deviation 0.03733209
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0220000 percentage of CD8+ T cells
Standard Deviation 0.02029778
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
|
0.0127111 percentage of CD8+ T cells
Standard Deviation 0.01056931
|
0.0030800 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0370000 percentage of CD8+ T cells
Standard Deviation 0.05232590
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 30 (Month 1)
|
0.0598512 percentage of CD8+ T cells
Standard Deviation 0.09417635
|
0.1423700 percentage of CD8+ T cells
Standard Deviation 0.17729995
|
0.0307000 percentage of CD8+ T cells
Standard Deviation 0.04702863
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 90 (Month 3)
|
0.0582231 percentage of CD8+ T cells
Standard Deviation 0.09890918
|
0.0672150 percentage of CD8+ T cells
Standard Deviation 0.08879140
|
0.0477333 percentage of CD8+ T cells
Standard Deviation 0.07132611
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 105
|
0.0113983 percentage of CD8+ T cells
Standard Deviation 0.01184397
|
0.0036900 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0410800 percentage of CD8+ T cells
Standard Deviation 0.06836592
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 120 (Month 4)
|
0.0652592 percentage of CD8+ T cells
Standard Deviation 0.11485350
|
0.0815250 percentage of CD8+ T cells
Standard Deviation 0.11098041
|
0.0249567 percentage of CD8+ T cells
Standard Deviation 0.03147802
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 360 (Month 12)
|
0.0482255 percentage of CD8+ T cells
Standard Deviation 0.06448748
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0038600 percentage of CD8+ T cells
Standard Deviation 0.00397394
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 15
|
0.0188293 percentage of CD8+ T cells
Standard Deviation 0.02998412
|
0.0054950 percentage of CD8+ T cells
Standard Deviation 0.00047376
|
0.0023870 percentage of CD8+ T cells
Standard Deviation 0.00145326
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 30 (Month 1)
|
0.0944508 percentage of CD8+ T cells
Standard Deviation 0.21411201
|
0.0699200 percentage of CD8+ T cells
Standard Deviation 0.09591196
|
0.0180433 percentage of CD8+ T cells
Standard Deviation 0.02775222
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 90 (Month 3)
|
0.0866393 percentage of CD8+ T cells
Standard Deviation 0.13212126
|
0.0516100 percentage of CD8+ T cells
Standard Deviation 0.06701958
|
0.0104300 percentage of CD8+ T cells
Standard Deviation 0.01696039
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 105
|
0.0439383 percentage of CD8+ T cells
Standard Deviation 0.05779160
|
0.0039700 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0182000 percentage of CD8+ T cells
Standard Deviation 0.03014830
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 120 (Month 4)
|
0.1042408 percentage of CD8+ T cells
Standard Deviation 0.16997426
|
0.0430000 percentage of CD8+ T cells
Standard Deviation 0.06081118
|
0.0129300 percentage of CD8+ T cells
Standard Deviation 0.01662924
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 360 (Month 12)
|
0.0624582 percentage of CD8+ T cells
Standard Deviation 0.07686613
|
0.0062300 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0005050 percentage of CD8+ T cells
Standard Deviation 0.00071418
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, C, Day 15
|
0.0008767 percentage of CD8+ T cells
Standard Deviation 0.00230893
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 30 (Month 1)
|
0.0068115 percentage of CD8+ T cells
Standard Deviation 0.00782670
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0026667 percentage of CD8+ T cells
Standard Deviation 0.00461880
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, C, Day 30 (Month 1)
|
0.0009874 percentage of CD8+ T cells
Standard Deviation 0.00211314
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0007800 percentage of CD8+ T cells
Standard Deviation 0.00135100
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, C, Day 90 (Month 3)
|
0.0009700 percentage of CD8+ T cells
Standard Deviation 0.00213416
|
0.0008200 percentage of CD8+ T cells
Standard Deviation 0.00115966
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, C, Day 105
|
0.0180160 percentage of CD8+ T cells
Standard Deviation 0.04024029
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, C, Day 120 (Month 4)
|
0.0042550 percentage of CD8+ T cells
Standard Deviation 0.00972955
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, C, Day 360 (Month 12)
|
0.0023250 percentage of CD8+ T cells
Standard Deviation 0.00398039
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 15
|
0.0032181 percentage of CD8+ T cells
Standard Deviation 0.01085890
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 30 (Month 1)
|
0.0056398 percentage of CD8+ T cells
Standard Deviation 0.01706862
|
0.0012400 percentage of CD8+ T cells
Standard Deviation 0.00135765
|
0.0008933 percentage of CD8+ T cells
Standard Deviation 0.00154730
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 90 (Month 3)
|
0.0021729 percentage of CD8+ T cells
Standard Deviation 0.00454334
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0002303 percentage of CD8+ T cells
Standard Deviation 0.00039895
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 105
|
0.0000094 percentage of CD8+ T cells
Standard Deviation 0.00002102
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 120 (Month 4)
|
0.0064197 percentage of CD8+ T cells
Standard Deviation 0.01469896
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0002230 percentage of CD8+ T cells
Standard Deviation 0.00038625
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 360 (Month 12)
|
0.0016022 percentage of CD8+ T cells
Standard Deviation 0.00296454
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 15
|
0.0015550 percentage of CD8+ T cells
Standard Deviation 0.00250835
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0012000 percentage of CD8+ T cells
Standard Deviation 0.00207846
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 30 (Month 1)
|
0.0085133 percentage of CD8+ T cells
Standard Deviation 0.03027644
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0016367 percentage of CD8+ T cells
Standard Deviation 0.00283479
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 90 (Month 3)
|
0.0036457 percentage of CD8+ T cells
Standard Deviation 0.01124294
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0009000 percentage of CD8+ T cells
Standard Deviation 0.00155885
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 105
|
0.0010662 percentage of CD8+ T cells
Standard Deviation 0.00230033
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0008033 percentage of CD8+ T cells
Standard Deviation 0.00139141
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 120 (Month 4)
|
0.0041225 percentage of CD8+ T cells
Standard Deviation 0.00963517
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0018367 percentage of CD8+ T cells
Standard Deviation 0.00318120
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 360 (Month 12)
|
0.0012100 percentage of CD8+ T cells
Standard Deviation 0.00158071
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 15
|
0.0021547 percentage of CD8+ T cells
Standard Deviation 0.00463731
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0034367 percentage of CD8+ T cells
Standard Deviation 0.00324179
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 120 (Month 4)
|
0.0040000 percentage of CD8+ T cells
Standard Deviation 0.00529150
|
0.0040000 percentage of CD8+ T cells
Standard Deviation 0.00565685
|
0.0066667 percentage of CD8+ T cells
Standard Deviation 0.01154701
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 30 (Month 1)
|
0.0165321 percentage of CD8+ T cells
Standard Deviation 0.03349865
|
0.0011350 percentage of CD8+ T cells
Standard Deviation 0.00160513
|
0.0035200 percentage of CD8+ T cells
Standard Deviation 0.00304882
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 90 (Month 3)
|
0.0106266 percentage of CD8+ T cells
Standard Deviation 0.01670632
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0038233 percentage of CD8+ T cells
Standard Deviation 0.00332250
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 105
|
0.0031980 percentage of CD8+ T cells
Standard Deviation 0.00289504
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0010800 percentage of CD8+ T cells
Standard Deviation 0.00187061
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 120 (Month 4)
|
0.0050200 percentage of CD8+ T cells
Standard Deviation 0.00831467
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0018300 percentage of CD8+ T cells
Standard Deviation 0.00316965
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 360 (Month 12)
|
0.0022100 percentage of CD8+ T cells
Standard Deviation 0.00348368
|
0.0030800 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0035050 percentage of CD8+ T cells
Standard Deviation 0.00495682
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 15
|
0.0041307 percentage of CD8+ T cells
Standard Deviation 0.00810849
|
0.0025350 percentage of CD8+ T cells
Standard Deviation 0.00091217
|
0.0033267 percentage of CD8+ T cells
Standard Deviation 0.00357693
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 120 (Month 4)
|
0.0588364 percentage of CD8+ T cells
Standard Deviation 0.17313721
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0005067 percentage of CD8+ T cells
Standard Deviation 0.00072507
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 360 (Month 12)
|
0.0090167 percentage of CD8+ T cells
Standard Deviation 0.02159530
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 360 (Month 12)
|
0.0015591 percentage of CD8+ T cells
Standard Deviation 0.00239132
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0070000 percentage of CD8+ T cells
Standard Deviation 0.00848528
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, C, Day 15
|
0.0152389 percentage of CD8+ T cells
Standard Deviation 0.04708044
|
0.0090000 percentage of CD8+ T cells
Standard Deviation 0.01272792
|
0.0033333 percentage of CD8+ T cells
Standard Deviation 0.00577350
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, C, Day 30 (Month 1)
|
0.0052506 percentage of CD8+ T cells
Standard Deviation 0.00585230
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0023333 percentage of CD8+ T cells
Standard Deviation 0.00208167
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, C, Day 90 (Month 3)
|
0.0044441 percentage of CD8+ T cells
Standard Deviation 0.00551617
|
0.0195000 percentage of CD8+ T cells
Standard Deviation 0.01060660
|
0.0043333 percentage of CD8+ T cells
Standard Deviation 0.00750555
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, C, Day 105
|
0.0078000 percentage of CD8+ T cells
Standard Deviation 0.01744133
|
0.0090000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0013333 percentage of CD8+ T cells
Standard Deviation 0.00115470
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 15
|
0.0003586 percentage of CD8+ T cells
Standard Deviation 0.00095429
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0003867 percentage of CD8+ T cells
Standard Deviation 0.00066973
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, C, Day 120 (Month 4)
|
0.0076250 percentage of CD8+ T cells
Standard Deviation 0.01245492
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0023333 percentage of CD8+ T cells
Standard Deviation 0.00404145
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, C, Day 360 (Month 12)
|
0.0159263 percentage of CD8+ T cells
Standard Deviation 0.01687248
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0095000 percentage of CD8+ T cells
Standard Deviation 0.01060660
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 15
|
0.0039386 percentage of CD8+ T cells
Standard Deviation 0.00920362
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0043333 percentage of CD8+ T cells
Standard Deviation 0.00585947
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 30 (Month 1)
|
0.0042890 percentage of CD8+ T cells
Standard Deviation 0.00519741
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0040000 percentage of CD8+ T cells
Standard Deviation 0.00692820
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 90 (Month 3)
|
0.0002343 percentage of CD8+ T cells
Standard Deviation 0.00074914
|
0.0009350 percentage of CD8+ T cells
Standard Deviation 0.00132229
|
0.0109367 percentage of CD8+ T cells
Standard Deviation 0.01894286
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 105
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0038700 percentage of CD8+ T cells
Standard Deviation 0.00670304
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 90 (Month 3)
|
0.0037368 percentage of CD8+ T cells
Standard Deviation 0.00647081
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0033333 percentage of CD8+ T cells
Standard Deviation 0.00577350
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 105
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0056667 percentage of CD8+ T cells
Standard Deviation 0.00737111
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 120 (Month 4)
|
0.0032727 percentage of CD8+ T cells
Standard Deviation 0.00392660
|
0.0020000 percentage of CD8+ T cells
Standard Deviation 0.00282843
|
0.0013333 percentage of CD8+ T cells
Standard Deviation 0.00230940
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 360 (Month 12)
|
0.0063789 percentage of CD8+ T cells
Standard Deviation 0.00762607
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0045000 percentage of CD8+ T cells
Standard Deviation 0.00494975
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 120 (Month 4)
|
0.0017572 percentage of CD8+ T cells
Standard Deviation 0.00350183
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0040167 percentage of CD8+ T cells
Standard Deviation 0.00695707
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 360 (Month 12)
|
0.0005464 percentage of CD8+ T cells
Standard Deviation 0.00126041
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 15
|
0.0008511 percentage of CD8+ T cells
Standard Deviation 0.00168955
|
0.0008500 percentage of CD8+ T cells
Standard Deviation 0.00120208
|
0.0033333 percentage of CD8+ T cells
Standard Deviation 0.00577350
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 15
|
0.0058029 percentage of CD8+ T cells
Standard Deviation 0.01553300
|
0.0060000 percentage of CD8+ T cells
Standard Deviation 0.00848528
|
0.0126667 percentage of CD8+ T cells
Standard Deviation 0.02193931
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 30 (Month 1)
|
0.0103476 percentage of CD8+ T cells
Standard Deviation 0.01374186
|
0.0090000 percentage of CD8+ T cells
Standard Deviation 0.00848528
|
0.0400000 percentage of CD8+ T cells
Standard Deviation 0.06928203
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 90 (Month 3)
|
0.0141552 percentage of CD8+ T cells
Standard Deviation 0.02722292
|
0.0070000 percentage of CD8+ T cells
Standard Deviation 0.00989949
|
0.0426667 percentage of CD8+ T cells
Standard Deviation 0.06379133
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 105
|
0.0141667 percentage of CD8+ T cells
Standard Deviation 0.02123598
|
0.0270000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0533333 percentage of CD8+ T cells
Standard Deviation 0.06880649
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 360 (Month 12)
|
0.0594618 percentage of CD8+ T cells
Standard Deviation 0.09358403
|
0.0030000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 15
|
0.0188947 percentage of CD8+ T cells
Standard Deviation 0.02597596
|
0.1070000 percentage of CD8+ T cells
Standard Deviation 0.13293607
|
0.2126667 percentage of CD8+ T cells
Standard Deviation 0.24855851
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
|
0.0218395 percentage of CD8+ T cells
Standard Deviation 0.03032141
|
0.0555000 percentage of CD8+ T cells
Standard Deviation 0.06010408
|
0.2116667 percentage of CD8+ T cells
Standard Deviation 0.21159946
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 105
|
0.0007740 percentage of CD8+ T cells
Standard Deviation 0.00154767
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
|
0.0011780 percentage of CD8+ T cells
Standard Deviation 0.00287673
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0035633 percentage of CD8+ T cells
Standard Deviation 0.00463250
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
|
0.0217506 percentage of CD8+ T cells
Standard Deviation 0.03474512
|
0.0770000 percentage of CD8+ T cells
Standard Deviation 0.10889444
|
0.2006667 percentage of CD8+ T cells
Standard Deviation 0.22830097
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 105
|
0.0232000 percentage of CD8+ T cells
Standard Deviation 0.01003494
|
0.0150000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.1756667 percentage of CD8+ T cells
Standard Deviation 0.14911181
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
|
0.0698280 percentage of CD8+ T cells
Standard Deviation 0.11664297
|
0.1095000 percentage of CD8+ T cells
Standard Deviation 0.13930004
|
0.1763333 percentage of CD8+ T cells
Standard Deviation 0.25602799
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
|
0.0789200 percentage of CD8+ T cells
Standard Deviation 0.08581529
|
0.0180000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.2550000 percentage of CD8+ T cells
Standard Deviation 0.34648232
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 15
|
0.0004690 percentage of CD8+ T cells
Standard Deviation 0.00108044
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 30 (Month 1)
|
0.0269048 percentage of CD8+ T cells
Standard Deviation 0.03805993
|
0.3430000 percentage of CD8+ T cells
Standard Deviation 0.33234019
|
0.1503333 percentage of CD8+ T cells
Standard Deviation 0.19894807
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 30 (Month 1)
|
0.0008031 percentage of CD8+ T cells
Standard Deviation 0.00199994
|
0.0047450 percentage of CD8+ T cells
Standard Deviation 0.00671044
|
0.0028333 percentage of CD8+ T cells
Standard Deviation 0.00490748
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 90 (Month 3)
|
0.0510614 percentage of CD8+ T cells
Standard Deviation 0.06214111
|
0.3680000 percentage of CD8+ T cells
Standard Deviation 0.5176021
|
0.1486667 percentage of CD8+ T cells
Standard Deviation 0.20771455
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 105
|
0.0508333 percentage of CD8+ T cells
Standard Deviation 0.05468242
|
0.1040000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.1286667 percentage of CD8+ T cells
Standard Deviation 0.16850618
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 90 (Month 3)
|
0.0010852 percentage of CD8+ T cells
Standard Deviation 0.00176370
|
0.0022150 percentage of CD8+ T cells
Standard Deviation 0.00313248
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 105
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0007067 percentage of CD8+ T cells
Standard Deviation 0.00122398
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 120 (Month 4)
|
0.0003138 percentage of CD8+ T cells
Standard Deviation 0.00073427
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0113500 percentage of CD8+ T cells
Standard Deviation 0.01026974
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 360 (Month 12)
|
0.0009045 percentage of CD8+ T cells
Standard Deviation 0.00166618
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 15
|
0.0010010 percentage of CD8+ T cells
Standard Deviation 0.00144763
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 360 (Month 12)
|
0.0016991 percentage of CD8+ T cells
Standard Deviation 0.00376328
|
0.0000400 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, C, Day 15
|
0.0003723 percentage of CD8+ T cells
Standard Deviation 0.00107549
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0010000 percentage of CD8+ T cells
Standard Deviation 0.00173205
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, C, Day 90 (Month 3)
|
0.0001547 percentage of CD8+ T cells
Standard Deviation 0.00044269
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0061467 percentage of CD8+ T cells
Standard Deviation 0.00600538
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, C, Day 105
|
0.0108000 percentage of CD8+ T cells
Standard Deviation 0.01819890
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, C, Day 120 (Month 4)
|
0.0037833 percentage of CD8+ T cells
Standard Deviation 0.01041435
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0083333 percentage of CD8+ T cells
Standard Deviation 0.01443376
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, C, Day 360 (Month 12)
|
0.0074013 percentage of CD8+ T cells
Standard Deviation 0.01825981
|
0.0000400 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0277150 percentage of CD8+ T cells
Standard Deviation 0.01515330
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 15
|
0.0004090 percentage of CD8+ T cells
Standard Deviation 0.00081029
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0170000 percentage of CD8+ T cells
Standard Deviation 0.02944486
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 30 (Month 1)
|
0.0004844 percentage of CD8+ T cells
Standard Deviation 0.00107834
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0002883 percentage of CD8+ T cells
Standard Deviation 0.00049941
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 90 (Month 3)
|
0.0003021 percentage of CD8+ T cells
Standard Deviation 0.00109132
|
0.0007600 percentage of CD8+ T cells
Standard Deviation 0.00107480
|
0.0118367 percentage of CD8+ T cells
Standard Deviation 0.01821354
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 105
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 360 (Month 12)
|
0.0011589 percentage of CD8+ T cells
Standard Deviation 0.00257448
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0377150 percentage of CD8+ T cells
Standard Deviation 0.01030255
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 15
|
0.0028214 percentage of CD8+ T cells
Standard Deviation 0.00421069
|
0.0020000 percentage of CD8+ T cells
Standard Deviation 0.00282843
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 30 (Month 1)
|
0.0046852 percentage of CD8+ T cells
Standard Deviation 0.00622110
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0040000 percentage of CD8+ T cells
Standard Deviation 0.00458258
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 90 (Month 3)
|
0.0014295 percentage of CD8+ T cells
Standard Deviation 0.00279758
|
0.0040000 percentage of CD8+ T cells
Standard Deviation 0.00565685
|
0.0023333 percentage of CD8+ T cells
Standard Deviation 0.00404145
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 120 (Month 4)
|
0.0494400 percentage of CD8+ T cells
Standard Deviation 0.05523830
|
0.5175000 percentage of CD8+ T cells
Standard Deviation 0.67952962
|
0.1460000 percentage of CD8+ T cells
Standard Deviation 0.21915291
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 120 (Month 4)
|
0.0030000 percentage of CD8+ T cells
Standard Deviation 0.00441073
|
0.0010000 percentage of CD8+ T cells
Standard Deviation 0.00141421
|
0.0003333 percentage of CD8+ T cells
Standard Deviation 0.00057735
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 360 (Month 12)
|
0.0044918 percentage of CD8+ T cells
Standard Deviation 0.00731866
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0060000 percentage of CD8+ T cells
Standard Deviation 0.00848528
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 15
|
0.0058100 percentage of CD8+ T cells
Standard Deviation 0.00997299
|
0.0025000 percentage of CD8+ T cells
Standard Deviation 0.00353553
|
0.0053333 percentage of CD8+ T cells
Standard Deviation 0.00378594
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 30 (Month 1)
|
0.0049679 percentage of CD8+ T cells
Standard Deviation 0.00700541
|
0.0015000 percentage of CD8+ T cells
Standard Deviation 0.00212132
|
0.0020000 percentage of CD8+ T cells
Standard Deviation 0.00346410
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 15
|
0.0220818 percentage of CD8+ T cells
Standard Deviation 0.05553037
|
0.0025100 percentage of CD8+ T cells
Standard Deviation 0.00083439
|
0.0020167 percentage of CD8+ T cells
Standard Deviation 0.00122676
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 30 (Month 1)
|
0.1106415 percentage of CD8+ T cells
Standard Deviation 0.28502664
|
0.0203700 percentage of CD8+ T cells
Standard Deviation 0.01466539
|
0.0049517 percentage of CD8+ T cells
Standard Deviation 0.00371622
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 90 (Month 3)
|
0.0434985 percentage of CD8+ T cells
Standard Deviation 0.10671828
|
0.0063250 percentage of CD8+ T cells
Standard Deviation 0.00279307
|
0.0043667 percentage of CD8+ T cells
Standard Deviation 0.00583981
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 105
|
0.0047020 percentage of CD8+ T cells
Standard Deviation 0.00507315
|
0.0052300 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0020467 percentage of CD8+ T cells
Standard Deviation 0.00354493
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 120 (Month 4)
|
0.0668900 percentage of CD8+ T cells
Standard Deviation 0.14991991
|
0.0060000 percentage of CD8+ T cells
Standard Deviation 0.00848528
|
0.0072167 percentage of CD8+ T cells
Standard Deviation 0.00913589
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 360 (Month 12)
|
0.0047733 percentage of CD8+ T cells
Standard Deviation 0.00369270
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0007200 percentage of CD8+ T cells
Standard Deviation 0.00101823
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 15
|
0.0001975 percentage of CD8+ T cells
Standard Deviation 0.00067344
|
0.0015500 percentage of CD8+ T cells
Standard Deviation 0.00219203
|
0.0064300 percentage of CD8+ T cells
Standard Deviation 0.00844954
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 30 (Month 1)
|
0.0006700 percentage of CD8+ T cells
Standard Deviation 0.00147478
|
0.0011950 percentage of CD8+ T cells
Standard Deviation 0.00168999
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 90 (Month 3)
|
0.0004426 percentage of CD8+ T cells
Standard Deviation 0.00153225
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0106033 percentage of CD8+ T cells
Standard Deviation 0.01836551
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 105
|
0.0001760 percentage of CD8+ T cells
Standard Deviation 0.00039355
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 360 (Month 12)
|
0.0039322 percentage of CD8+ T cells
Standard Deviation 0.00916710
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 120 (Month 4)
|
0.0040000 percentage of CD8+ T cells
Standard Deviation 0.00418994
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0093333 percentage of CD8+ T cells
Standard Deviation 0.01137248
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 360 (Month 12)
|
0.0084900 percentage of CD8+ T cells
Standard Deviation 0.00839871
|
0.0060000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0120000 percentage of CD8+ T cells
Standard Deviation 0.00707107
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 15
|
0.0031157 percentage of CD8+ T cells
Standard Deviation 0.00523026
|
0.0010000 percentage of CD8+ T cells
Standard Deviation 0.00141421
|
0.0010000 percentage of CD8+ T cells
Standard Deviation 0.00173205
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 30 (Month 1)
|
0.0031300 percentage of CD8+ T cells
Standard Deviation 0.00536305
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0070000 percentage of CD8+ T cells
Standard Deviation 0.00500000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 105
|
0.0010000 percentage of CD8+ T cells
Standard Deviation 0.00244949
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0013333 percentage of CD8+ T cells
Standard Deviation 0.00230940
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 120 (Month 4)
|
0.0011667 percentage of CD8+ T cells
Standard Deviation 0.00251661
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0036667 percentage of CD8+ T cells
Standard Deviation 0.00635085
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 360 (Month 12)
|
0.0050373 percentage of CD8+ T cells
Standard Deviation 0.00755522
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0080000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 15
|
0.0020662 percentage of CD8+ T cells
Standard Deviation 0.00415237
|
0.0025000 percentage of CD8+ T cells
Standard Deviation 0.00353553
|
0.0050000 percentage of CD8+ T cells
Standard Deviation 0.00458258
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 120 (Month 4)
|
0.0006105 percentage of CD8+ T cells
Standard Deviation 0.00166994
|
0.0014550 percentage of CD8+ T cells
Standard Deviation 0.00205768
|
0.0050000 percentage of CD8+ T cells
Standard Deviation 0.00556776
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 360 (Month 12)
|
0.0016056 percentage of CD8+ T cells
Standard Deviation 0.00247607
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0097150 percentage of CD8+ T cells
Standard Deviation 0.01373908
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 90 (Month 3)
|
0.0020010 percentage of CD8+ T cells
Standard Deviation 0.00385930
|
0.0035000 percentage of CD8+ T cells
Standard Deviation 0.00494975
|
0.0023333 percentage of CD8+ T cells
Standard Deviation 0.00404145
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 105
|
0.0016667 percentage of CD8+ T cells
Standard Deviation 0.00265832
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0053333 percentage of CD8+ T cells
Standard Deviation 0.00404145
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, C, Day 15
|
0.0103350 percentage of CD8+ T cells
Standard Deviation 0.01602034
|
0.0230000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0760000 percentage of CD8+ T cells
Standard Deviation 0.06919538
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 120 (Month 4)
|
0.0142545 percentage of CD8+ T cells
Standard Deviation 0.01922025
|
0.0440000 percentage of CD8+ T cells
Standard Deviation 0.06222540
|
0.0120000 percentage of CD8+ T cells
Standard Deviation 0.02078461
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 360 (Month 12)
|
0.0237878 percentage of CD8+ T cells
Standard Deviation 0.03150909
|
0.0080000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 15
|
0.0066860 percentage of CD8+ T cells
Standard Deviation 0.01511548
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 30 (Month 1)
|
0.0076840 percentage of CD8+ T cells
Standard Deviation 0.01657770
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 360 (Month 12)
|
0.0080456 percentage of CD8+ T cells
Standard Deviation 0.00651373
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0050000 percentage of CD8+ T cells
Standard Deviation 0.00565685
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 360 (Month 12)
|
0.0427178 percentage of CD8+ T cells
Standard Deviation 0.07626460
|
0.0050000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0150000 percentage of CD8+ T cells
Standard Deviation 0.02121320
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 15
|
0.0014671 percentage of CD8+ T cells
Standard Deviation 0.00263630
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 15
|
0.0031952 percentage of CD8+ T cells
Standard Deviation 0.00507926
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0056667 percentage of CD8+ T cells
Standard Deviation 0.00550757
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 30 (Month 1)
|
0.0049365 percentage of CD8+ T cells
Standard Deviation 0.00709962
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0036667 percentage of CD8+ T cells
Standard Deviation 0.00404145
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 90 (Month 3)
|
0.0043447 percentage of CD8+ T cells
Standard Deviation 0.00780649
|
0.0040000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0046667 percentage of CD8+ T cells
Standard Deviation 0.00568624
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 105
|
0.0052000 percentage of CD8+ T cells
Standard Deviation 0.00589067
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0050000 percentage of CD8+ T cells
Standard Deviation 0.00624500
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 120 (Month 4)
|
0.0027273 percentage of CD8+ T cells
Standard Deviation 0.00405194
|
0.0065000 percentage of CD8+ T cells
Standard Deviation 0.00919239
|
0.0073333 percentage of CD8+ T cells
Standard Deviation 0.00945163
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 360 (Month 12)
|
0.0067122 percentage of CD8+ T cells
Standard Deviation 0.00782834
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0045000 percentage of CD8+ T cells
Standard Deviation 0.00212132
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 15
|
0.0090000 percentage of CD8+ T cells
Standard Deviation 0.01403916
|
0.0255000 percentage of CD8+ T cells
Standard Deviation 0.00494975
|
0.0260000 percentage of CD8+ T cells
Standard Deviation 0.04503332
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 30 (Month 1)
|
0.0099805 percentage of CD8+ T cells
Standard Deviation 0.01591483
|
0.0205000 percentage of CD8+ T cells
Standard Deviation 0.01343503
|
0.0383333 percentage of CD8+ T cells
Standard Deviation 0.04645787
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 15
|
0.0157619 percentage of CD8+ T cells
Standard Deviation 0.02615375
|
0.0595000 percentage of CD8+ T cells
Standard Deviation 0.05868986
|
0.1193333 percentage of CD8+ T cells
Standard Deviation 0.06900242
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 90 (Month 3)
|
0.0107505 percentage of CD8+ T cells
Standard Deviation 0.01922024
|
0.0205000 percentage of CD8+ T cells
Standard Deviation 0.02899138
|
0.0056667 percentage of CD8+ T cells
Standard Deviation 0.00513160
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 105
|
0.0202000 percentage of CD8+ T cells
Standard Deviation 0.02198181
|
0.0070000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0130000 percentage of CD8+ T cells
Standard Deviation 0.01473092
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 30 (Month 1)
|
0.0026483 percentage of CD8+ T cells
Standard Deviation 0.00397803
|
0.0020800 percentage of CD8+ T cells
Standard Deviation 0.00294156
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 90 (Month 3)
|
0.0018358 percentage of CD8+ T cells
Standard Deviation 0.00385801
|
0.0016100 percentage of CD8+ T cells
Standard Deviation 0.00227688
|
0.0002253 percentage of CD8+ T cells
Standard Deviation 0.00039029
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 105
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0027000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 120 (Month 4)
|
0.0008555 percentage of CD8+ T cells
Standard Deviation 0.00283722
|
0.0008400 percentage of CD8+ T cells
Standard Deviation 0.00118794
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 15
|
0.0003738 percentage of CD8+ T cells
Standard Deviation 0.00092592
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 30 (Month 1)
|
0.0009323 percentage of CD8+ T cells
Standard Deviation 0.00205020
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 90 (Month 3)
|
0.0003679 percentage of CD8+ T cells
Standard Deviation 0.00110265
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 105
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0027000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 120 (Month 4)
|
0.0002582 percentage of CD8+ T cells
Standard Deviation 0.00058436
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 360 (Month 12)
|
0.0002267 percentage of CD8+ T cells
Standard Deviation 0.00068000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 15
|
0.0103743 percentage of CD8+ T cells
Standard Deviation 0.01256981
|
0.0017750 percentage of CD8+ T cells
Standard Deviation 0.00019092
|
0.0052593 percentage of CD8+ T cells
Standard Deviation 0.00613561
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 30 (Month 1)
|
0.0138195 percentage of CD8+ T cells
Standard Deviation 0.01653836
|
0.0125800 percentage of CD8+ T cells
Standard Deviation 0.01190768
|
0.0101350 percentage of CD8+ T cells
Standard Deviation 0.00905302
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 90 (Month 3)
|
0.0082212 percentage of CD8+ T cells
Standard Deviation 0.01488787
|
0.0048250 percentage of CD8+ T cells
Standard Deviation 0.00682358
|
0.0045720 percentage of CD8+ T cells
Standard Deviation 0.00505935
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 105
|
0.0066820 percentage of CD8+ T cells
Standard Deviation 0.00839444
|
0.0150000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0066967 percentage of CD8+ T cells
Standard Deviation 0.00634139
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 120 (Month 4)
|
0.0150073 percentage of CD8+ T cells
Standard Deviation 0.01487729
|
0.0162450 percentage of CD8+ T cells
Standard Deviation 0.01058539
|
0.0029540 percentage of CD8+ T cells
Standard Deviation 0.00453868
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 360 (Month 12)
|
0.0149633 percentage of CD8+ T cells
Standard Deviation 0.02271217
|
0.0058400 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0170000 percentage of CD8+ T cells
Standard Deviation 0.02404163
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 15
|
0.0059200 percentage of CD8+ T cells
Standard Deviation 0.01028071
|
0.0036850 percentage of CD8+ T cells
Standard Deviation 0.00289207
|
0.0002477 percentage of CD8+ T cells
Standard Deviation 0.00042897
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 30 (Month 1)
|
0.0154140 percentage of CD8+ T cells
Standard Deviation 0.02895635
|
0.0261500 percentage of CD8+ T cells
Standard Deviation 0.02807214
|
0.0023900 percentage of CD8+ T cells
Standard Deviation 0.00272666
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 90 (Month 3)
|
0.0076211 percentage of CD8+ T cells
Standard Deviation 0.01271810
|
0.0046900 percentage of CD8+ T cells
Standard Deviation 0.00005657
|
0.0020187 percentage of CD8+ T cells
Standard Deviation 0.00116433
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 105
|
0.0061340 percentage of CD8+ T cells
Standard Deviation 0.00559455
|
0.0081100 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 120 (Month 4)
|
0.0059764 percentage of CD8+ T cells
Standard Deviation 0.00713827
|
0.0037600 percentage of CD8+ T cells
Standard Deviation 0.00294156
|
0.0009700 percentage of CD8+ T cells
Standard Deviation 0.00149362
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 360 (Month 12)
|
0.0034878 percentage of CD8+ T cells
Standard Deviation 0.00469261
|
0.0029200 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0004985 percentage of CD8+ T cells
Standard Deviation 0.00070499
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 15
|
0.0006238 percentage of CD8+ T cells
Standard Deviation 0.00118351
|
0.0016350 percentage of CD8+ T cells
Standard Deviation 0.00231224
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 30 (Month 1)
|
0.0003618 percentage of CD8+ T cells
Standard Deviation 0.00078989
|
0.0000350 percentage of CD8+ T cells
Standard Deviation 0.00004950
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 90 (Month 3)
|
0.0005989 percentage of CD8+ T cells
Standard Deviation 0.00122750
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 105
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 120 (Month 4)
|
0.0012515 percentage of CD8+ T cells
Standard Deviation 0.00280308
|
0.0014600 percentage of CD8+ T cells
Standard Deviation 0.00206475
|
0.0053333 percentage of CD8+ T cells
Standard Deviation 0.00923760
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 360 (Month 12)
|
0.0005133 percentage of CD8+ T cells
Standard Deviation 0.00152134
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0047150 percentage of CD8+ T cells
Standard Deviation 0.00666802
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 15
|
0.0048171 percentage of CD8+ T cells
Standard Deviation 0.00860057
|
0.0060000 percentage of CD8+ T cells
Standard Deviation 0.00848528
|
0.0046667 percentage of CD8+ T cells
Standard Deviation 0.00416333
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 90 (Month 3)
|
0.0027321 percentage of CD8+ T cells
Standard Deviation 0.00433336
|
0.0050000 percentage of CD8+ T cells
Standard Deviation 0.00707107
|
0.0006667 percentage of CD8+ T cells
Standard Deviation 0.00115470
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 105
|
0.0000000 percentage of CD8+ T cells
Standard Deviation 0.00000000
|
0.0080000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0076667 percentage of CD8+ T cells
Standard Deviation 0.00929157
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 120 (Month 4)
|
0.0023636 percentage of CD8+ T cells
Standard Deviation 0.00273030
|
0.0060000 percentage of CD8+ T cells
Standard Deviation 0.00848528
|
0.0123333 percentage of CD8+ T cells
Standard Deviation 0.01721434
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 90 (Month 3)
|
0.0124347 percentage of CD8+ T cells
Standard Deviation 0.01836407
|
0.0125000 percentage of CD8+ T cells
Standard Deviation 0.01767767
|
0.0330000 percentage of CD8+ T cells
Standard Deviation 0.02868798
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 105
|
0.0238000 percentage of CD8+ T cells
Standard Deviation 0.02763512
|
0.0240000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0176667 percentage of CD8+ T cells
Standard Deviation 0.01703917
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 120 (Month 4)
|
0.0106618 percentage of CD8+ T cells
Standard Deviation 0.01504292
|
0.0300000 percentage of CD8+ T cells
Standard Deviation 0.03535534
|
0.0293333 percentage of CD8+ T cells
Standard Deviation 0.05080682
|
—
|
|
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 360 (Month 12)
|
0.0337200 percentage of CD8+ T cells
Standard Deviation 0.04946269
|
0.0000000 percentage of CD8+ T cells
Standard Deviation NA
SD was not estimable for a single participant.
|
0.0800000 percentage of CD8+ T cells
Standard Deviation 0.11313708
|
—
|
SECONDARY outcome
Timeframe: Days 6, 9, 12, 15, 30 (Month 1), 90 (Month 3), 96, 99, 102, 105, 120 (Month 4)Population: Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set. Number analyzed is the number of participants with data available for analysis for the specified category.
Vaccine viremia was assessed for each of the four vaccine strain serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. Vaccine viral ribonucleic acid (RNA) was detected by a quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assay. Percentages were rounded off to the nearest decimal place.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=22 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=4 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
n=1 Participants
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 12: TDV-2
|
50.0 percentage of participants
Interval 28.2 to 71.8
|
25.0 percentage of participants
Interval 0.6 to 80.6
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 12: TDV-3
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 12: TDV-4
|
4.5 percentage of participants
Interval 0.1 to 22.8
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 15: TDV-1
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 30 (Month 1): TDV-2
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 96: TDV-2
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 99: TDV-1
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 99: TDV-2
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 99: TDV-3
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 99: TDV-4
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 102: TDV-1
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 102: TDV-2
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 102: TDV-3
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 102: TDV-4
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 105: TDV-2
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 120 (Month 4): TDV-2
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 120 (Month 4): TDV-4
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 6: TDV-3
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 6: TDV-1
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 6: TDV-2
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
33.3 percentage of participants
Interval 0.8 to 90.6
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 15: TDV-3
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 6: TDV-4
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 9: TDV-1
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 9: TDV-2
|
19.0 percentage of participants
Interval 5.4 to 41.9
|
75.0 percentage of participants
Interval 19.4 to 99.4
|
66.7 percentage of participants
Interval 9.4 to 99.2
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 9: TDV-3
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 15: TDV-4
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 30 (Month 1): TDV-1
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 30 (Month 1): TDV-3
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 30 (Month 1): TDV-4
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 90 (Month 3): TDV-1
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 90 (Month 3): TDV-2
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 90 (Month 3): TDV-3
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 9: TDV-4
|
4.8 percentage of participants
Interval 0.1 to 23.8
|
25.0 percentage of participants
Interval 0.6 to 80.6
|
33.3 percentage of participants
Interval 0.8 to 90.6
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 12: TDV-1
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 15: TDV-2
|
36.4 percentage of participants
Interval 17.2 to 59.3
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 90 (Month 3): TDV-4
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 96: TDV-1
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 120 (Month 4): TDV-1
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 120 (Month 4): TDV-3
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 96: TDV-3
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 96: TDV-4
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 105: TDV-1
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 105: TDV-3
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
|
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 105: TDV-4
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
0.0 percentage of participants
The 95% CI was not estimable as no participants had vaccine viremia.
|
SECONDARY outcome
Timeframe: Up to Day 120 (Month 4)Population: Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set. Overall number analyzed=participants with data available for analyses. Number analyzed= participants with data available for analysis for the specified category.
The duration of vaccine viremia for each vaccine strain was defined as the date when vaccine viremia was last detected (positive result) to date when vaccine viremia was first detected (positive result) + 1 day. It was assessed for each of the four vaccine strains: TDV-1, TDV-2, TDV-3 and TDV-4. Vaccine viral RNA was detected by qRT-PCR assay. Safety Analysis Set included all participants who received at least 1 dose of trial vaccine.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=14 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=4 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
Duration of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
TDV-2
|
4.0 days
Interval 1.0 to 8.0
|
1.0 days
Interval 1.0 to 2.0
|
2.5 days
Interval 1.0 to 4.0
|
—
|
|
Duration of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
TDV-4
|
3.0 days
Interval 3.0 to 3.0
|
1.0 days
Interval 1.0 to 1.0
|
1.0 days
Interval 1.0 to 1.0
|
—
|
SECONDARY outcome
Timeframe: Days 6, 9, 12, and 15Population: Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set. Overall number analyzed=participants with data available for analyses. Number analyzed= participants with data available for analysis for the specified category.
Vaccine viremia was assessed for each of the four vaccine strain serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. Vaccine viral RNA was detected by qRT-PCR assay.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=22 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=4 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
Level of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 6: TDV-2
|
—
|
—
|
3.17 log10 of genome equivalent per mL
Standard Deviation NA
SD was not estimable for a single participant.
|
—
|
|
Level of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 9: TDV-2
|
3.46 log10 of genome equivalent per mL
Standard Deviation 0.485
|
3.94 log10 of genome equivalent per mL
Standard Deviation 0.568
|
4.06 log10 of genome equivalent per mL
Standard Deviation 1.003
|
—
|
|
Level of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 9: TDV-4
|
3.98 log10 of genome equivalent per mL
Standard Deviation NA
SD was not estimable for a single participant.
|
3.90 log10 of genome equivalent per mL
Standard Deviation NA
SD was not estimable for a single participant.
|
3.71 log10 of genome equivalent per mL
Standard Deviation NA
SD was not estimable for a single participant.
|
—
|
|
Level of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 12: TDV-2
|
3.43 log10 of genome equivalent per mL
Standard Deviation 0.140
|
3.65 log10 of genome equivalent per mL
Standard Deviation NA
SD was not estimable for a single participant.
|
—
|
—
|
|
Level of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 12: TDV-4
|
3.80 log10 of genome equivalent per mL
Standard Deviation NA
SD was not estimable for a single participant.
|
—
|
—
|
—
|
|
Level of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Day 15: TDV-2
|
3.32 log10 of genome equivalent per mL
Standard Deviation 0.172
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Within 7 days after each of the vaccine dose given on Day 1 (Month 0) and 90 (Month 3)Population: Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set. Number analyzed is the number of participants with data available for analysis for the specified category.
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included injection site pain \[Grade 0 (no pain), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity with or without treatment) and 3 (severe: prevents daily activity with or without treatment)\], injection site erythema \[Grade 0 (\<25 mm), 1 (25 - ≤ 50 mm), 2 (\>50 - ≤ 100 mm), 3 (\> 100 mm)\] and injection site swelling \[Grade 0 (\<25 mm), 1 (25 - ≤ 50 mm), 2 (\>50 - ≤ 100 mm), 3 (\> 100 mm)\]. Only categories for which there was at least 1 participant are reported.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=22 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=4 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
n=1 Participants
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination
After First Vaccination: Any Solicited Local AEs
|
54.5 percentage of participants
|
25.0 percentage of participants
|
66.7 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination
After First Vaccination: Pain
|
40.9 percentage of participants
|
25.0 percentage of participants
|
66.7 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination
After First Vaccination: Erythema
|
40.9 percentage of participants
|
0 percentage of participants
|
33.3 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination
After Second Vaccination: Any Solicited Local AEs
|
68.2 percentage of participants
|
50.0 percentage of participants
|
66.7 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination
After Second Vaccination: Pain
|
59.1 percentage of participants
|
50.0 percentage of participants
|
66.7 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination
After Second Vaccination: Erythema
|
31.8 percentage of participants
|
0 percentage of participants
|
33.3 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination
After Second Vaccination: Swelling
|
9.1 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
SECONDARY outcome
Timeframe: Within 14 days after each of the vaccine dose given on Day 1 (Month 0) and 90 (Month 3)Population: Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set. Number analyzed is the number of participants with data available for analysis for the specified category.
Solicited systemic AEs were collected by participants using diary cards within 14 days after vaccination and will include fever, headache, asthenia, malaise and myalgia. Severity grades are: Grade 0: none, Grade 1: mild (no interference with daily activity), Grade 2: moderate (interference with daily activity with or without treatment), Grade 3: severe (prevents normal daily activity with or without treatment). A systemic AE of fever (defined as body temperature ≥ 100.4°F regardless of method taken) was derived from a daily temperature reading recorded within 14 days after vaccination. Only categories for which there was at least 1 participant are reported.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=22 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=4 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
n=1 Participants
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
Percentage of Participants With Solicited Systemic Reactions Following Each Vaccination
After Second Vaccination: Headache
|
13.6 percentage of participants
|
0 percentage of participants
|
66.7 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Systemic Reactions Following Each Vaccination
After Second Vaccination: Asthenia
|
18.2 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Systemic Reactions Following Each Vaccination
After First Vaccination: Any Solicited Systemic AE
|
68.2 percentage of participants
|
75.0 percentage of participants
|
100.0 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Systemic Reactions Following Each Vaccination
After First Vaccination: Headache
|
50.0 percentage of participants
|
50.0 percentage of participants
|
33.3 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Systemic Reactions Following Each Vaccination
After First Vaccination: Myalgia
|
40.9 percentage of participants
|
25.0 percentage of participants
|
100.0 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Systemic Reactions Following Each Vaccination
After First Vaccination: Asthenia
|
31.8 percentage of participants
|
25.0 percentage of participants
|
66.7 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Systemic Reactions Following Each Vaccination
After First Vaccination: Malaise
|
54.5 percentage of participants
|
25.0 percentage of participants
|
100.0 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Systemic Reactions Following Each Vaccination
After First Vaccination: Fever
|
4.5 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Systemic Reactions Following Each Vaccination
After Second Vaccination: Any Solicited Systemic AE
|
27.3 percentage of participants
|
0 percentage of participants
|
66.7 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Systemic Reactions Following Each Vaccination
After Second Vaccination: Myalgia
|
9.1 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With Solicited Systemic Reactions Following Each Vaccination
After Second Vaccination: Malaise
|
13.6 percentage of participants
|
0 percentage of participants
|
66.7 percentage of participants
|
0 percentage of participants
|
SECONDARY outcome
Timeframe: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose given on Day 1 (Month 0) and 90 (Month 3)Population: Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set. Number analyzed is the number of participants with data available for analysis for the specified category.
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a study vaccine; it does not necessarily have to have a causal relationship with study vaccine administration.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=22 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=4 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
n=1 Participants
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
Percentage of Participants With at Least One Unsolicited Adverse Events (AEs) Following Each Vaccination
After First Vaccination
|
63.6 percentage of participants
|
75.0 percentage of participants
|
66.7 percentage of participants
|
0 percentage of participants
|
|
Percentage of Participants With at Least One Unsolicited Adverse Events (AEs) Following Each Vaccination
After Second Vaccination
|
36.4 percentage of participants
|
0 percentage of participants
|
100.0 percentage of participants
|
0 percentage of participants
|
SECONDARY outcome
Timeframe: From first vaccination (Day 1) through end of study (Day 360 [Month 12])Population: Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
A SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or / significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the aforementioned criteria.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=22 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=4 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
n=1 Participants
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
Percentage of Participants With Serious Adverse Events (SAEs)
|
4.5 percentage of participants
|
25.0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
SECONDARY outcome
Timeframe: From first vaccination (Day 1) through end of study (Day 360 [Month 12])Population: Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
MAAEs was defined as AEs leading to a medical visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria.
Outcome measures
| Measure |
TDV: Flavivirus-naïve
n=22 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=4 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 Participants
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
n=1 Participants
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
Percentage of Participants With Medically Attended AEs (MAAEs)
|
45.5 percentage of participants
|
50.0 percentage of participants
|
33.3 percentage of participants
|
0 percentage of participants
|
Adverse Events
TDV: Flavivirus-naïve
Serious events: 1 serious events
Other events: 22 other events
Deaths: 0 deaths
TDV: DENV Immune: DENV-1 Positive
Serious events: 1 serious events
Other events: 4 other events
Deaths: 0 deaths
TDV: DENV Immune: DENV-3 Positive
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Unassigned Group
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
TDV: Flavivirus-naïve
n=22 participants at risk
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=4 participants at risk
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 participants at risk
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
n=1 participants at risk
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
Cardiac disorders
Atrial fibrillation
|
4.5%
1/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
Injury, poisoning and procedural complications
Forearm fracture
|
0.00%
0/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
25.0%
1/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
Other adverse events
| Measure |
TDV: Flavivirus-naïve
n=22 participants at risk
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants who were flavivirus-naïve were included in this group.
|
TDV: DENV Immune: DENV-1 Positive
n=4 participants at risk
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by DENV-1 were included in this group.
|
TDV: DENV Immune: DENV-3 Positive
n=3 participants at risk
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by DENV-3 were included in this group.
|
Unassigned Group
n=1 participants at risk
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
|
|---|---|---|---|---|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
4.5%
1/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
25.0%
1/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
General disorders
Asthenia
|
40.9%
9/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
25.0%
1/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
66.7%
2/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
4.5%
1/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
33.3%
1/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
33.3%
1/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
Immune system disorders
Drug hypersensitivity
|
9.1%
2/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
59.1%
13/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
25.0%
1/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
66.7%
2/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
Eye disorders
Eye pain
|
4.5%
1/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
25.0%
1/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
Nervous system disorders
Headache
|
63.6%
14/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
50.0%
2/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
66.7%
2/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
General disorders
Injection site bruising
|
4.5%
1/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
25.0%
1/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
33.3%
1/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
General disorders
Injection site pruritus
|
9.1%
2/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
General disorders
Malaise
|
59.1%
13/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
25.0%
1/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
100.0%
3/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
Injury, poisoning and procedural complications
Muscle strain
|
9.1%
2/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
50.0%
11/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
25.0%
1/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
100.0%
3/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
Gastrointestinal disorders
Nausea
|
9.1%
2/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
25.0%
1/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
4.5%
1/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
33.3%
1/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
General disorders
Pain
|
68.2%
15/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
25.0%
1/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
66.7%
2/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
Skin and subcutaneous tissue disorders
Rash erythematous
|
0.00%
0/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
25.0%
1/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
25.0%
1/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
General disorders
Swelling
|
36.4%
8/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
25.0%
1/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
33.3%
1/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
|
Infections and infestations
Viral upper respiratory tract infection
|
22.7%
5/22 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/4 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
33.3%
1/3 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
0.00%
0/1 • All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: OTHER